As filed with the Securities and Exchange Commission on November 12, 2001
Registration No. 333-_____
________________________________________________________________________________
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM SB-2
REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933
_________________________
THE FEMALE HEALTH COMPANY
(Name of Small Business Issuer in its Charter)
_________________________
Wisconsin 3069 39-1144397
(State or Other Jurisdiction (Primary Standard (I.R.S. Employer
of Incorporation or Industrial Classification Identification No.)
Organization) Code Number)
O.B. Parrish, Chairman
515 North State Street of the Board and Chief
Suite 2225 Executive Officer
Chicago, Illinois 60610 515 North State Street
(312) 595-9123 Suite 2225
Chicago, Illinois 60610
(312) 595-9123
(Address and Telephone Number
of Principal Executive Offices and (Name, Address and Telephone
Principal Place of Business) Number of Agent for Service)
Copies to:
James M. Bedore, Esq.
Reinhart Boerner Van Deuren s.c.
1000 North Water Street, Suite 2100
Milwaukee, WI 53202
(414) 298-1000
Approximate date of proposed sale to the public: As soon as practicable after
the effective date of this Registration Statement.
If any of the securities being registered on this form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. [X]
If this form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ]
If this form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
CALCULATION OF REGISTRATION FEE
==================================================================================================================
PROPOSED MAXIMUM
TITLE OF EACH CLASS OF AMOUNT TO BE PROPOSED MAXIMUM OFFERING AGGREGATE AMOUNT OF
SECURITIES TO BE REGISTERED REGISTERED PRICE PER SHARE OFFERING PRICE REGISTRATION FEE
- ------------------------------------------------------------------------------------------------------------------
Common Stock, $0.01 par value 6,950,000 $ 0.44 (1) $ 3,058,000 (1) $ 765 (1)
200,000 (2)
4,025,844 (3)
1,075,000 (4)
----------------
12,250,844
==================================================================================================================
(1) Calculated in accordance with Rule 457(c) based on the average of the bid and asked prices of the Common
Stock as reported on the Over the Counter Bulletin Board on November 5, 2001, solely for the purposes of
calculating the amount of the registration fee.
(2) Paid previously with the filing of Registration Statement File No. 333-68515.
(3) Paid previously with the filing of Registration Statement File No. 333-89273.
(4) Paid previously with the filing of Registration Statement File No. 333-46314.
The registrant hereby amends this registration statement on such date or dates
as may be necessary to delay its effective date until the registrant shall file
a further amendment which specifically states that this registration statement
shall thereafter become effective in accordance with section 8(a) of the
Securities Act of 1933 or until the registration statement shall become
effective on such date as the Commission, acting pursuant to said section 8(a),
may determine.
Pursuant to Rule 429 under the Securities Act, this Registration Statement is
related to (i) the registrant's Registration Statement File No. 333-68515 on
Form SB-2, originally filed on December 8, 1998, with respect to 200,000 shares,
(ii) the registrant's Registration Statement File No. 333-89273, originally
filed on October 19, 1999, with respect to 4,025,844 shares, and (iii) the
registrant's Registration Statement File No. 333-46314, originally filed on
September 21, 2000, with respect to 1,075,000 shares.
2
PROSPECTUS PRELIMINARY PROSPECTUS
SUBJECT TO COMPLETION-DATED NOVEMBER 9, 2001
THE FEMALE HEALTH COMPANY
12,250,844 SHARES OF COMMON STOCK
This prospectus may be used only by the stockholders listed under the
section entitled "Selling Stockholders" in the prospectus for their resale of up
to 12,250,844 shares of our common stock. We will not receive any proceeds from
the sale of the shares by the selling stockholders.
Our common stock is quoted on the Over the Counter Bulletin Board
under the symbol "FHCO." On November 8, 2001, the closing sale price of the
common stock was $0.60 per share.
YOU SHOULD CONSIDER THE "RISK FACTORS" BEGINNING ON PAGE 6 BEFORE PURCHASING OUR
COMMON STOCK.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS
A CRIMINAL OFFENSE.
_______, 2001
TABLE OF CONTENTS
PAGE
----
Prospectus Summary. . . . . . . . . . . . . . . . . . 3
Risk Factors. . . . . . . . . . . . . . . . . . . . . 6
Forward-Looking Statements May Prove to be Inaccurate 11
Use of Proceeds . . . . . . . . . . . . . . . . . . . 11
Price Range of Common Stock . . . . . . . . . . . . . 11
Dividend Policy . . . . . . . . . . . . . . . . . . . 11
Determination of Offering Price . . . . . . . . . . . 12
Capitalization. . . . . . . . . . . . . . . . . . . . 13
Management's Discussion and Analysis of Financial
Condition and Results of Operations . . . . . . . . . 14
Business. . . . . . . . . . . . . . . . . . . . . . . 18
Management. . . . . . . . . . . . . . . . . . . . . . 23
Principal Shareholders. . . . . . . . . . . . . . . . 28
Related Party Transactions. . . . . . . . . . . . . . 30
Description of Capital Stock. . . . . . . . . . . . . 32
Selling Stockholders. . . . . . . . . . . . . . . . . 35
Plan of Distribution. . . . . . . . . . . . . . . . . 40
Legal Matters . . . . . . . . . . . . . . . . . . . . 41
Experts . . . . . . . . . . . . . . . . . . . . . . . 41
The Female Health Company Index to Consolidated
Financial Statements. . . . . . . . . . . . . . . . . F-1
2
PROSPECTUS SUMMARY
THIS SUMMARY PROVIDES AN OVERVIEW OF SELECTED INFORMATION CONTAINED
ELSEWHERE IN THIS PROSPECTUS AND DOES NOT CONTAIN ALL OF THE INFORMATION YOU
SHOULD CONSIDER. THEREFORE, YOU SHOULD ALSO READ THE MORE DETAILED INFORMATION
IN THIS PROSPECTUS AND OUR FINANCIAL STATEMENTS.
OUR BUSINESS
The Female Health Company manufactures, markets and sells the female condom. We
were incorporated in Wisconsin in 1971 and established in our current form as
The Female Health Company on February 1, 1996.
Initially, we expended significant time and resources in the development of
the female condom and securing FDA approval to market the female condom in the
United States. During this time, we also operated our original recreational
products business. After considering various alternatives, in 1995 our Board of
Directors selected the female condom as the central focus for our strategic
direction. As a result, in January 1996, we sold our recreational products
business, changed our name to The Female Health Company and devoted ourselves
solely to the commercialization of the female condom.
As part of this restructuring, on February 1, 1996, we acquired the stock
of Chartex Resources Limited, the manufacturer and owner of worldwide rights to,
and our then sole supplier of, the female condom. As a result of these
transactions, our sole business now consists of the manufacture, marketing and
sale of the female condom. We own global intellectual property rights for the
female condom, including:
- patents in the United States, the European Union, Japan and various
other countries;
- a Pre-Market Approval granted by the United States Food and Drug
Administration (FDA) approving and permitting marketing of the female
condom in the United States;
- a CE mark in the European Union representing that the product, as a
medical device, has been approved by the European Union for marketing
in the member countries of the European Union;
- regulatory approvals in various other countries, including Japan; and
- proprietary manufacturing technology.
We also lease a state of the art manufacturing facility in London, England,
capable of producing 60 million female condoms per year. The facility has been
inspected and approved by the FDA and the European Union.
Our principal executive offices are located at 515 North State Street,
Suite 2225, Chicago, Illinois 60610, and our telephone number is 312-595-9123.
3
THE OFFERING
Common stock offered by the selling stockholders. 12,250,844 shares (1)(2)(3)
Common stock outstanding as of September 30, 2001 15,668,219 shares (4)
Over the Counter Bulletin Board symbol. . . . . . FHCO
_________________
(1) Includes:
- Up to 3,000,000 shares of common stock issuable upon exercise of
warrants currently owned by five selling stockholders. The warrants
are exercisable in the aggregate to purchase the number of shares of
our common stock equal to $1,500,000 divided by the warrant purchase
price as of the date of exercise. The warrant purchase price is the
price per share equal to 70% of the market price of our common stock
at the time of exercise, but in no event will the warrant purchase
price be less than $0.50 per share or more than $1.00 per share. These
warrants have been pledged to a bank to secure guarantees executed by
these selling stockholders on our behalf;
- Up to 1,000,000 shares of common stock issuable upon exercise of a
warrant currently owned by a selling stockholder. The warrant is
exercisable in the aggregate to purchase the number of shares of our
common stock equal to $500,000 divided by the warrant purchase price
as of the date of exercise. The warrant purchase price is the price
per share equal to 70% of the market price of our common stock at the
time of exercise, but in no event will the warrant purchase price be
less than $0.50 per share or more than $1.00 per share;
- 200,000 shares of common stock issuable upon exercise of warrants
currently owned by two selling stockholders. These warrants have been
pledged to a bank to secure guarantees executed by these selling
stockholders on our behalf;
- 2,887,500 shares of common stock issuable upon exercise of warrants
currently owned by 11 selling stockholders.
- 900,000 shares of common stock which may be received by three selling
stockholders upon conversion of convertible debentures in the
aggregate principal amount of $450,000; and
- 4,263,344 shares of common stock owned by 21 selling stockholders.
(2) A total of 5,300,844 shares of common stock offered under this prospectus
were previously registered and are included in this prospectus as allowed
under Rule 429 under the Securities Act of 1933. A total of 6,950,000
shares of common stock are being newly registered under this prospectus,
including 4,500,000 shares beneficially owned by our directors or executive
officers.
(3) A total of 5,433,338 shares of common stock offered under this prospectus
are beneficially owned by our directors or executive officers, including up
to 2,800,000 shares issuable upon exercise of warrants and 500,000 shares
issuable upon conversion of a convertible debenture.
(4) Does not include:
- 8,297,500 shares of common stock issuable upon exercise of warrants
outstanding as of September 30, 2001;
- 2,859,533 shares of common stock issuable upon exercise of stock
options outstanding as of September 30, 2001;
- 660,000 shares of common stock issuable upon conversion of outstanding
preferred stock; and
- 900,000 shares issuable upon conversion of $450,000 of convertible
debentures outstanding.
4
SUMMARY FINANCIAL INFORMATION
The summary financial information below is derived from our financial
statements appearing elsewhere in this prospectus. You should read this
information in conjunction with those financial statements, including the notes
to the financial statements.
YEAR ENDED SEPTEMBER 30, NINE MONTHS ENDED
1998 1999 2000 JUNE 30, 2001
------------ ------------ ------------ -----------------
STATEMENTS OF OPERATIONS DATA:
Net revenues. . . . . . . . . . $ 5,451,399 $ 4,715,477 $ 5,766,868 $ 4,959,512
Cost of products sold . . . . . 5,273,369 4,598,747 5,184,735 3,998,978
Net loss. . . . . . . . . . . . (3,357,316) (3,750,309) (3,690,163) (976,404)
Net loss attributable to common
stockholders. . . . . . . . (4,306,985) (3,884,228) (3,822,358) (1,076,133)
Net loss per common share
outstanding . . . . . . . . $ (0.43) $ (0.36) $ (0.30) $ (0.07)
SEPTEMBER 30, 2000 JUNE 30, 2001
-------------------- ---------------
CONSOLIDATED BALANCE SHEET DATA:
Working capital. . . . . . . . . $ (1,425,516) $ 199,245
Total assets . . . . . . . . . . 4,120,782 4,095,862
Long-term debt and capital lease
obligations . . . . . . . . . . - 1,048,471
Stockholders' deficit. . . . . . (693,067) (418,317)
5
RISK FACTORS
You should carefully consider the following risk factors, as well as the
other information contained in this prospectus, before purchasing our common
stock.
WE NEED ADDITIONAL CAPITAL TO SUPPORT OUR OPERATIONS. WE MAY NOT BE ABLE TO
RAISE SUFFICIENT AMOUNTS OF ADDITIONAL CAPITAL WHEN NEEDED AND, IF WE DO RAISE
ADDITIONAL CAPITAL, IT COULD DILUTE THE HOLDINGS OF OUR SHAREHOLDERS.
Sales of our sole product, the female condom, are currently insufficient to
cover our fixed manufacturing overhead, advertising and general and
administrative costs. Consequently, we must secure additional capital to fund
operating losses. We may not be successful in raising sufficient amounts of
additional capital when needed and, even if we are able to raise additional
capital, the terms of our financing activities may be costly and/or dilute the
holdings of our shareholders.
We estimate that we may need up to $0.5 million before the end of 2001 to
fund our anticipated cash needs for working capital, capital expenditures and
debt obligations, depending on the level of sales of our product. However, at
this stage in our development, the amount and timing of our future capital
requirements cannot be precisely determined. Many of the factors affecting our
capital requirements, including new market launches by our international
partners and sales orders from existing customers, are outside of our control.
We expect to raise additional capital through one or more of the following
means:
- the sale of debt or equity securities;
- the sale of assets or rights; or
- by discounting receivables and/or letters of credit to facilitate
collection.
We can make no assurance that we will be successful in raising additional
capital. Further, we can make no assurance that any amount, if raised, will be
sufficient to continue our operations until sales of the female condom generate
sufficient revenues to fund operations.
OUR SUCCESS IS COMPLETELY DEPENDENT UPON THE SUCCESS OF THE FEMALE CONDOM.
We expect to derive our future revenues from sales of the female condom,
our sole current product. Our current level of expenditures has been
established to support a higher level of revenues. For us to begin generating
cash from operations, sales of the female condom will have to increase to
approximately 15 million per year based upon the current average selling price
per unit, which would represent approximately 25% of our manufacturing capacity
compared to approximately 13% of our manufacturing capacity that we used in
fiscal 2000. If sales do not increase from current levels to this degree or if
the cost to obtain this level of sales is prohibitive, we will continue to
experience operating losses and, ultimately, our viability will be in jeopardy.
Our ability to achieve a higher level of revenues is uncertain because the
product is in the early stages of its commercialization. Accordingly, the
ultimate level of acceptance of the female condom by public health advocates as
well as users around the world, which includes the decision to use the female
condom versus other available products, is not yet known.
WE HAVE A HISTORY OF SIGNIFICANT LOSSES AND, DUE TO THAT AND OTHER FACTORS, OUR
INDEPENDENT AUDITOR HAS ISSUED A QUALIFIED OPINION ON OUR FINANCIAL STATEMENTS.
We had a net loss attributable to common stockholders of $1.1 million for
the first nine months of fiscal 2001, $3.8 million for fiscal 2000 and $3.9
million for fiscal 1999. As of June 30, 2001, we had an accumulated deficit of
$50.1 million, working capital of $0.2 million and a stockholders' deficit of
$0.4 million. Historically, we have experienced cash operating losses relating
to expenses to develop, manufacture and promote the female condom. Consistent
with the availability of resources, we expect to make substantial expenditures
in future periods in an effort to
6
support our manufacturing operations and increase awareness and distribution of
the female condom around the globe. Until our internally generated funds are
sufficient to meet cash requirements, we will remain dependent upon our ability
to generate sufficient capital from outside sources. We can make no assurance
that we will achieve a profitable level of operations in the near term or at
all.
Our independent auditor's reports on our consolidated financial statements
for the fiscal years ended September 30, 2000, 1999, 1998 and 1997 were
qualified as to our ability to continue as a going concern. While many factors
are considered by the auditor in reaching its opinion, the primary reason for
the going concern opinion was due to our continued deficit cash flows from
operations, driven largely by continued operating losses. Our net cash used in
operations was $0.6 million for the first nine months of fiscal 2001, $1.0
million for fiscal 2000 and $2.8 million for fiscal 1999.
In the near term, we expect operating costs to continue to exceed funds
generated from operations due principally to our fixed manufacturing costs
relative to our current production volumes. We can make no assurance that we
will achieve positive cash flows from our operations in the near term or at all.
We believe we must first achieve, on a continuing basis, positive cash flow from
operations and net operating profits in order for our independent auditors to
re-evaluate their going concern opinion.
BECAUSE OUR PRODUCT FACES SIGNIFICANT COMPETITION FROM OTHER PRODUCTS, SUCH AS
THE MALE CONDOM, WE MAY NOT BE ABLE TO ACHIEVE ANTICIPATED GROWTH LEVELS OR
PROFIT MARGINS.
We may be unable to compete successfully against current and future
competitors, and competitive pressures could have a negative effect on our
revenues, cash flows and profit margins. Although we believe that there is
currently no other female condom sold in the world, other parties may seek to
develop an intravaginal pouch which does not infringe our patents. These
products, if developed, could be distributed by companies with greater financial
resources and customer contacts than us. In addition, there are a number of
other products currently marketed which have a higher degree of accepted
efficacy for preventing pregnancy than does the female condom. These products
include male condoms, birth control pills, Norplant and Depo Provera. However,
other than the female condom, only the latex male condom is generally recognized
as being efficacious in preventing unintended pregnancies and sexually
transmitted diseases. Companies manufacturing these competing products are
generally much larger than we are and have access to significantly greater
resources than we do. In addition, the female condom is generally sold at
prices comparatively greater than the price of the latex male condom.
Accordingly, the female condom will not be able to compete with the latex male
condom solely on the basis of price.
FUTURE SALES OF OUR COMMON STOCK IN THE PUBLIC MARKET MAY REDUCE THE STOCK'S
TRADING PRICE.
A large number of our shares of common stock which are currently
outstanding or which we may issue in the near future may be immediately resold
in the public market. Sales of our common stock in the public market or the
perception that sales may occur, could cause the market price of our common
stock to decline even if our business is doing well. Virtually all of the
15,668,219 shares of our common stock and 660,000 shares of our convertible
preferred stock outstanding as of September 30, 2001 may be immediately resold
in the public market, although sales of our shares by our directors, executive
officers or other persons who may control us may be subject to restrictions
under Rule 144, including limitations on the number of shares that may be sold.
Further, as of September 30, 2001, we have issued options and warrants to
purchase 11,157,033 shares of common stock and convertible debentures
convertible into 900,000 shares of common stock. We have filed or intend to file
registration statements under the Securities Act to register the sale of the
shares underlying these options and warrants and, accordingly, any shares
received upon exercise of these options or warrants will also be freely
tradable, except for shares received by our directors, executive officers or
other persons who may control us which are subject to the restrictions under
Rule 144.
SINCE OUR COMMON STOCK IS NO LONGER LISTED ON THE AMERICAN STOCK EXCHANGE, YOU
MAY HAVE GREATER DIFFICULTY BUYING AND SELLING OUR COMMON STOCK.
On February 5, 1999, our common stock was delisted from the American Stock
Exchange since it did not meet all of the criteria for continued listing.
Commencing on approximately February 10, 1999, the common stock has been quoted
on the OTC Bulletin Board under the symbol "FHCO." You may find it more
difficult to obtain accurate
7
quotations of the price of the our common stock and to sell the common stock on
the open market than was the case when the common stock was listed on the
American Stock Exchange. In addition, companies whose stock is listed on the
American Stock Exchange must adhere to the rules of that exchange. These rules
include various corporate governance procedures which, among other items,
require a company to obtain shareholder approval prior to completing various
types of important transactions including issuances of common stock equal to 20%
or more of the company's then outstanding common stock for less than the greater
of book or market value or most issuances of stock options. Since our stock is
quoted on the OTC Bulletin Board, we are not subject to those or any comparable
rules.
OUR STOCK PRICE HAS BEEN EXTREMELY VOLATILE AND, AS A RESULT, THE PRICE COULD BE
DOWN AT A TIME WHEN YOU DESIRE TO SELL YOUR SHARES.
The market price of our common stock has been and may continue to be
affected by quarter-to-quarter variations in our operating results,
announcements by our competitors and other factors. In addition, the stock
market has from time to time experienced extreme price and volume fluctuations,
particularly among the stock of emerging growth companies, which have often been
unrelated to the operating performance of particular companies. Factors not
directly related to our performance, such as governmental regulation or negative
industry reports, may also have a significant adverse impact on the market price
of our common stock.
BECAUSE OUR COMMON STOCK IS A "PENNY STOCK," TRADING IN IT IS SUBJECT TO THE
PENNY STOCK RULES WHICH COULD AFFECT YOUR ABILITY TO RESELL THE STOCK IN THE
MARKET.
The Securities Enforcement and Penny Stock Reform Act of 1990 imposes
restrictions when making trades in any stock such as our common stock which is
defined as a "penny stock." The SEC's regulations generally define a penny stock
as an equity security that has a price of less than $5.00 per share, other than
securities which are traded on markets such as the New York Stock Exchange, the
American Stock Exchange or the Nasdaq Stock Market. As a result of being a penny
stock, the market liquidity for our common stock may be adversely affected since
the regulations on penny stocks could limit the ability of broker-dealers to
sell our common stock and thus your ability to sell our common stock in the
secondary market. The regulations restricting trades in penny stock include:
- a requirement that stock brokers deliver to their customers, prior to
any transaction involving a penny stock, a disclosure schedule
explaining the penny stock market and the risks associated with the
penny stock market; and
- a requirement that broker-dealers who recommend penny stocks to
persons other than their established customers and a limited class of
accredited investors must make a special written suitability
determination for the purchaser and receive the purchaser's written
agreement to the transaction prior to the sale of the securities.
AS A MANUFACTURER AND MARKETER OF A CONSUMER PRODUCT, WE COULD EXPERIENCE
PRODUCT LIABILITY CLAIMS.
The nature of our product may expose us to significant product liability
risks. We maintain product liability insurance with coverage limits of $5
million per year on the female condom. We can make no assurance that we will be
able to maintain this insurance on acceptable terms or that the insurance will
provide adequate coverage against product liability claims. While no product
liability claims on the female condom have been brought against us to date, a
successful product liability claim against us in excess of our insurance
coverage could be extremely damaging to us.
SINCE WE SELL PRODUCT IN FOREIGN MARKETS, WE ARE SUBJECT TO FOREIGN CURRENCY AND
OTHER INTERNATIONAL BUSINESS RISKS THAT COULD ADVERSELY AFFECT OUR OPERATING
RESULTS.
We manufacture the female condom in a leased facility located in London,
England. In addition, a material portion of our future sales are likely to be in
foreign markets. Manufacturing costs and sales to foreign markets are subject to
inherent risks and challenges that could adversely affect our revenues, cash
flows and profit margins, including:
- normal currency risks associated with changes in the exchange rate of
foreign currencies relative to the United States dollar;
8
- unexpected changes in international regulatory requirements and
tariffs;
- difficulties in staffing and managing foreign operations;
- greater difficulty in accounts receivable collection;
- political or economic changes, especially in developing nations; and
- price controls and other restrictions on foreign currency.
To date, we have not used currency hedging strategies to manage our
currency risks. On an ongoing basis, we will continue to evaluate our commercial
transactions and will consider employing currency hedging strategies if
appropriate.
OUR PRODUCT IS SUBJECT TO SUBSTANTIAL GOVERNMENT REGULATION WHICH EXPOSES US TO
RISKS THAT WE WILL BE FINED OR EXPOSED TO CIVIL OR CRIMINAL LIABILITY, RECEIVE
NEGATIVE PUBLICITY OR BE PREVENTED FROM SELLING OUR PRODUCT.
The female condom is subject to regulation by the FDA under the Food, Drug
and Cosmetic Act, and by other state and foreign regulatory agencies. Under the
Food, Drug and Cosmetic Act, medical devices must receive FDA clearance before
they can be sold. FDA regulations also require us to adhere to "Good
Manufacturing Practices," which include testing, quality control and
documentation procedures. Our compliance with applicable regulatory requirements
is monitored through periodic inspections by the FDA and other foreign
regulatory agencies. If we fail to comply with applicable regulations, we could:
- be fined or exposed to civil or criminal liability;
- face suspensions of clearances, seizures or recalls of products or
operating restrictions;
- receive negative publicity; or
- be prevented from selling our product in the United States or in
foreign markets.
OUR SHAREHOLDERS MAY BE PERSONALLY LIABLE FOR UP TO $.01 FOR EACH SHARE HELD IF
WE FAIL TO REPAY OUR DEBTS TO OUR EMPLOYEES FOR UNPAID COMPENSATION.
Since we are a Wisconsin corporation, our shareholders may be personally
liable for our debts to our employees for services performed. Wisconsin law
limits the potential amount of our shareholders' liability to the par value of
our shares, which is $.01 per share, for each share held. Potential liability
is also limited to debts for a maximum of six months' services.
A LIMITED NUMBER OF OUR SHAREHOLDERS CAN EXERCISE SUBSTANTIAL INFLUENCE OVER OUR
COMPANY.
As of September 30, 2001, our directors and executive officers and their
affiliates beneficially own in the aggregate approximately 46.0% of our
outstanding shares of common stock. If these shareholders were to vote together
as a group, they would have the ability to exert significant influence over our
board of directors and policies. For instance, these shareholders would be able
to exert a significant influence over the outcome of all shareholder votes,
including votes concerning director elections, by-law amendments and possible
mergers, corporate control contests and other significant corporate
transactions. See "Principal Shareholders" for more information.
9
A HOLDER OF CONVERTIBLE DEBENTURES HAS ALLEGED THAT WE DEFAULTED IN OUR
OBLIGATIONS UNDER THE CONVERTIBLE DEBENTURES AND HAS DEMANDED THAT WE ISSUE
1,500,000 SHARES OF OUR COMMON STOCK UNDER THE DEFAULT PROVISIONS OF THE
CONVERTIBLE DEBENTURES.
We issued convertible debentures in the principal amount of $1.5 million to
five investors on May 19, 1999 and June 3, 1999. These convertible debentures
were secured by a first security interest in all of our assets. The holder of
convertible debentures in the principal amount of $1 million has alleged that we
are in default with respect to the perfection of the investors' security
interest in our assets, and has made a demand pursuant to the default provisions
of the convertible debentures for the immediate repayment of all amounts
outstanding under the convertible debentures and for the issuance of 1,500,000
shares of our common stock to the investors. In May 2001, we repaid the
principal amount outstanding under the convertible debentures using the proceeds
of a new loan agreement. The holder of the convertible debentures, however, has
not released his claim or acted to terminate the security interest of the
investors in our assets. We dispute this claim and intend to vigorously defend
our position. However, any resolution of this matter may result in dilution to
our existing shareholders and may adversely affect our results of operations.
10
FORWARD-LOOKING STATEMENTS MAY PROVE TO BE INACCURATE
We have made forward-looking statements in this prospectus that are subject
to risks and uncertainties. When we use the words "believes," "expects,"
"anticipates" or similar expressions, we are making forward-looking statements.
Because many factors can materially affect results, including those listed under
"Risk Factors," you should not regard our inclusion of forward-looking
information as a representation by us or any other person that our objectives or
plans will be achieved. Our assumptions relating to budgeting, research, sales,
results and market penetration and other management decisions are subjective in
many respects and thus are susceptible to interpretations and periodic revisions
based on actual experience and business developments. The impact of any of these
factors may cause us to alter our capital expenditures or other budgets, which
may in turn affect our business, financial position, results of operations and
cash flows. Therefore, you should not place undue reliance on forward-looking
statements contained in this prospectus, which speak only as of the date of this
prospectus. Factors that might cause actual results to differ from those
anticipated in the forward-looking statements include, but are not limited to,
those described in "Risk Factors."
USE OF PROCEEDS
The proceeds from the sale of the shares offered by this prospectus will be
received directly by the selling stockholders. We will not receive any proceeds
from the sale of the shares.
PRICE RANGE OF COMMON STOCK
Our common stock is currently quoted on the OTC Bulletin Board under the
symbol "FHCO." As of September 30, 2001, there were approximately 447 holders of
record of our common stock.
Prior to February 5, 1999, our common stock was listed on the American
Stock Exchange. The following table lists the historical high and low sale
prices of a share of our common stock on the American Stock Exchange for periods
prior to February 5, 1999 and on the OTC Bulletin Board for periods on or after
February 9, 1999:
COMMON STOCK
SALE PRICE
-------------
HIGH LOW
----- -----
1999 Fiscal Year:
Quarter ended:
December 31, 1998. $2.00 $1.13
March 31, 1999 2.06 1.06
June 30, 1999 2.00 0.88
September 30, 1999 1.69 0.69
2000 Fiscal Year
Quarter ended:
December 31, 1999 1.59 0.78
March 31, 2000 1.25 0.75
June 30, 2000 1.09 0.50
September 30, 2000 0.72 0.41
2001 Fiscal Year
Quarter ended:
December 31, 2000 0.84 0.38
March 31, 2001 0.66 0.41
June 30, 2001 0.59 0.34
September 30, 2001 0.80 0.41
The sale price quotations above reflect inter-dealer prices, without
retail mark-ups, mark-downs or commissions.
DIVIDEND POLICY
We have not paid a dividend on our common stock and do not anticipate
paying any dividends in the foreseeable future.
11
DETERMINATION OF OFFERING PRICE
The common stock offered by this prospectus may be offered for sale by the
selling stockholders from time to time in transactions on the OTC Bulletin
Board, in negotiated transactions, or otherwise, or by a combination of these
methods, at fixed prices which may be changed, at market prices at the time of
sale, at prices related to market prices or at negotiated prices. As such, the
offering price is indeterminate as of the date of this prospectus. See "Plan of
Distribution."
12
CAPITALIZATION
The following table includes information regarding our unaudited short-term
indebtedness and stockholders' equity as of June 30, 2001.
JUNE 30, 2001
-------------
(UNAUDITED)
Short-term indebtedness:
Notes payable, related party, net
of unamortized discount. . . . . . . . . . . . . . . . . . . . $ 1,281,956
Long-term indebtedness:
Note payable, bank, net
of unamortized discount. . . . . . . . . . . . . . . . . . . . 598,471
Convertible debentures . . . . . . . . . . . . . . . . . . . . . 450,000
-------------
Total long-term indebtedness . . . . . . . . . . . . . . . . 1,048,471
-------------
Stockholders' equity:
Class A Convertible Preferred Stock-Series 1, par value $.01 per
Share, 5,000,000 shares authorized, 660,000 shares issued and
outstanding as of March 31, 2001 . . . . . . . . . . . . . . . 6,600
Common stock, par value $.01 per share, 27,000,000 shares
authorized, 14,668,219 shares issued and outstanding as of
June 30, 2001. . . . . . . . . . . . . . . . . . . . . . . . . 146,683
Additional paid-in capital . . . . . . . . . . . . . . . . . . . 49,625,703
Unearned consulting compensation . . . . . . . . . . . . . . . . (104,637)
Accumulated other comprehensive income . . . . . . . . . . . . . 18,003
Accumulated deficit. . . . . . . . . . . . . . . . . . . . . . . (50,078,593)
Treasury stock, at cost. . . . . . . . . . . . . . . . . . . . . (32,076)
-------------
Total stockholders' deficit. . . . . . . . . . . . . . . . . (418,317)
-------------
Total liabilities and stockholders' deficit. . . . . . . . . $ 4,095,862
=============
13
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The following discussion is intended to provide an analysis of our
financial condition and results of operations and should be read in conjunction
with our financial statements and the notes to our financial statements
contained elsewhere in this prospectus. The discussion also includes
forward-looking statements. As indicated in "Forward-Looking Statements May
Prove To Be Inaccurate," you should not place undue reliance on forward-looking
statements.
OVERVIEW
Over the past few years, we have completed significant aspects of the
development and commercialization of the female condom. These initiatives have
resulted in our attainment of proprietary manufacturing technology and product
design patents, necessary regulatory approvals, endorsements from various
organizations within the world medical community and the development of
significant manufacturing capacity. These steps, taken as part of our plan to
develop and sell a product with global commercial and humanitarian value, have
required the expenditure of significant amounts of capital and resulted in
significant operating losses including the period 1996 through the present.
We have begun the process of developing the market for the female condom
around the world. As part of this plan, we have entered into a number of
distribution agreements and are pursuing other arrangements for the marketing
and sale of the female condom. We believe that as the number of markets in
which the female condom is sold increases, sales will grow and, if our sales
increase significantly, we will become profitable. However, we can make no
assurance that we will achieve profitability in the near term or at all.
RESULTS OF OPERATIONS
NINE MONTHS ENDED JUNE 30, 2001 COMPARED TO NINE MONTHS ENDED JUNE 30, 2000
We had revenues of $4,959,512 and a net loss of $1,076,133 for the nine
months ended June 30, 2001 compared to revenues of $3,923,425 and a net loss of
$3,225,119 for the nine months ended June 30, 2000.
Our operating loss for the nine months ended June 30, 2001 was $613,205
compared to $1,942,792 for the nine months ended June 30, 2000 for a decrease of
68%. As discussed more fully below, the decrease in our net operating loss was
result of an increase in gross profit coupled with a decrease in operating
expenses. The decrease in our net loss resulted from reductions in our
operating loss, amortization of debt issuance costs and non-operating interest
expenses.
Sales increased $1,036,087 for the nine months ended June 30, 2001, or 26%,
compared with the nine months ended June 30, 2000. The increased sales resulted
from higher unit sales shipped to both global public sector and domestic
customers.
We expect significant quarter to quarter variation due to the timing of
receipt of large orders, subsequent production scheduling, and shipping of
products as various countries launch the product. We believe this variation
between quarters will continue for several quarters to come until reorders form
an increasing portion of total sales.
Cost of goods sold increased $386,762 to $3,998,978 for the nine months
ended June 30, 2001 from $3,612,216 for nine months ended June 30, 2000. The
cost of goods increase of 11% on a 26% sales increase resulted because costs of
goods as a percentage of sales decreased to 81% in the current year compared to
92% during the same period in the prior year. The decline in the cost of goods
sold percentage as a percentage of sales is due to several factors. One factor
impacting the change is that nearly all of the our sales for the nine months
ended June 30, 2001 were comprised of a new less expensive (1000 pack) bulk
sized product which was not available during the nine months ended June 30,
2000. Another key factor is our absorption of our fixed costs as we reach
higher production and sales levels.
Advertising and promotional expenditures decreased $58,845 to $110,155 for
the nine months ended June 30, 2001 from $169,000 for the nine months ended June
30, 2000. The decrease primarily resulted from a reduction of in-store
promotion expenses between the current and prior fiscal year.
14
Selling, general and administrative expenses decreased $621,417, or 29%, to
$1,463,584 for the nine months ended June 30, 2001 from $2,085,001 for the nine
months ended June 30, 2000. The decline is a result of a reduction of finance,
sales and administrative staff and thereby related labor costs, as well as
reduced costs in the areas of investor relations, consulting, and research and
development during the nine months ended June 30, 2001 compared to that incurred
during the nine months ended June 30, 2000.
We did not incur non-cash amortization of debt issuance costs during the
nine months ended June 30, 2001 compared to $245,676 for the nine months ended
June 30, 2000. The elimination of these costs is due to the completion of the
amortization period in the third quarter of fiscal 2000. The amortization of
debt issuance costs related to the issuance of convertible debentures which
began in May and June 1999. We have not issued new convertible debentures with
a discount feature in any subsequent period.
Net interest and non-operating expenses decreased $574,362 to $363,199 for
the nine months ended June 30, 2001 from $937,561 for the nine months ended June
30, 2000. The decrease exists because we had a smaller amount of non-cash
expenses incurred from the amortization of discounts on notes payable and
convertible debentures during the nine months ended June 30, 2001 compared to
that incurred during the nine months ended June 30, 2000.
FISCAL YEAR ENDED SEPTEMBER 30, 2000 COMPARED TO FISCAL YEAR ENDED SEPTEMBER 30,
1999
We had net revenues of $5.8 million and a net loss attributable to common
stockholders of $(3.8) million, or $(0.30) per share in 2000 compared to net
revenues of $4.7 million and a net loss attributable to common stockholders of
$(3.9) million, or $(0.36) per share in 1999.
Our operating loss for 2000 was $(2,392,631) compared to $(2,851,873) for
1999, for a decrease of 16%. As discussed in more detail in the following
paragraphs, the decrease in our net operating loss was a result of gross profit
improvements while operating expenses between years had a negligible change.
The decline in net loss was smaller, however, due to increases in non-operating
interest expenses and amortization of debt issuance costs.
Net revenues increased $1.1 million, or 23%, in 2000 over the prior year.
The higher net revenues primarily resulted from increased unit sales shipped to
international customers.
Cost of goods sold increased $585,988, or 12%, to $5,184,735 for 2000 from
$4,598,747 for 1999. The increase was not in proportion with the sales increase
as a result of a larger portion of our total sales being comprised of
international and global public sector business (63%) in 2000 than in the prior
year (50%). The costs of goods sold per unit for such customers' business is
less expensive because of the efficiencies related to the production of the bulk
sized product sold. Our U.K.-based manufacturing facility utilized
approximately 13% of its capacity in 2000 compared with approximately 11% of its
capacity in 1999.
Advertising and promotion expenditures did not change materially between
years, decreasing 1% to $0.2 million in 2000 compared to $0.3 million in 1999.
Advertising and promotion relates exclusively to the U.S. market and includes
the costs of print advertising, trade and consumer promotions, product samples
and other marketing costs incurred to increase consumer awareness and purchases
of the female condom. We entered an agreement with Mayer Laboratories, Inc. to
distribute the female condom to the wholesale retail trade in the United Sates
effective October 1, 2000. We will continue to distribute directly to U.S.
Public sector customers. Mayer currently distributes birth control and STD
prevention products and its objective is to increase unit sales of the female
condom in the wholesale retail trade arena. This agreement complements our
strategy to serve as a manufacturer supplying public sector customers and
commercial partners worldwide. Additionally, due to the consolidation of
administrative functions we estimate this agreement will permit us to save $0.3
million in expenses annually.
Selling, general and administrative expenses were $2.7 million in 2000 and
1999. As a percentage of net revenues, the selling, general and administrative
expenses were 47% in 2000 compared with 57% in 1999. The decrease as a
percentage of net revenues exists, because although the change in general and
administrative expenses was flat, net revenues increased 22% between 2000 and
1999. Selling, general and administrative expenses did not proportionately
increase, however, because increases in investor relations and selling expenses
were offset by reductions in legal and research and development costs.
15
Our strategy is to act as a manufacturer supplying the public sector and
commercial partners throughout the world. Our partners pay for all marketing
and shipping costs. Consequently, as the our sales volume increases our
operating expenses will not increase significantly.
Non-cash amortization of debt issuance costs increased $71,552 to $245,676
for 2000 from $174,124 for 1999. The increase is due to the amortization period
of debt issuance costs relating to the issuance of convertible debentures in May
and June 1999.
Net interest and non-operating expenses increased $327,544, or 45%, to
$1,051,856 for 2000 compared to $724,312 for 1999. The increase exists because
we had a higher level of debt outstanding during 2000 than 1999 as a result of
the issuance of convertible debentures. The result is a larger amount of
non-cash expenses incurred from the amortization of discounts on notes payable
and convertible debentures for 2000 than for 1999.
We were able to cover fixed manufacturing overhead costs and exceeded
break-even at the gross profit level. However, we must achieve cumulative
annual unit sales of approximately 19 million female condoms based upon the
current average selling price per unit in order to cover operating and
non-operating expenses or approximately 32% of manufacturing capacity.
LIQUIDITY AND SOURCES OF CAPITAL
Historically, we have incurred cash operating losses relating to expenses
incurred to develop and promote the female condom. During the first nine months
of fiscal 2001, cash used in operations totaled $0.6 million. Cash used in
operations was $1.0 million in fiscal 2000 and $2.8 million in fiscal 1999. We
used net proceeds from the issuance of our common stock and convertible
debentures in order to fund cash used in operations; thereby avoiding a
reduction of our cash position.
We entered into a loan agreement on May 18, 2001, providing for a
three-year loan commitment from a bank of up to $2,000,000. We may borrow under
this loan agreement from time to time subject to a number of conditions,
including obtaining personal guarantees of 125% of the amount outstanding under
the loan. In May 2001, we borrowed a total of $1.5 million under this loan
agreement, and used the proceeds to repay convertible debentures that we
originally issued on May 19, 1999 and June 3, 1999 to five investors in the
principal amount of $1.5 million. Borrowings under the loan accrue interest at
an annual rate of 10% and payments of interest are due monthly. Final maturity
of the principal amount of the loan and accrued but unpaid interest is on May
18, 2004.
In connection with the loan, we issued warrants to the lender to purchase
the number of shares of our common stock equal to $500,000 divided by the
warrant purchase price as of the date of exercise. The warrant purchase price
is the price per share equal to 70% of the market price of our common stock at
the time of exercise, but in no event will the warrant purchase price be less
than $0.50 per share or more than $1.00 per share.
Five persons provided guarantees equal in total to the $1.5 million
outstanding under the loan. The guarantors included James R. Kerber, a member
of our board of directors, Stephen M. Dearholt, a member of our board of
directors, Richard E. Wenninger, a member of our board of directors, and a trust
for the benefit of O.B. Parrish, our Chairman of the Board and Chief Executive
Officer. Each guarantor may be liable to the lender for up to 125% of the
guarantor's guarantee amount if we default under the loan. We issued warrants
to the guarantors to purchase the number of shares of our common stock equal to
the guarantee amount of such guarantor divided by the warrant purchase price as
of the date of exercise. The warrant purchase price is the price per share
equal to 70% of the market price of our common stock at the time of exercise,
but in no event will the warrant purchase price be less than $0.50 or more than
$1.00. We also issued additional warrants to purchase 100,000 shares of our
common stock at an exercise price of $0.50 per share to each of Stephen M.
Dearholt and Richard E. Wenninger because each of them guaranteed $500,000 under
the loan.
At June 30, 2001, we had current liabilities of $2.2 million including a
$1.0 million note payable due March 25, 2001 to Stephen M. Dearholt, a member of
our board of directors. We subsequently agreed with Mr. Dearholt to extend the
note to March 25, 2002 and, in connection with the extension, we issued to Mr.
Dearholt a warrant to purchase 280,000 shares of our common stock at an exercise
price of $0.45 per share.
16
We also extended a $50,000 note payable from O.B. Parrish, our Chairman of
the Board and Chief Executive Officer, to February 18, 2002 and a $250,000 note
payable from Stephen M. Dearholt to February 12, 2002. In connection with the
extensions, we issued to Mr. Parrish a warrant to purchase 14,000 shares of our
common stock at an exercise price of $0.45 per share and we issued to Mr.
Dearholt a warrant to purchase 70,000 shares of our common stock at an exercise
price of $0.45 per share. We subsequently repaid these notes.
Effective March 30, 2001, we issued a convertible debenture to Richard E.
Wenninger in the principal amount of $250,000. The convertible debenture bears
interest at an annual rate of 12% and has a three-year term. Mr. Wenninger may
convert the convertible debenture into common stock at any time based on a
conversion rate of $0.50 per share.
On June 1, 2001, we issued a total of $200,000 of convertible debentures to
two accredited investors. The debentures are due on May 30, 2004, bear interest
payable at the rate of 10% per year and are convertible into shares of our
common stock at a rate of $0.50 per share. We did not issue warrants to the
investors in connection with this issuance.
On August 1, 2001, we issued 1,000,000 shares of our common stock to
Richard E. Wenninger for a total purchase price of $500,000.
In the near term, we expect operating and capital costs to continue to
exceed funds generated from operations, due principally to our fixed
manufacturing costs relative to current production volumes and the ongoing need
to commercialize the female condom around the world. We estimate that our cash
burn rate, with revenues, is less than $100,000 per month.
While we believe that revenue from sales of the female condom will
eventually exceed operating costs, and that, ultimately, operations will
generate sufficient funds to meet capital requirements, we can make no assurance
that we will achieve such level of operations in the near term or at all.
Likewise, we can make no assurance that we will be able to source all or any
portion of our required capital through the sale of debt or equity or, if
raised, the amount will be sufficient to operate until sales of the female
condom generate sufficient revenues to fund operations. In addition, any funds
raised may be costly to us and/or dilutive to our shareholders.
If we are not able to source the required funds or any future capital which
becomes required, we may be forced to sell part or all of our assets or rights
or cease operations. Further, if we are not able to source additional capital,
the lack of funds to promote the female condom may significantly limit our
ability to realize value from the sale of such assets or rights or otherwise
capitalize on the investments made in the female condom.
17
BUSINESS
GENERAL
We manufacture, market and sell the female condom around the world. The
female condom is the only FDA-approved product under a woman's control which can
prevent unintended pregnancy and sexually transmitted diseases ("STDs"),
including HIV/AIDS.
The female condom has undergone extensive testing for efficacy, safety and
acceptability, not only in the United States but also in over 50 additional
countries. Several of the studies show that having the female condom available
increases protected sex acts and decreases the incidence of STDs.
The product is currently sold or available in various venues including
commercial sector outlets, public sector clinics and research programs in over
75 countries. It is commercially marketed in 14 countries, including the U.S.,
the U.K., Canada, France and Japan.
In the U.S., the product is marketed to city and state public health
clinics as well as not-for-profit organizations. Under an agreement with the
Joint United Nations Programme on AIDS ("UNAIDS"), UNAIDS facilitates the
availability and distribution of the female condom in the developing world and
we sell the product to developing countries at a reduced price based on the
total number of units purchased. The current price is 38 pence sterling, or
approximately $0.55 per unit. Under this agreement, the product is currently
available in 70 countries with major programs in about 10 countries including
Zimbabwe, Tanzania, Brazil, Uganda, South Africa, Namibia, Ghana and Haiti.
PRODUCT
The female condom is made of polyurethane, a thin but strong material which
is resistant to rips and tears during use. The female condom consists of a
soft, loose fitting sheath and two flexible O rings. One of the rings is used
to insert the device and hold it in place. The other ring remains outside the
vagina after insertion and lines the vagina, preventing skin from touching skin
during intercourse. The female condom is prelubricated and disposable and is
intended for use during one sex act.
GLOBAL MARKET POTENTIAL
Male condom market: It is estimated the global annual market for male
condoms is 5.4 billion units. The major segments are in the Global Public
sector, the U.S., Japan, India and The People's Republic of China. However, the
majority of all acts of sexual intercourse, excluding those intended to result
in pregnancy, are completed without protection. As a result, it is estimated
the potential market for barrier contraceptives is much larger than the
identified male condom market.
HIV/AIDS is an epidemic far more extensive than what was predicted. UNAIDS
and the World Health Organization ("WHO") now estimate that the number of people
living with HIV/AIDS stands at about 36 million, more than 50% higher than WHO's
original projection in 1991 for year end 2000. Further, African countries with
over 80% of the reported cases are experiencing devastating effects to their
economic growth. Gross domestic product in hard-hit countries such as South
Africa is projected to decrease 13% - 22% by 2010. Based on these recently
released figures, UNAIDS has initiated a new strong campaign which brings
together African leaders, public and private donors to immediately address
various aspects to thwart the plague including aggressive and broad education
out-reach prevention programs specifically including female and male condoms.
The focus is also extending to Eastern Europe and Asia as the estimated
number of bases of HIV/AIDS has, according to UNAIDS, exponentially jumped in
the last year. Major prevention and education out-reach programs are being
planned and implemented in these countries.
18
In the United States, the Center for Disease Control and Prevention reports
that one in four Americans has an STD, one in five adults over the age of 12 has
Herpes and 1 in every 3 sexually active people will get an STD by age 24. Women
are currently the fastest growing group infected with HIV and are expected to
comprise the majority of the new cases by the coming year.
Currently, there are only two products that prevent the sexual transmission
of HIV/AIDS and other STDs - the latex male condom and the female condom.
ADVANTAGES VERSUS THE MALE CONDOM
The female condom is currently the only available barrier contraceptive
method controlled by women which allows them to protect themselves against
unintended pregnancy and STDs, including HIV/AIDS. The most important advantage
is that a woman can control whether or not she is protected as many men do not
like to wear male condoms and may refuse to do so.
The polyurethane material that is used for the female condom offers a
number of benefits over latex, the material that is most commonly used in male
condoms. Polyurethane is 40% stronger than latex, reducing the probability that
the female condom sheath will tear during use. Unlike latex, polyurethane
quickly transfers heat, so the female condom immediately warms to body
temperature when it is inserted, which may result in increased pleasure and
sensation during use. The product offers an additional benefit to the 7% to 20%
of the population that is allergic to latex and who, as a result, may be
irritated by latex male condoms. To our knowledge, there is no reported allergy
to date to polyurethane. The female condom is also more convenient, providing
the option of insertion hours before sexual arousal and as a result is less
disruptive during sexual intimacy than the male condom which requires sexual
arousal for application.
COST EFFECTIVENESS
Over the past two years several studies have been completed which show that
providing the female condom in public clinics in both the United States and
countries in the developing world is, at a minimum, cost effective and usually
cost saving. This is important information for governments to have in
determining where their public health dollars are allocated. These studies have
been or are about to be published and also presented at various scientific
meetings around the world.
WORLDWIDE REGULATORY APPROVALS
The female condom received PMA approval as a Class III Medical Device from
the FDA in 1993. The extensive clinical testing and scientific data required
for FDA approval laid the foundation for approvals throughout the rest of the
world, including receipt of a CE Mark in 1997 which allows us to market the
female condom throughout the European Union. In addition to the United States
and the European Union, several other countries have approved the female condom
for sale, including Brazil, Mexico, Canada, The People's Republic of China,
Japan, Russia, and Australia.
We believe that the female condom's PMA approval and FDA classification as
a Class III Medical Device create a significant barrier to entry. We estimate
that it would take a minimum of four to six years to implement, execute and
receive FDA approval of a PMA to market another type of female condom.
We believe there are no material issues or material costs associated with
our compliance with environmental laws related to the manufacture and
distribution of the female condom.
STRATEGY
Our strategy is to act as a manufacturer, selling the female condom to the
global public sector, United States public sector and commercial partners for
country-specific marketing. The public sector and commercial partners assume
the cost of shipping and marketing the product. As a result, as volume
increases, our operating expenses will not increase significantly.
19
COMMERCIAL MARKETS
We have commercial partners which have launched the product in countries,
including the U.S., the U.K., Canada, Japan and France.
RELATIONSHIPS AND AGREEMENTS WITH PUBLIC SECTOR ORGANIZATIONS
Currently, it is estimated more than 1.7 billion male condoms are
distributed worldwide by the public sector each year. The female condom is seen
as an important addition to prevention strategies by the public sector because
studies show that the availability of the female condom decreases the amount of
unprotected sex by as much as one-third over offering only a male condom.
We have a multi-year agreement with UNAIDS to supply the female condom to
developing countries at a reduce price which is negotiated each year based on
our cost of production. The current price per unit is approximately 0.38
(pounds) or $0.55.
In the United States, the product is marketed to city and state public
health clinics, as well as not-for-profit organizations. The female condom is
available in all 50 states with major programs in the states of New York,
Florida, California, Louisiana, Maryland, New Jersey, South Carolina and
Illinois and the cities of Chicago, Philadelphia, New York and Houston. All
major cities and states have reordered product after their initial shipments.
STATE-OF-THE-ART MANUFACTURING FACILITY
We manufacture the female condom in a 40,000 square foot leased facility in
London, England. The facility is currently capable of producing 60 million
units per year. With additional equipment, this capacity can be significantly
increased.
GOVERNMENT REGULATION
In the U.S., the female condom is regulated by the FDA. Section 515(a)(3)
of the Safe Medical Amendments Act of 1990 authorizes the FDA to temporarily
suspend approval and initiate withdrawal of the PMA if the FDA finds that the
female condom is unsafe or ineffective, or on the basis of new information with
respect to the device, which, when evaluated together with information available
at the time of approval, indicates a lack of reasonable assurance that the
device is safe or effective under the condition of use prescribed, recommended
or suggested in the labeling. Failure to comply with the conditions of FDA
approval invalidates the approval order. Commercial distribution of a device
that is not in compliance with these conditions is a violation of the Safe
Medical Amendments Act of 1990.
COMPETITION
The female condom competes in part with male condoms. Latex male condoms
cost less and have brand names that are more widely recognized than the female
condom. In addition, male condoms are generally manufactured and marketed by
companies with significantly greater financial resources than we have. It is
also possible that other parties may develop a female condom. Competing
products could be manufactured, marketed and sold by companies with
significantly greater financial resources than we have.
EMPLOYEES
As of September 30, 2001, we had 89 full-time employees within the U.S. and
the U.K. and one part-time employee. None of our employees are represented by a
labor union. We believe that our employee relations are good.
BACKLOG
At September 30, 2001, we had unfilled orders of $0.8 million. The
comparable amount as of the same date of the prior year was $0.4 million. All
of these unfilled orders are expected to be filled during fiscal 2001. The
unfilled orders are a result of requested shipping dates from our customers
rather than delays in manufacturing.
20
PATENTS AND TRADEMARKS
We currently hold product and technology patents in the United States,
Japan, the United Kingdom, France, Italy, Germany, Spain, the European Patent
Convention, Canada, The People's Republic of China, New Zealand, Singapore, Hong
Kong and Australia. These patents expire between 2005 and 2013. Due to a
change in patent regulations, the U.S. product patent, which formerly expired on
April 14, 2005, has had its expiration extended to April 14, 2007 providing us
with two additional years of protection. Additional product and technology
patents are pending in Brazil, South Korea, Germany, Japan and several other
countries. The patents cover the key aspects of the female condom, including
its overall design and manufacturing process. We recently began distribution of
the product in the United States under the new trademark "FC female condom" and
we plan to end our license for the trademark "Reality" in the United States. We
made this change because we wish to introduce commonality across countries as
the product is most often referred to as "the female condom." We hold other
trademarks on the names "femidom" and "femy" in a number of foreign countries.
We have also secured, or applied for, 27 trademarks in 14 countries to protect
the various names and symbols used in marketing the product around the world.
In addition, the experience that has been gained through years of manufacturing
the female condom has allowed us to develop trade secrets and know-how,
including proprietary production technologies, that further secure our
competitive position.
RESEARCH AND DEVELOPMENT
We had research and development costs from continuing operations of
$67,099 in fiscal 2000 and $122,196 in fiscal 1999. These expenditures were
primarily related to conducting acceptability studies and analyzing second
generation products. We did not have any research and development costs from
continuing operations for the nine months ended June 30, 2001.
INDUSTRY SEGMENTS AND FINANCIAL INFORMATION ABOUT FOREIGN AND DOMESTIC
OPERATIONS
See Note 11 to Notes to Consolidated Financial Statements, included
elsewhere in this prospectus.
HISTORY
The female condom was invented by a Danish physician who obtained a U.S.
patent for the product in 1988. The physician subsequently sold rights to the
female condom to Chartex Resources Limited. In the years that followed,
Chartex, with resources provided by a nonprofit Danish foundation, developed the
manufacturing processes and completed other activities associated with bringing
the female condom to market in a number of non-U.S. countries. Wisconsin
Pharmacal Company, Inc., which then had a license from Chartex to the female
condom in the U.S., Canada and Mexico, pursued the pre-clinical and clinical
studies and overall development of the product for worldwide use and U.S. FDA
approval of the product.
We are the successor to Wisconsin Pharmacal Company, Inc., a company which
previously manufactured and marketed a wide variety of disparate specialty
chemical and branded consumer products in addition to licensing rights to the
female condom described above.
In fiscal 1995, our Board of Directors approved a plan to complete a series
of actions designed, in part, to maximize the potential of the female condom.
First, we restructured and transferred all of our assets and liabilities, other
than those related primarily to the female condom, to a newly-formed,
wholly-owned subsidiary, WPC Holdings, Inc. In January 1996, we sold WPC
Holdings to an unrelated third party. Then, in February 1996, we acquired
Chartex, renamed The Female Health Company - UK in 1997, the manufacturer and
owner of worldwide rights to, and our then sole supplier of, the female condom.
As a result of the sale of WPC Holdings and the acquisition of Chartex, we
evolved to our current state with our sole business consisting of the
manufacture, marketing and sale of the female condom.
The FDA approved the female condom for distribution in 1993 and our
manufacturing facility in 1994. Since that time, we have sold over 39 million
female condoms around the world.
21
PROPERTIES
We lease approximately 3,000 square feet of office space at 515 North State
Street, Suite 2225, Chicago, Illinois 60610 under a lease that expires in 2006.
We utilize warehouse space and sales fulfillment services of an independent
public warehouse located near Minneapolis, Minnesota, for storage and
distribution of the female condom. We manufacture the female condom in a 40,000
square foot leased facility located in London, England under a lease that
expires in 2015. The FDA-approved manufacturing process is subject to periodic
inspections by the FDA as well as the European Union quality group. Current
capacity at the manufacturing facility is approximately 60 million female
condoms per year. We believe the properties are adequately insured.
LEGAL PROCEEDINGS
We are not currently involved in any material pending legal proceedings.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We file reports, proxy statements and other information with the Securities
and Exchange Commission. You may read and copy any reports, proxy statements or
other information we file at the SEC's public reference room at 450 Fifth
Street, N.W., Washington, D.C. You can obtain information concerning the
operation of the public reference rooms by calling the SEC at 1-800-SEC-0330.
In addition, we have filed the registration statement of which this prospectus
is a part and other filings with the SEC through its EDGAR system, and our
filings are publicly available through the SEC's site on the World Wide Web on
the Internet located at www.sec.gov.
This prospectus does not contain all of the information in the registration
statement of which this prospectus is a part and which we have filed with the
SEC. For further information about us and the securities offered by this
prospectus, you should review the registration statement, including the exhibits
filed as a part of the registration statement, at the public reference rooms.
We may update information about us by filing appendices or supplements to this
prospectus.
22
MANAGEMENT
DIRECTORS AND EXECUTIVE OFFICERS
Our directors and executive officers as of September 30, 2001 are as
follows:
NAME TITLE AGE
O.B. Parrish Chairman of the Board, Chief Executive Officer 68
and Director
Mary Ann Leeper, Ph.D. President, Chief Operating Officer and Director 61
Jack Weissman Vice President-Trade Sales 53
Michael Pope Vice President, General Manager of The Female 45
Health Company (UK) Plc.
Mitchell Warren Vice President-International Affairs 35
Robert R. Zic Principal Accounting Officer 38
William R. Gargiulo, Jr. Secretary and Director 73
David R. Bethune Director 61
Stephen M. Dearholt Director 55
Michael R. Walton Director 64
James R. Kerber Director 69
Richard E. Wenninger Director 54
Mr. Parrish has served as our Chief Executive Officer since 1994, and as
our Chairman of the Board and a Director since 1987. Mr. Parish also served as
our acting Chief Financial Officer and Accounting Officer from February 1996 to
March 1999. Mr. Parrish is a shareholder and has served as the President and as
a Director of Phoenix Health Care of Illinois, Inc. since 1987. Phoenix Health
Care of Illinois owns approximately 295,000 shares of our common stock. Mr.
Parrish also was the Co-Chairman and a Director of Inhalon Pharmaceuticals, Inc.
until its sale to Medeva Plc, and is Chairman and a Director of ViatiCare,
L.L.C., a financial services company, Chairman and a Director of MIICRO, Inc., a
neuroimmaging company, and a Director of Amerimmune Pharmaceuticals, Inc. Mr.
Parrish is also a trustee of Lawrence University. From 1977 until 1986, Mr.
Parrish was the President of the Global Pharmaceutical Group of G.D. Searle &
Co., a pharmaceutical/consumer products company. From 1974 until 1977, Mr.
Parrish was the President of Searle International, the foreign sales operation
of Searle. Prior to that, Mr. Parrish was Executive Vice President of Pfizer's
International Division.
Dr. Leeper has served as our President and Chief Operating Officer since
1996, as a Director since 1987, as President and Chief Executive Officer of The
Female Health Company division from May 1994 until January 1996 and as our
Senior Vice President - Development from 1989 until January 1996. Dr. Leeper is
a shareholder and has served as a Vice President and Director of Phoenix Health
Care of Illinois since 1987. From 1981 until 1986, Dr. Leeper served as Vice
President - Market Development for Searle's Pharmaceutical Group and in various
Searle research and development management positions. As Vice President -
Market Development for Searle's Pharmaceutical Group, Dr. Leeper was
23
responsible for worldwide licensing and acquisition, marketing and market
research. In earlier positions, she was responsible for preparation of new drug
applications and was a liaison with the FDA. Dr. Leeper currently serves on the
Board of Directors of the Temple University School of Pharmacy and on the Board
of Directors of the Northwestern University School of Music. She is on the
Board of CEDPA, an international not-for-profit organization working on women's
issues in the developing world. Dr. Leeper is also a director of Influx, Inc.,
a pharmaceutical research company.
Mr. Weissman has served as our Vice President-Trade Sales since June 1995.
From 1992 until 1994, Mr. Weissman was Vice President - Sales for Capitol
Spouts, Inc., a manufacturer of pouring spouts for gable paper cartons. From
1989 to 1992, Mr. Weissman acted as General Manager - HTV Group, an investment
group involved in the development of retail stores. Mr. Weissman joined
Searle's consumer products group in 1979 and held positions of increasing
responsibility, including National Account Manager and Military Sales Manager.
From 1985 to 1989, Mr. Weissman was Account Manager - Retail Business
Development, for the NutraSweet Company, a Searle subsidiary. Prior to Searle,
Mr. Weissman worked in the consumer field as Account Manager and Territory
Manager for Norcliff Thayer and Whitehall Laboratories.
Mr. Pope has served as our Vice President since 1996 and as General Manager
of The Female Health Company (UK) Plc., formerly Chartex International, Plc.,
since our 1996 acquisition of Chartex. Mr. Pope has also served as a Director
of The Female Health Company, Ltd., formerly Chartex Resources Limited, and The
Female Health Company (UK) Plc. since 1995. From 1990 until 1996, Mr. Pope was
Director of Technical Operations for Chartex with responsibility for
manufacturing, engineering, process development and quality assurance. Mr. Pope
was responsible for the development of the high speed proprietary manufacturing
technology for the female condom and securing the necessary approvals of the
manufacturing process by regulatory organizations, including the FDA. Mr. Pope
was also instrumental in developing and securing Chartex's relationship with its
Japanese marketing partner. Prior to joining Chartex, from 1986 to 1990, Mr.
Pope was Production Manager and Technical Manager for Franklin Medical, a
manufacturer of disposable medical devices. From 1982 to 1986, Mr. Pope was
Site Manager, Engineering and Production Manager, Development Manager and
Silicon Manager for Warne Surgical Products.
Mr. Warren has served as our Vice President - International Affairs since
February 2000 and as our Director of International Affairs from January 1999 to
February 2000. From 1993 to 1998, Mr. Warren was employed by Population
Services International (PSI), an international social marketing and
communications organization, first as Executive Director of PSI/South Africa and
then of PSI/Europe. From 1989 to 1993, Mr. Warren was Program Director of
Medical Education for South African Blacks.
Mr. Zic has served as our Principal Accounting Officer since March 1999.
From 1998 to 1999, Mr. Zic held the dual positions of Acting Controller and
Acting Chief Financial Officer at Ladbroke's Pacific Racing Association. From
1995 to 1998, Mr. Zic served as the Chief Accounting Manager and Assistant
Controller at Argonaut Insurance Company. In this capacity, he was responsible
for the financial and accounting operations at Argonaut's ten divisions and the
external and internal financial reporting of Argonaut and its four subsidiaries.
From 1990 to 1994, Mr. Zic was the Assistant Controller of CalFarm Insurance
Company, where he was responsible for the company's external financial reporting
duties. From 1988 to 1990, Mr. Zic was a Senior Accountant responsible for the
statutory-based financials of Allstate Insurance Company. Mr. Zic's career
began in 1986 as an auditor with Arthur Andersen & Co.
Mr. Gargiulo has served as a Director since 1987, as our Secretary since
1996, as our Vice President from 1996 to September 30, 1998, as our Assistant
Secretary from 1989 to 1996, as Vice President International of The Female
Health Company Division from 1994 until 1996, as our Chief Operating Officer
from 1989 to 1994, and as our General Manager from 1988 to 1994. Mr. Gargiulo
is a Trustee of a trust which is a shareholder of Phoenix Health Care of
Illinois. From 1984 until 1986, Mr. Gargiulo was the Executive Vice President
of the Pharmaceutical Group of G.D. Searle & Co., in charge of Searle's European
operations. From 1976 until 1984, Mr. Gargiulo was the Vice President of
Searle's Latin American operations.
Mr. Bethune has served as a Director since January 1996. Mr. Bethune has
been Chairman and Chief Executive Officer of Atrix Laboratories since 1999. From
1997 to 1998, Mr. Bethune held the position of President and Chief Operating
Officer of the IVAX Corporation. From 1996 to 1997, Mr. Bethune was a consultant
to the pharmaceutical industry. From 1995 to 1996, Mr. Bethune was President and
Chief Executive Officer of Aesgen, Inc., a generic pharmaceutical company. From
1992 to 1995, Mr. Bethune was Group Vice President of American Cyanamid Company
24
and a member of its Executive Committee until the sale of the company to
American Home Products. He had global executive authority for human
biologicals, consumer health products, pharmaceuticals and opthalmics, as well
as medical research. Mr. Bethune is on the Board of Directors of the Southern
Research Institute, Atrix Pharmaceuticals and the American Foundation for
Pharmaceutical Education, Partnership for Prevention. He is a founding trustee
of the American Cancer Society Foundation and an associate member of the
National Wholesale Druggists' Association and the National Association of Chain
Drug Stores. He is the founding chairman of the Corporate Council of the
Children's Health Fund in New York City and served on the Arthritis Foundation
Corporate Advisory Council.
Mr. Dearholt has served as a Director since April 1996. Mr. Dearholt is a
co-founder of and has been a partner in Insurance Processing Center, Inc., one
of the largest privately owned life insurance marketing organizations in the
United States, since 1972. He has over 23 years of experience in direct
response advertising and database marketing of niche products. Since 1985, he
has been a 50% owner of R.T. of Milwaukee, a private investment holding company
which operates a stock brokerage business in Milwaukee, Wisconsin. In late
1995, Mr. Dearholt arranged, on very short notice, a $1 million bridge loan
which assisted us in our purchase of Chartex. Mr. Dearholt is also very active
in the nonprofit sector. He is currently on the Board of Directors of
Children's Hospital Foundation of Wisconsin, an honorary board member of the
Zoological Society of Milwaukee, and the national Advisory Council of the
Hazelden Foundation. He is a past board member of Planned Parenthood
Association of Wisconsin, and past Chairman of the Board of the New Day Club,
Inc.
Mr. Walton has served as a Director since April 1999. Mr. Walton is
President and owner of Sheboygan County Broadcasting Co., Inc., a company he
founded in 1972. In addition to its financial assets, Sheboygan County
Broadcasting Co. currently owns four radio stations. The company has focused on
start-up situations, and growing value in underperforming, and undervalued
business situations. It has purchased and sold properties in Wisconsin,
Illinois and Michigan. Prior to 1972, Mr. Walton was owner and President of
Walton Co., an advertising representative firm which he founded in New York
City. He has held sales and management positions with Forbes Magazine, The
Chicago Sun Times and Gorman Publishing Co., a trade magazine publisher
specializing in new magazines which was subsequently sold to a large
international publishing concern. Mr. Walton has served on the Boards of the
American Red Cross, the Salvation Army and the Chamber of Commerce.
Mr. Kerber has served as a Director since April 1999. Mr. Kerber has been
a business consultant to the insurance industry since January 1996. He has over
40 years of experience in operating insurance companies, predominantly those
associated with life and health. From October 1994 until January 1996, he was
Chairman, President, Chief Executive Officer and director of the 22 life and
health insurance companies which comprise the ICH Group. In 1990, Mr. Kerber
was founding partner in the Life Partners Group where he was Senior Executive
Vice President and a director. Prior to that, he was involved with operating
and consolidating over 200 life and health companies for ICH Corporation, HCA
Corporation and US Life Corporation.
Mr. Wenninger has served as a Director since July 2001. Mr. Wenninger has
served as President and Chief Executive Officer of Wenninger Company, Inc., a
mechanical contracting and engineering company, since 1976. He is also
Secretary of Wenn Soft, Inc., a software development, sales and service company
he founded in 1990, and President of WENNREAL, LLC, a real estate company he
founded in 1997. From 1992 to 1999, Mr. Wenninger served as Secretary of
Liftco, Inc. Mr. Wenninger is a current board member of the Boys & Girls Club
of Milwaukee, a former President and board member of the Milwaukee Athletic
Club, a former board member of the Wisconsin Psychoanalytic Foundation, a former
board member of University Lake School, the former President and a current board
member of the Plumbing and Mechanical Contractors Association of Milwaukee, the
former President and a former board member of the Sheet Metal Contractors
Association of Milwaukee and a former board member of the Mechanical Contractors
Association of America.
EXECUTIVE COMPENSATION
SUMMARY COMPENSATION TABLE
The table below gives information for each of our last three fiscal years
regarding all annual, long-term and other compensation paid by us to our chief
executive officer and the only executive officer whose total annual salary and
bonus exceeded $100,000 for services rendered during the fiscal year ended
September 30, 2001. The individuals listed in this table are referred to
elsewhere in this prospectus as the "named executive officers."
25
ANNUAL LONG-TERM COMPENSATION
COMPENSATION AWARDS
------------- -------------------------
RESTRICTED SECURITIES
NAME AND STOCK UNDERLYING
PRINCIPAL FISCAL SALARY AWARDS OPTIONS/SARS
POSITION YEAR ($) ($) (#)
- ---------------------- ------ ------------- ---------- -------------
O.B. Parrish . . . . . 2001 90,000 -- --
Chairman and . . . . 2000 90,000 -- --
Chief Executive. . . 1999 90,000 -- 200,000
Officer
Mary Ann Leeper, Ph.D. 2001 225,000 -- --
President and. . . . 2000 225,000 -- --
Chief Operating. . . 1999 225,000 -- 500,000
Officer
OPTION GRANTS DURING LAST FISCAL YEAR
No stock options were granted to the named executive officers during the
fiscal year ended September 30, 2001.
FISCAL YEAR-END OPTION/SAR VALUES
The following table sets forth the number and value of unexercised options
held by the named executive officers at September 30, 2001:
NUMBER OF SECURITIES UNDERLYING VALUE OF UNEXERCISED IN-
UNEXERCISED OPTIONS AT THE-MONEY OPTIONS AT
FISCAL YEAR END FISCAL YEAR-END
NAME EXERCISABLE/UNEXERCISABLE EXERCISABLE/UNEXERCISABLE
- ---------------------- ------------------------------- --------------------------
O.B. Parrish 88,000/376,000 $ 0/0
Mary Ann Leeper, Ph.D. 96,667/693,333 $ 0/0
EMPLOYMENT AGREEMENTS
We entered into an employment agreement with Dr. Leeper effective May 1,
1994. The original term of Dr. Leeper's employment extended to April 30, 1997
and after April 30, 1997 her employment term renews automatically for additional
three-year terms unless notice of termination is given. The employment
agreement has automatically renewed for a term ending on April 30, 2003. We may
terminate the employment agreement at any time for cause. If Dr. Leeper's
employment is terminated without cause, we are obligated to continue to pay Dr.
Leeper her base salary and any bonus to which she would otherwise have been
entitled for a period equal to the longer of two years from date of termination
or the remainder of the then applicable term of the employment agreement. In
addition, we are obligated to continue Dr. Leeper's participation in any of our
health, life insurance or disability plans in which Dr. Leeper participated
prior to her termination of employment. Dr. Leeper's employment agreement
provided for a base salary of $175,000 for the first year of her employment
term, $195,000 for the second year of her employment term and $225,000 for the
third year of her employment term, subject to the achievement of performance
goals established by Dr. Leeper and the Board of Directors. If the employment
agreement is renewed beyond the initial three-year term, it requires her base
salary to be increased annually by the Board of Directors based upon her
performance and any other factors that the Board of Directors considers
appropriate. For fiscal 1998 and 1999, Dr. Leeper's base salary was $225,000
per year. The employment agreement also provides Dr. Leeper with various fringe
benefits including an annual cash bonus of up to 100% of her base salary. The
Board of Directors may award the cash bonus to Dr. Leeper in its discretion. To
date, Dr. Leeper has not been awarded a cash bonus.
26
CHANGE OF CONTROL AGREEMENTS
In fiscal 1999, we entered into Change of Control Agreements with each of
O.B. Parrish, our Chairman and Chief Executive Officer, Mary Ann Leeper, our
President and Chief Operating Officer, and Michael Pope, our Vice President. In
fiscal 2000, we entered into a Change of Control Agreement with Mitchell Warren,
our Vice President - International Affairs. These agreements essentially act as
springing employment agreements which provide that, upon a change of control, as
defined in the agreement, we will continue to employ the executive for a period
of three years in the same capacities and with the same compensation and
benefits as the executive was receiving prior to the change of control, in each
case as specified in the agreements. If the executive is terminated without
cause or if he or she quits for good reason, in each case as defined in the
agreements, after the change of control, the executive is generally entitled to
receive a severance payment from us equal to the amount of compensation
remaining to be paid to the executive under the agreement for the balance of the
three-year term.
27
PRINCIPAL SHAREHOLDERS
The following table provides information regarding the beneficial ownership
of our common stock as of September 30, 2001 by:
- each person known by us to be the beneficial owner of more than 5% of
our common stock;
- each director;
- each named executive officer; and
- all directors and executive officers as a group.
We have determined beneficial ownership in accordance with the rules of the
Securities and Exchange Commission. Unless otherwise indicated, the persons and
entities included in the table have sole voting and investment power with
respect to all shares beneficially owned, except to the extent authority is
shared by spouses under applicable law. Shares of common stock subject to
options that are either currently exercisable or exercisable within 60 days of
September 30, 2001, and shares of common stock subject to the conversion of
preferred stock or convertible debentures outstanding as of September 30, 2001,
are treated as outstanding and beneficially owned by the holder for the purpose
of computing the percentage ownership of the holder. However, these shares are
not treated as outstanding for the purpose of computing the percentage ownership
of any other person.
SHARES
BENEFICIALLY OWNED
----------------------------
NAME NUMBER PERCENT
- --------------------------------- ------------- -------------
O.B. Parrish (1) 920,501 5.7%
Mary Ann Leeper, Ph.D. (1) 462,068 2.9
William R. Gargiulo, Jr. (1) 352,168 2.2
David R. Bethune (2) 50,000 *
Michael R. Walton (3) 539,900 3.4
James R. Kerber (4) 573,710 3.6
Stephen M. Dearholt (5) 4,158,083 22.6
Richard E. Wenninger (6) 3,346,941 19.4
Gary O. Benson (7) 1,680,450 9.8
All directors and executive
officers as a group (12 persons)
(1)(3)(4)(5)(6)(8) 9,784,369 46.0
__________
* Less than 1%.
(1) Includes 294,501 shares owned by Phoenix Health Care of Illinois and 30,000
shares under option to Phoenix Health Care of Illinois. Under the rules of
the Securities and Exchange Commission, Messrs. Parrish and Gargiulo and
Dr. Leeper may share voting and dispositive power as to these shares since
Mr. Gargiulo is a trustee of a trust which is a shareholder, and Mr.
Parrish and Dr. Leeper are officers, directors and shareholders, of Phoenix
Health Care of Illinois. For Dr. Leeper, also includes 40,900 shares owned
by her and 96,667 shares under option to her; for Mr. Parrish, also
includes 71,500 shares owned by him, 36,500 shares under warrants to him,
88,000 shares under option to him and 400,000 shares under warrants held by
the Geneva O. Parrish 1996 Living Trust of which Mr. Parrish is beneficiary
and for which Mr. Parrish may be deemed to share voting and investment
power; and for Mr. Gargiulo, also includes 10,500 shares owned by him,
16,667 shares under option to him and 500 shares held by
28
the William R. Gargiulo 1991 Convertible Trust of which Mr. Gargiulo and
his spouse are the trustees and share voting and investment power over such
shares.
(2) Represents options which are currently exercisable.
(3) Includes 200,000 shares of our common stock owned directly by Mr. Walton,
155,999 shares of preferred stock owned by Mr. Walton, warrants to purchase
30,900 shares owned by Mr. Walton and 153,001 shares of preferred stock
held by a trust of which Mr. Walton is trustee.
(4) Includes 30,000 shares of common stock subject to exercise of options and
200,000 shares of common stock subject to exercise of warrants. The
warrants have been pledged to a bank to secure a guarantee by Mr. Kerber on
our behalf.
(5) Includes 733,605 shares owned directly by Mr. Dearholt. Also includes
69,500 shares held by the Dearholt, Inc. Profit Sharing Plan; 9,680 shares
held by Response Marketing Money Purchase Plan; 13,700 shares held in a
self-directed IRA; 162,898 shares held by the Mary C. Dearholt Trust of
which Mr. Dearholt, a sibling and his mother are trustees; 18,100 shares
held by Mr. Dearholt's minor child; 418,100 shares held by the John W.
Dearholt Trust of which Mr. Dearholt is a co-trustee with a sibling; and
60,000 shares of preferred stock held by the Mary C. Dearholt Trust, of
which Mr. Dearholt, a sibling and his mother are trustees, that are
convertible share-for-share into our common stock. Mr. Dearholt shares the
power to vote and dispose of 640,998 shares of common stock (including
60,000 shares of preferred stock convertible into common stock) held by the
Mary C. Dearholt Trust and the John W. Dearholt Trust. Mr. Dearholt has
sole power to vote and dispose of the remaining shares of common stock,
except that North Central Trust has the sole power to vote and dispose of
the 9,680 shares of common stock held by the Response Marketing Money
Purchase Plan. Also includes warrants to purchase 2,622,500 shares of
common stock (of which warrants to purchase up to 1,100,000 shares have
been pledged to a bank to secure a guarantee executed by Mr. Dearholt on
behalf of us) and options to purchase 50,000 shares.
(6) Includes (a) 500,000 shares of common stock subject to conversion of a
convertible debenture due March 30, 2004 (based upon $250,000 of principal
under such convertible debenture, divided by the conversion rate of $0.50),
(b) 5,000 shares of common stock held by Mr. Wenninger's spouse (Mr.
Wenninger disclaims beneficial ownership of the shares held by his spouse),
and (c) 1,100,000 shares of common stock subject to exercise of warrants,
consisting of a warrant to purchase 100,000 shares and a warrant to
purchase a maximum of 1,000,000 shares. The warrants described in (c) above
have been pledged to a bank to secure a guarantee executed by Mr. Wenninger
on our behalf.
(7) Includes warrants to purchase 1,500,000 shares of common stock.
(8) Includes 50,000 shares under option held by Mr. Bethune.
29
RELATED PARTY TRANSACTIONS
On February 18, 1999, we borrowed $50,000 from O.B. Parrish, our Chairman
and Chief Executive Officer. The borrowing was completed through the execution
of a $50,000, one-year promissory note payable by us to Mr. Parrish and a Note
Purchase and Warrant Agreement and Stock Issuance Agreement. Mr. Parrish was
granted warrants to purchase 10,000 shares of our common stock at an exercise
price of $1.35 per share. The exercise price of the warrants equaled 80% of the
average market price of our common stock for the five trading days prior to the
date of issuance. The warrants expire upon the earlier of their exercise or
nine years after the date of their issuance. Effective February 18, 2000, we
extended the due date of the note to February 18, 2001, and in connection with
this extension, we issued to Mr. Parrish warrants to purchase 12,500 shares of
our common stock at an exercise price of $0.72 per share, which equaled 80% of
the average market price of our common stock for the five trading days prior to
the date of issuance. Effective February 18, 2001, we extended the due date of
the note to February 18, 2002, and in connection with this extension, we issued
to Mr. Parrish warrants to purchase 14,000 shares of our common stock at an
exercise price of $0.40 per share, which equaled 75% of the average market price
of our common stock for the fair trading days prior to the date of issuance.
The warrants expire upon the earlier of their exercise or ten years after the
date of their issuance. We also granted Mr. Parrish securities registration
rights for any common stock he receives from us under these warrants or the
Stock Issuance Agreement. We subsequently repaid this note in full.
On February 12, 1999, we borrowed $250,000 from Mr. Dearholt. The
borrowing was completed through the execution of a $250,000, one-year promissory
note payable by us to Mr. Dearholt. As part of this transaction, we entered
into a Note Purchase and Warrant Agreement and a Stock Issuance Agreement. Mr.
Dearholt received a warrant to purchase 50,000 shares of our common stock at an
exercise price of $1.248 per share. The exercise price of the warrants equaled
80% of the average market price of our common stock for the five trading days
prior to the date of issuance. The warrants expire upon the earlier of their
exercise or nine years after the date of their issuance. Effective February 12,
2000, we extended the due date of the note to February 12, 2001, and in
connection with this extension, we issued to Mr. Dearholt warrants to purchase
62,500 shares of our common stock at an exercise price of $0.77 per share, which
equaled 80% of the average market price of our common stock for the five trading
days prior to the date of issuance. Effective February 12, 2001, we extended
the due date of the note to February 12, 2002, and, in connection with this
extension, we issued to Mr. Dearholt warrants to purchase 70,000 shares of our
common stock at an exercise price of $0.40 per share, which equaled 75% of the
average market price of our common stock for the five trading days prior to the
date of issuance. The warrants expire upon the earlier of their exercise or ten
years after the date of their issuance. We also granted Mr. Dearholt securities
registration rights for any common stock he receives from us under these
warrants or the Stock Issuance Agreement. We subsequently repaid this note in
full.
On March 25, 1997, 1998, 1999, 2000 and 2001, we extended a $1 million,
one-year promissory note payable by us to Mr. Dearholt for a previous loan Mr.
Dearholt made to us. The promissory note is now payable in full on March 25,
2002 and bears interest at 12% annually, payable monthly. The borrowing
transactions were effected in the form of a promissory note from us to Mr.
Dearholt and related Note Purchase and Warrant Agreements and a Stock Issuance
Agreement. Under the 1997, 1998 and 1999 Note Purchase and Warrant Agreements,
we issued to Mr. Dearholt warrants to purchase 200,000 shares of common stock in
1997 at an exercise price of $1.848 per share, 200,000 shares of common stock in
1998 at an exercise price of $2.25 per share and 200,000 shares of common stock
in 1999 at an exercise price of $1.16 per share. In connection with the
extension of the note to March 25, 2001, we issued warrants to purchase 250,000
shares of our common stock in 2000 at an exercise price of $0.71 per share. In
connection with the extension of the note to March 25, 2002, we issued warrants
to purchase 280,000 shares of our common stock in 2001 at an exercise price of
$0.45 per share. In each case, the exercise price of the warrants equaled 80%
of the market price of our common stock on the date of issuance. The warrants
expire upon the earlier of their exercise or on March 25, 2005 for the warrants
issued in 1997, March 25, 2007 for the warrants issued in 1998, March 25, 2009
for the warrants issued in 1999, March 25, 2010 for the warrants issued in 2000,
and March 25, 2011 for the warrants issued in 2001. Under the Stock Issuance
Agreement, if we fail to pay the $1 million under the note when due, we must
issue 200,000 shares of our common stock to Mr. Dearholt. This issuance will
not, however, alleviate our liability under the note. We also granted Mr.
Dearholt securities registration rights for any common stock he receives from us
under these warrants or the Stock Issuance Agreement. In consideration of Mr.
Dearholt's agreement to extend the note's due date to March 25, 2000, we
extended the expiration date of warrants held by Mr. Dearholt to purchase
200,000 shares of our common stock from March 25, 2001 to March 25, 2002.
30
On September 24, 1999, we completed a private placement of 666,671 shares
of our common stock to various investors at a purchase price of $0.75 per share,
representing a discount of 12% from the closing price of a share of our common
stock on the Over the Counter Bulletin Board on that date. Stephen M. Dearholt,
one of our directors, purchased 266,667 shares for $200,000 in this private
placement. The terms of Mr. Dearholt's purchase were identical to the terms
offered to the other, unrelated investors. As part of this private placement,
we granted all of the investors, including Mr. Dearholt, registration rights
which require that we register the investors' resale of these shares.
On June 14, 2000, we completed a private placement of 400,000 shares of our
common stock to The John W. Dearholt Trust at a price of $0.50 per share,
representing a discount of 6% from the closing price of our common stock on the
Over the Counter Bulletin Board on that date. Stephen M. Dearholt is a
co-trustee of this trust. As part of this private placement, we granted the
investor registration rights which require that we register the investor's
resale of those shares.
We entered into a loan agreement on May 18, 2001, providing for a
three-year loan commitment from a bank of up to $2,000,000. We may borrow under
this loan agreement from time to time subject to a number of conditions,
including obtaining personal guarantees of 125% of the amount outstanding under
the loan. In May 2001, we borrowed a total of $1.5 million under this loan
agreement. Five persons provided guarantees equal in total to the $1.5 million
outstanding under the loan. The guarantors included James R. Kerber, a member
of our board of directors, Stephen M. Dearholt, a member of our board of
directors, Richard E. Wenninger, a member of our board of directors, and a trust
for the benefit of O.B. Parrish, our Chairman of the Board and Chief Executive
Officer. Each guarantor may be liable to the lender for up to 125% of the
guarantor's guarantee amount if we default under the loan. We issued warrants
to the guarantors to purchase the number of shares of our common stock equal to
the guarantee amount of such guarantor divided by the warrant purchase price as
of the date of exercise. The warrant purchase price is the price per share
equal to 70% of the market price of our common stock at the time of exercise,
but in no event will the warrant purchase price be less than $0.50 per share or
more than $1.00 per share. We also issued additional warrants to purchase
100,000 shares of our common stock at an exercise price of $0.50 per share to
each of Stephen M. Dearholt and Richard E. Wenninger because each of them
guaranteed $500,000 under the loan. We granted all of the guarantors
registration rights which require that we register the shares of common stock
underlying the warrants. The registration statement, of which this prospectus
is a part, registers the guarantors' resale from time to time of those shares.
Effective March 30, 2001, we issued a $250,000 convertible debenture to
Richard E. Wenninger. Mr. Wenninger subsequently became a member of our board
of directors in July 2001. The convertible debenture bears interest at 12% per
annum and has a three-year term. Mr. Wenninger may convert the convertible
debenture into common stock at any time based on a conversion rate of $0.50 per
share.
In August 2001, we issued 1,000,000 shares of common stock to Richard E.
Wenninger for a total purchase price of $500,000. We granted Mr. Wenninger
registration rights which require that we register the shares of common stock we
issued to Mr. Wenninger. The registration statement, of which this prospectus
is a part, registers Mr. Wenninger's resale from time to time of those shares.
It has been and currently is our policy that transactions between us and
our officers, directors, principal shareholders or affiliates are to be on terms
no less favorable to us than could be obtained from unaffiliated parties. We
intend that any future transactions between us and our officers, directors,
principal shareholders or affiliates will be approved by a majority of the
directors who are not financially interested in the transaction.
31
DESCRIPTION OF CAPITAL STOCK
Our authorized capital stock consists of 27 million shares of common stock,
$.01 par value per share and 5 million shares of Class A Preferred Stock, $.01
par value per share. The Class A Preferred Stock may be issued in series, at
any times and with any terms, that the Board of Directors considers appropriate.
To date, the Board of Directors has authorized for issuance 1,040,000 shares of
Class A Preferred Stock--Series 1, of which 660,000 shares are currently
outstanding and 1,500,000 shares of Class A Preferred Stock--Series 2, of which
no shares are currently issued and outstanding since the 729,927 shares of Class
A Preferred Stock--Series 2 which were previously issued have all converted into
a like number of shares of common stock. Our Amended and Restated Articles of
Incorporation provide that any shares of Class A Preferred Stock which are
issued and subsequently converted into common stock may not be reissued.
Accordingly, we currently have 2,460,000 shares of Class A Preferred Stock
authorized and available for issuance in series designated by the Board.
COMMON STOCK
Holders of common stock are entitled to one vote for each share held of
record on all matters to be voted on by the shareholders. Subject to the prior
rights of the holders of Class A Preferred Stock, as described below, holders of
common stock are entitled to receive dividends when and as declared by the Board
of Directors out of funds legally available for the payment of dividends. Upon
liquidation or dissolution, holders of common stock are entitled to share, based
on the number of shares owned, in our remaining assets which may be available
for distribution after payment of our creditors and satisfaction of any accrued
but unpaid dividends on the Class A Preferred Stock and the liquidation
preferences, if any, of the Class A Preferred Stock. Holders of common stock
have no preemptive, subscription or redemption rights. The common stock has no
cumulative voting rights. As a result, holders of more than 50% of the
outstanding shares of common stock can elect all of our directors.
All outstanding shares of common stock are fully paid and nonassessable.
Wisconsin law, however, may make our shareholders personally liable for unpaid
wages due employees for up to six months' services, but not in an amount greater
than the par value of the shares.
CLASS A PREFERRED STOCK
The Board of Directors is authorized, subject to the limitations described
below, to issue from time to time, without shareholder authorization, in one or
more designated series, shares of Class A Preferred Stock and to determine the
dividend, redemption, liquidation, sinking fund and conversion rights of each
particular series. No dividends or other distributions will be payable on the
common stock unless dividends are paid in full on the Class A Preferred Stock
and all sinking fund obligations for the Class A Preferred Stock, if any, are
fully funded. Dividends on the Class A Preferred Stock will be cumulative from
the date of issuance. In the event of a liquidation or dissolution, the Class A
Preferred Stock would have priority over the common stock to receive the amount
of the liquidation preference as specified in each particular series, together
with any accrued but unpaid dividends out of our remaining assets. Holders of
shares of Class A Preferred Stock will have the right, at any time on or before
the redemption of the shares, to surrender the certificate evidencing the shares
of Class A Preferred Stock and receive upon conversion of the shares of Class A
Preferred Stock, a certificate evidencing one share of common stock for each
share of Class A Preferred Stock so surrendered. The holders of Class A
Preferred Stock are entitled to cast one vote per share held of record by them
at all meetings of our shareholders.
Class A Preferred Stock--Series 1
As authorized by our Articles of Incorporation, on August 15, 1997, the
Board of Directors by resolution designated the relative rights and preferences
of the first series of Class A Preferred Stock which was designated "Class A
Preferred Stock--Series 1." The Board authorized for issuance 1,040,000 shares
of this Series 1 Preferred Stock and 680,000 shares were issued, 660,000 of
which are currently outstanding. We have no present intention of issuing any
additional shares of Series 1 Preferred Stock. The Series 1 Preferred Stock
accrues dividends on a daily basis at the rate of 8% per year on the
"liquidation value" of the Series 1 Preferred Stock, which currently is $2.50
per share and is subject to adjustment and increase for accrued dividends. The
dividends will accrue through the earliest of the date of repurchase of the
Series 1 Preferred Stock, its conversion into common stock or liquidation.
Dividends on the Series 1 Preferred
32
Stock must be paid in full before dividends may be paid on any other class of
our stock or before any sums may be set aside for the redemption or purchase of
any of the Preferred Stock. Dividends will accrue whether or not they have been
declared and whether or not there are funds legally available for the payment of
dividends. Dividends are payable on October 1 of each year. Dividends which
are not paid on the dividend reference date will accrue and be added to the
liquidation value of each share of Series 1 Preferred Stock. No dividends can
be declared and set aside for any shares of common stock unless the Board
declares a dividend payable on the outstanding shares of Series 1 Preferred
Stock, in addition to the dividends which the Series 1 Preferred Stock is
otherwise entitled as described above. Additional dividends on the Series 1
Preferred Stock must be declared in the same amount per share of Series 1
Preferred Stock as would be declared payable on the shares of common stock into
which each share of Series 1 Preferred Stock could be converted.
On or after August 1, 1998, each share of Series 1 Preferred Stock is
convertible into one share of common stock. Upon conversion, certificates for
shares of common stock will be issued together with, to the extent legally
available, an amount of cash equal to the remaining accrued but unpaid dividends
on the shares of Series 1 Preferred Stock so converted. We may redeem the
Series 1 Preferred Stock on or after August 1, 2000, unless the holder converts
the shares before our redemption is effective, at a price of $2.50 per share
plus all accrued but unpaid dividends. Upon a liquidation, the Series 1
Preferred Stock is entitled to a liquidation preference equal to $2.50 per share
plus any accrued but unpaid dividends. This amount must be paid prior to any
distribution on shares of common stock. Except as provided above, the Series 1
Preferred Stock will have the same rights, preferences and limitations as any
other series of Preferred Stock to be issued in the future, whenever designated
and issued.
Class A Preferred Stock--Series 2
On December 30, 1997, the Board of Directors by resolution designated the
relative rights and preferences of the second series of Class A Preferred Stock
which is designated "Class A Preferred Stock-Series 2." The Board authorized for
issuance 1,500,000 shares of this Series 2 Preferred Stock and 729,927 shares
were issued. However, as of the date of this prospectus, no shares of Series 2
Preferred Stock are issued and outstanding since they all converted into shares
of common stock on a one-for-one basis on April 3, 1998. The Series 2 Preferred
Stock does not carry any dividend preference. Upon a liquidation, each share of
the Series 2 Preferred Stock outstanding at the time of liquidation is entitled
to a liquidation preference equal to the purchase price paid for each share.
This amount must be paid prior to any distribution on shares of common stock,
however, the liquidation preference on the Series 1 Preferred Stock must be paid
before the liquidation preference on the Series 2 Preferred Stock is paid.
The issuance of one or more series of Class A Preferred Stock could have an
adverse effect on the rights of the holders of common stock, including dividend
rights, rights upon liquidation and voting rights. The Preferred Stock could
also be issued by us to defend against the threat of a takeover, if the Board of
Directors determines that the takeover is not in our best interests or the best
interests of our shareholders. This could occur even if a takeover was favored
by a majority of shareholders and was at a premium to the market price of the
common stock. We have no current plans or intention to issue additional shares
of Class A Preferred Stock.
TRANSFER AGENT
The transfer agent and registrar for the common stock is Firstar Bank,
N.A., Milwaukee, Wisconsin.
WISCONSIN ANTI-TAKEOVER PROVISIONS
Section 180.1150 of the Wisconsin Business Corporation Law provides that
the voting power of shares of public corporations, such as us, which are held by
any person holding in excess of 20% of the voting power of our stock shall be
limited to 10% of the full voting power of the shares. This statutory voting
restriction does not apply to shares acquired directly from us, acquired in a
transaction incident to which our shareholders vote to restore the full voting
power of the shares and under other circumstances more fully described in
section 180.1150. In addition, this statutory voting restriction is not
applicable to shares of common stock acquired before April 22, 1986.
33
Section 180.1141 of the Wisconsin Business Corporation Law provides that a
"resident domestic corporation," such as us, may not engage in a "business
combination" with a person beneficially owning 10% or more of the voting power
of our outstanding stock for three years after the date the interested
shareholder acquired his 10% or greater interest, unless the business
combination or the acquisition of the 10% or greater interest was approved
before the stock acquisition date by our Board of Directors. After the
three-year period, a business combination that was not so approved can be
completed only if it is approved by a majority of the outstanding voting shares
not held by the interested shareholder or is made at a specified price intended
to provide a fair price for the shares held by noninterested shareholders.
Section 180.1141 is not applicable to shares of common stock acquired by a
shareholder prior to the registration of the common stock under the Securities
Exchange Act of 1934 and shares acquired before September 10, 1987.
INDEMNIFICATION
Our directors and officers are entitled to statutory rights to be
indemnified by us against litigation-related liabilities and expenses if the
director or officer is either successful in the defense of litigation or is
otherwise determined not to have engaged in willful misconduct, knowingly
violated the law, failed to deal fairly with us or our shareholders or derived
an improper personal benefit in the performance of his duties to us. These
rights are incorporated in our By-Laws. To the extent that indemnification for
liabilities arising under the Securities Act may be permitted to our directors,
officers and controlling persons, we have been advised that in the opinion of
the Securities and Exchange Commission, the indemnification provisions are
against public policy as expressed in the Securities Act and are, therefore,
unenforceable.
34
SELLING STOCKHOLDERS
Information regarding beneficial ownership of our common stock by the
selling stockholders as of September 30, 2001 follows. The table assumes that
the selling stockholders sell all shares offered under this prospectus. We can
make no assurance as to how many of the shares offered that the selling
stockholders will in fact sell.
SHARES OWNED SHARES BEING SHARES OWNED
SELLING STOCKHOLDER BEFORE OFFERING OFFERED AFTER OFFERING
- --------------------- ----------------------- ------------ -------------------
NUMBER PERCENT NUMBER PERCENT
------------- -------- --------- --------
Gary Benson 1,680,450(1) 9.8% 1,500,000(1) 180,450 12%
2925 Dean Parkway
Minneapolis, MN 55416
Daniel Bishop 210,800(2) 1.3% 150,000(2) 60,800 *
17235 Two Mile Road
Franksville, WI 53126
Mike Snow 388,800(3) 2.4% 300,000(3) 88,800 *
3300 Norwest Center
90 South Seventh Street
Minneapolis, MN 55402
Robert Johander 150,000(4) * 150,000(4) 0 0%
8480 Montgomery Court
Eden Prairie, MN 55347
W.G. Securities Limited 150,000(5) * 150,000(5) 0 0%
Partnership
PMB 452
774 Mays Boulevard, No. 10
Incline Village, NV 89451
R.J. Steichen & Company 33,750(6) * 33,750(6) 0 0%
Suite 100
120 South Sixth Street
Minneapolis, MN 55402
Chip Rice 168,750(7) 1.1% 168,750(7) 0 0%
c/o R. J. Steichen & Company
Suite 100
120 South Sixth Street
Minneapolis, MN 55402
John E. Feltl 101,250(8) * 101,250(8) 0 0%
c/o R. J. Steichen & Company
Suite 100
120 South Sixth Street
Minneapolis, MN 55402
Wayne Mills 33,750(9) * 33,750(9) 0 0%
c/o R. J. Steichen & Company
Suite 100
120 South Sixth Street
Minneapolis, MN 55402
Stephen M. Dearholt 4,158,083(10) 22.6% 1,766,671(11) 2,391,412 13.8%
759 North Milwaukee Street
Suite 316
Milwaukee, WI 53202
Thomas W. Bodine and 138,000(12) * 80,000(12) 58,000 *
Peggy L. Bodine as
Joint owners with right
of survivorship
c/o PaineWebber, Inc.
Suite 1500
8000 Maryland Avenue
St. Louis, MO 63105
Thomas W. Bodine 400,000(13) 2.5% 400,000(13) 0 0%
14 Huntleigh Manor
St. Louis, MO 63131
35
SHARES OWNED SHARES BEING SHARES OWNED
SELLING STOCKHOLDER BEFORE OFFERING OFFERED AFTER OFFERING
- --------------------- ----------------------- ------------ -------------------
NUMBER PERCENT NUMBER PERCENT
------------- -------- --------- --------
Leo B. Schmid Trust 20,000(14) * 20,000(14) 0 0%
c/o PaineWebber, Inc.
Suite 1500
8000 Maryland Avenue
St. Louis, MO 63105
Jerome F. Martin and 33,334(15) * 33,334(15) 0 0%
Diane M. Martin as
Joint Tenants
c/o PaineWebber, Inc.
Suite 1500
8000 Maryland Avenue
St. Louis, MO 63105
John H. Biggs Revocable 133,334(16) * 133,334(16) 0 0%
Trust
Apt. 23D
240 East 47th Street
New York, NY 10097
Love Family Charitable 36,334(17) * 33,334(17) 3,000 *
Foundation
Suite 201
212 South Central
St. Louis, MO 63105
Andrew Sproule Love 33,334(17) * 33,334(17) 0 0%
Suite 201
212 South Central
St. Louis, MO 63105
Love Group Joint Venture 80,934(17) * 33,334(17) 47,600 *
Suite 201
212 South Central
St. Louis, MO 63105
Love Real Estate Company 33,334(17) * 33,334(17) 0 0%
Profit Sharing Plan (1994)
Suite 201
212 South Central
St. Louis, MO 63105
James Chase 610,000 3.9% 575,000(18) 35,000 *
7815 North River Road
Milwaukee, WI 53217
William Witcroft 143,334(19) * 133,334(19) 10,000 *
7160 N. Barnett Lane
Milwaukee, WI 53217
Gregory P. DiCresce and 150,334(20) * 133,334(20) 17,000 *
Nancy L.P. DiCresce
Joint owners with right
of survivorship
12 Myrtle Street
Saratoga Springs, NY 12866
John Burke 50,000(21) * 50,000(21) 0 0%
622 Water Street
Suite 200
Milwaukee, WI 53202
36
SHARES OWNED SHARES BEING SHARES OWNED
SELLING STOCKHOLDER BEFORE OFFERING OFFERED AFTER OFFERING
- --------------------- ----------------------- ------------ -------------------
NUMBER PERCENT NUMBER PERCENT
------------- -------- --------- --------
Kingsbridge Capital Limited 300,000(22) 1.9% 300,000 (22) 0 0%
P.O. Box 3340
Dawson Building
Main Street
Tortola
British Virgin Islands
John O. Robertson 303,857(23) 2.4% 200,000(23) 103,857 *
336 Danforth Street
Portland, ME 04102
Richard E. Wenninger 3,346,941(24) 9.9% 2,866,667(25) 480,274 3.1%
855 W. Dean Road
Milwaukee, WI 53217
T. Benjamin Wenninger 21,667(26) * 6,667(26) 15,000 *
855 W. Dean Road
Milwaukee, WI 53217
Margaret E. Wenninger 21,667(26) * 6,667(26) 15,000 *
855 W. Dean Road
Milwaukee, WI 53217
Jerry Popiel 150,000 * 100,000(27) 50,000 *
Geotek
8036 40th Avenue
Denver, CO 80207
Gerald Stein 506,000 3.2% 225,000(28) 281,000 1.8%
2510 West Dean Road
Milwaukee, WI 53217-2009
Michael R. Walton 539,900(29) 3.4% 200,000(30) 339,900 *
1626 North Prospect Avenue
No. 2310
Milwaukee, WI 53202
James R. Kerber 573,710(31) 3.6% 200,000(32) 373,710 2.4%
8547 East Arapahoe Road
#J217
Englewood, CO 80112
The Geneva O. Parrish 400,000(33) 2.5% 400,000(33) 0 0%
1996 Living Trust
515 North State Street
Suite 2225
Chicago, IL 60610
Heartland Bank 1,000,000(34) 6.0% 1,000,000(34) 0 0%
212 S. Central Avenue
St. Louis, MO 63105
Dr. James P. Elmes IRA 567,249 (35) 2.9% 500,000(35) 67,249 *
c/o Larry Fey
655 N. LaGrange Road
Suite 202
Frankfurt, IL 60423
Larry Fey 200,000(36) 1.3% 200,000(36) 0 0%
655 N. LaGrange Road
Suite 202
Frankfurt, IL 60423
Total 12,250,844
=============
____________
* less than 1%
(1) Represents 180,450 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001, and 1,500,000 shares receivable upon exercise of
warrants owned by the selling stockholder. The shares being offered by the selling
stockholder consist of the shares receivable upon exercise of the warrants.
37
(2) Represents 60,800 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001, and 150,000 shares receivable upon exercise of
warrants owned by the selling stockholder. The shares being offered by the selling
stockholder consist of the shares receivable upon exercise of the warrants.
(3) Represents 88,800 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001, and 300,000 shares receivable upon exercise of
warrants owned by the selling stockholder. The shares being offered by the selling
stockholder consist of the shares receivable upon exercise of the warrants.
(4) Represents 150,000 shares receivable upon exercise of warrants owned by the
selling stockholder.
(5) Represents 150,000 shares receivable upon exercise of warrants owned by the
selling stockholder. William Deters and Graceanne K. Deters are the general partners of
the selling stockholder and share beneficial ownership of these shares.
(6) Represents 33,750 shares receivable by the selling stockholder upon exercise of
warrants currently owned by the selling stockholder. John E. Feltl is the sole beneficial
owner of these shares.
(7) Represents 168,750 shares receivable by the selling stockholder upon exercise of
warrants currently owned by the selling stockholder.
(8) Represents 101,250 shares receivable by the selling stockholder upon exercise of
warrants currently owned by the selling stockholder.
(9) Represents 33,750 shares receivable by the selling stockholder upon exercise of
warrants currently owned by the selling stockholder.
(10) Represents 4,158,083 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001. Mr. Dearholt is one of our directors. See
"Principal Shareholders."
(11) Represents 266,671 shares of common stock purchased from us on September 24,
1999, 400,000 shares purchased by a trust for the benefit of Mr. Dearholt's child on June
14, 2000, and 1,100,000 shares subject to exercise of warrants that have been pledged to a
bank to secure a guarantee executed by Mr. Dearholt on our behalf, including a warrant to
purchase up to a maximum of 1,000,000 shares of common stock (based on a guarantee amount
of $500,000 divided by the minimum warrant purchase price of $0.50 per share).
(12) Represents 138,000 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001, including the 80,000 shares purchased from us on
September 24, 1999 and offered for sale by the selling stockholder by this prospectus.
(13) Consists of shares of common stock subject to a warrant to purchase up to a
maximum of 400,000 shares of common stock (based on a guarantee amount of $200,000 divided
by the minimum warrant purchase price of $0.50 per share). This warrant has been pledged
to a bank to secure a guarantee executed by Mr. Bodine on our behalf.
(14) Represents 20,000 shares purchased from us on September 24, 1999 and offered for
sale by the selling stockholder by this prospectus. Leo B. Schmid is the sole beneficial
owner of these shares.
(15) Represents 33,334 shares purchased from us on September 24, 1999 and offered for
sale by the selling stockholder by this prospectus.
(16) Represents 133,334 shares purchased from us on September 24, 1999 and offered for
sale by the selling stockholder by this prospectus. John H. Biggs is the sole beneficial
owner of these shares.
(17) Represents 36,334 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001, including the 33,334 shares purchased from us on
September 24, 1999 and offered for sale by the selling stockholder by this prospectus.
Also includes the shares owned by Love Family Charitable Foundation, Andrew Sproule Love,
Love Group Joint Venture and Love Real Estate Company Profit Sharing Plan (1994). Andrew
Sproule Love is the sole beneficial owner of these shares.
(18) Represents shares which the selling stockholder received as compensation for
investor relations and other consulting services which the selling stockholder performed
for us.
(19) Represents 143,334 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001, including the 133,334 shares purchased from us on
November 4, 1999 and offered for sale by the selling stockholder by this prospectus.
38
(20) Represents 150,334 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001, including the 133,334 shares purchased from us on
November 22, 1999 and offered for sale by the selling stockholder by this prospectus.
(21) Represents 50,000 shares purchased from us on November 23, 1999 and offered for
sale by the selling stockholder by this prospectus.
(22) Represents 300,000 shares of which will be received by the selling stockholder
upon exercise of warrants currently owned by the selling stockholder.
(23) Represents 303,857 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001, including 100,000 shares purchased from us on
January 31, 2000 and 100,000 shares purchased from us in March 2001 and offered for sale
by the selling stockholder by this prospectus.
(24) Represents 3,346,941 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001. Mr. Wenninger is one or our directors. See
"Principal Shareholders."
(25) Includes 66,667 shares of common stock purchased from us on February 1, 2000,
shares of common stock subject to a warrant to purchase up to a maximum of 1,000,000
shares of common stock (based on a guarantee amount of $500,000 divided by the minimum
warrant purchase price of $0.50 per share) and a warrant to purchase 100,000 shares of
common stock. These warrants have been pledged to a bank to secure a guarantee executed
by Mr. Wenninger on our behalf. Also includes (a) 500,000 shares of common stock subject
to conversion of a convertible debenture due March 30, 2004 (based upon $250,000 of
principal under the convertible debenture, divided by the conversion rate of $0.50), (b)
200,000 shares of common stock purchased by Mr. Wenninger in November 2000, and (c)
1,000,000 shares of common stock purchased by Mr. Wenninger in July 2001.
(26) Represents 21,667 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001, including 6,667 shares purchased from us on February
1, 2000 and offered for sale by the selling stockholder by this prospectus.
(27) Represents 100,000 shares of common stock purchased from us on June 14, 2000 and
offered for sale by the selling stockholder by this prospectus.
(28) Represents 225,000 shares of common stock purchased from us on October 2, 2000
and offered for sale by the selling stockholder by this prospectus.
(29) Represents 539,900 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001. Mr. Walton is one of our directors. See "Principal
Shareholders."
(30) Represents 200,000 shares of common stock purchased from us on October 2, 2000
and offered for sale by the selling stockholder by this prospectus.
(31) Represents 573,710 shares of common stock beneficially owned by the selling
stockholder as of September 30, 2001. Mr. Kerber is one of our directors. See "Principal
Shareholders."
(32) Consists of shares of common stock subject to a warrant to purchase up to a
maximum of 200,000 shares of common stock (based on a guarantee amount of $100,000 divided
by the minimum warrant purchase price of $0.50 per share). This warrant has been pledged
to a bank to secure a guarantee executed by Mr. Kerber on our behalf.
(33) Consists of shares of common stock subject to a warrant to purchase up to a
maximum of 400,000 shares of common stock (based on a guarantee amount of $200,000 divided
by the minimum warrant purchase price of $0.50 per share). This warrant has been pledged
to a bank to secure a guarantee executed by The Geneva O. Parrish 1996 Living Trust on our
behalf. O.B. Parrish, our Chairman of the Board and Chief Executive Officer, is the
beneficiary of The Geneva O. Parrish 1996 Living Trust and may be deemed to share voting
and investment power over the warrants in the trust. The number of shares listed in the
table does not include any shares beneficially owned by Mr. Parrish. See "Principal
Shareholders."
(34) Consists of shares of common stock subject to a warrant to purchase up to a
maximum of 1,000,000 shares of common stock (based on $500,000 divided by the minimum
warrant purchase price of $0.50 per share).
(35) Represents 567,249 shares of common stock beneficially owned by the seller
stockholder as of September 30, 2001, including the following shares offered for sale by
the selling stockholder by this prospectus: (a) 200,000 shares of common stock subject to
conversion of a convertible debenture due May 30, 2004 (based upon $100,000 of principal
under the convertible debenture, divided by the conversion rate of $0.50), and (b)
300,000 shares of common stock purchased by the selling stockholder in November 2000.
39
(36) Consists of 200,000 shares of common stock subject to conversion of a convertible
debenture due May 30, 2004 (based upon $100,000 of principal under the convertible
debenture, divided by the conversion rate of $0.50).
We have agreed to bear certain expenses (other than broker discounts and
commissions, if any) in connection with the registration statement.
PLAN OF DISTRIBUTION
We have been advised by the selling stockholders that the selling
stockholders may sell the shares from time to time in transactions on the OTC
Bulletin Board, in negotiated transactions, or otherwise, or by a combination of
these methods, at fixed prices which may be changed, at market prices at the
time of sale, at prices related to market prices or at negotiated prices. The
selling stockholders may effect these transactions by selling the shares to or
through broker-dealers, who may receive compensation in the form of discounts,
concessions or commissions from the selling stockholders or the purchasers of
the shares for whom the broker-dealer may act as an agent or to whom it may sell
the shares as a principal, or both. The compensation to a particular
broker-dealer may be in excess of customary commissions.
Broker-dealers who act in connection with the sale of the shares may be
underwriters. Profits on any resale of the shares as a principal by such
broker-dealers and any commissions received by such broker-dealers may be
underwriting discounts and commissions under the Securities Act.
Any broker-dealer participating in transactions as agent may receive
commissions from the selling stockholders and, if they act as agent for the
purchaser of the shares, from the purchaser. Broker-dealers may agree with the
selling stockholders to sell a specified number of shares at a stipulated price
per share and, to the extent a broker-dealer is unable to do so acting as agent
for the selling stockholders, to purchase as principal any unsold shares at the
price required to fulfill the broker-dealer commitment to the selling
stockholders. Broker-dealers who acquire shares as principal may resell the
shares from time to time in transactions (which may involve crosses and block
transactions and which may involve sales to and through other broker-dealers,
including transactions of the nature described above) in the over-the-counter
market, in negotiated transactions or otherwise at market prices prevailing at
the time of sale or at negotiated prices, and may pay to or receive from the
purchasers of the shares commissions computed as described above. To the extent
required under the Securities Act, a supplemental prospectus will be filed,
disclosing:
- the name of the broker-dealers;
- the number of shares involved;
- the price at which the shares are to be sold;
- the commissions paid or discounts or concessions allowed to the
broker-dealers, where applicable;
- that broker-dealers did not conduct any investigation to verify the
information in this prospectus, as supplemented; and
- other facts material to the transaction.
Under applicable rules and regulations under the Exchange Act, any person
engaged in a distribution of the shares may not simultaneously engage in market
making activities with the common stock for a period beginning when the person
becomes a distribution participant and ending upon the person's completion of
participation in a distribution, including stabilization activities in the
common stock to effect covering transactions, to impose penalty bids or to
effect passive market making bids. In addition, we and the selling stockholders
will be subject to applicable provisions of the Exchange Act, including Rule
10b-5 and to the extent we and the selling stockholders are distribution
participants, Regulation M. These rules and regulations may affect the
marketability of the shares.
40
The selling stockholders will pay all commissions associated with the sale
of the shares. The shares offered by this prospectus are being registered to
comply with contractual obligations, and we have paid the expenses of the
preparation of this prospectus. We have also agreed to indemnify the selling
stockholders against various liabilities, including liabilities under the
Securities Act, or, if the indemnity is unavailable, to contribute toward
amounts required to be paid.
LEGAL MATTERS
The validity of the securities offered by this prospectus will be passed
upon for us by Reinhart Boerner Van Deuren s.c., Milwaukee, Wisconsin.
EXPERTS
The consolidated financial statements of The Female Health Company at
September 30, 2000 and for the two years in the period ended September 30, 2000
included in this prospectus have been audited by McGladrey & Pullen LLP,
independent auditors, as set forth in their report (which contains an
explanatory paragraph with respect to conditions which raise substantial doubt
about our ability to continue as a going concern), in reliance upon such report
given upon the authority of such firm as experts in accounting and auditing.
The consolidated financial statements do not include any adjustments to reflect
the possible future effects on the recoverability and classification of assets
or amounts and classification of liabilities that might result from the outcome
of that uncertainty.
41
The Female Health Company
Index to Consolidated Financial Statements
Document Page No.
- ----------------------------------------------------------------------------- -------------------
Audited Consolidated Financial Statements.
Report of McGladrey & Pullen, LLP, Independent Auditors.. . . . . . . . . . . F-2
Consolidated Balance Sheet as of September 30, 2000.. . . . . . . . . . . . . F-3
Consolidated Statements of Operations for the years ended
September 30, 2000 and 1999.. . . . . . . . . . . . . . . . . . . . . . . . F-4
Consolidated Statements of Stockholders' Equity (Deficit) for the years ended
September 30, 2000 and 1999.. . . . . . . . . . . . . . . . . . . . . . . . F-5 and F-6
Consolidated Statements of Cash Flows for the years ended
September 30, 2000 and 1999.. . . . . . . . . . . . . . . . . . . . . . . . F-7
Notes to Consolidated Financial Statements. . . . . . . . . . . . . . . . . . F-8 through F-23
Unaudited Condensed Consolidated Financial Statements.
Unaudited Condensed Consolidated Balance Sheet
as of June 30, 2001.. . . . . . . . . . . . . . . . . . . . . . . . . . . . F-24
Unaudited Condensed Consolidated Statements of Operations
for the Nine Months Ended June 30, 2001 and 2000. . . . . . . . . . . . . . F-25
Unaudited Condensed Consolidated Statements of Cash Flows
for the Nine Months Ended June 30, 2001 and 2000. . . . . . . . . . . . . . F-26
Notes to Unaudited Condensed Consolidated Financial Statements. . . . . . . . F-27 through F-32
F-1
INDEPENDENT AUDITOR'S REPORT
To the Board of Directors and Stockholders
The Female Health Company
Chicago, Illinois
We have audited the accompanying consolidated balance sheet of The Female Health
Company and subsidiaries, as of September 30, 2000, and the related consolidated
statements of operations, stockholders' equity (deficit), and cash flows for the
years ended September 30, 2000 and 1999. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of The Female Health
Company and subsidiaries as of September 30, 2000, and the results of their
operations and their cash flows for the years ended September 30, 2000 and 1999,
in conformity with generally accepted accounting principles.
The accompanying consolidated financial statements have been presented assuming
that The Female Health Company will continue as a going concern. As more fully
described in Note 14, the Company has experienced slower than expected growth in
revenues from its sole product, which has adversely affected the Company's
current results of operations and liquidity. These conditions raise substantial
doubt about the Company's ability to continue as a going concern. Management's
plans in regard to these matters are also described in Note 14. The
consolidated financial statements do not include any adjustments to reflect the
possible future effects on the recoverability and classification of assets or
the amounts of classification of liabilities that may result from the outcome of
this uncertainty.
/s/ McGladrey & Pullen, LLP
Schaumburg, Illinois
November 17, 2000
F-2
THE FEMALE HEALTH COMPANY
CONSOLIDATED BALANCE SHEET
SEPTEMBER 30, 2000
- --------------------------------------------------------------------------------
ASSETS
Current Assets
Cash. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 457,122
Accounts receivable, net of allowance for doubtful accounts
of $86,200 and allowance for product returns of $31,800 . . . . . . . 847,979
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 490,815
Prepaid expenses and other current assets . . . . . . . . . . . . . . . 192,460
-------------
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . 1,988,376
-------------
Other Assets
Intellectual property, net of accumulated amortization of $513,600. . . 594,421
Other Assets. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144,652
-------------
739,073
-------------
Property, Plant and Equipment
Equipment, furniture and fixtures . . . . . . . . . . . . . . . . . . . 3,674,398
Less accumulated depreciation . . . . . . . . . . . . . . . . . . . . . 2,281,065
-------------
1,393,333
-------------
$ 4,120,782
=============
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Notes payable, related parties, net of unamortized discount of $88,155. $ 1,211,845
Convertible debentures, net of unamortized discount of $101,664 . . . . 1,398,336
Accounts payable. . . . . . . . . . . . . . . . . . . . . . . . . . . . 427,556
Accrued expenses and other current liabilities. . . . . . . . . . . . . 244,155
Preferred dividends payable . . . . . . . . . . . . . . . . . . . . . . 132,000
-------------
Total current liabilities. . . . . . . . . . . . . . . . . . . . . . 3,413,892
-------------
Long-Term Liabilities
Deferred gain on sale of facility . . . . . . . . . . . . . . . . . . . 1,373,212
Other long-term liabilities . . . . . . . . . . . . . . . . . . . . . . 26,745
-------------
1,399,957
-------------
Stockholders' Equity (Deficit)
Convertible preferred stock, Series 1, par value $.01 per share.
Authorized 5,000,000 shares; issued and outstanding 660,000 shares. . 6,600
Common stock, par value $.01 per share. Authorized 27,000,000
shares; issued and outstanding 13,803,699 shares. . . . . . . . . . . 138,037
Additional paid-in capital. . . . . . . . . . . . . . . . . . . . . . . 48,231,986
Unearned consulting fees. . . . . . . . . . . . . . . . . . . . . . . . (90,815)
Accumulated other comprehensive income. . . . . . . . . . . . . . . . . 55,661
Accumulated deficit . . . . . . . . . . . . . . . . . . . . . . . . . . (49,002,460)
-------------
(660,991)
Treasury Stock, at cost, 20,000 shares of common stock. . . . . . . . . (32,076)
-------------
(693,067)
-------------
$ 4,120,782
=============
See Notes to Consolidated Financial Statements.
F-3
THE FEMALE HEALTH COMPANY
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED SEPTEMBER 30, 2000 AND 1999
- --------------------------------------------------------------------------------
2000 1999
------------ ------------
Net revenues . . . . . . . . . . . . . . . . . . . . $ 5,766,868 $ 4,715,477
Cost of products sold. . . . . . . . . . . . . . . . 5,184,735 4,598,747
------------ ------------
Gross Profit. . . . . . . . . . . . . . . . . . 582,133 116,730
------------ ------------
Operating expenses:
Advertising and promotion. . . . . . . . . . . . . 247,222 251,867
Selling, general and administrative. . . . . . . . 2,727,542 2,716,736
------------ ------------
Total operating expenses. . . . . . . . . . . . 2,974,764 2,968,603
------------ ------------
Operating (loss). . . . . . . . . . . . . . . . (2,392,631) (2,851,873)
------------ ------------
Nonoperating income (expense):
Amortization of debt issuance costs. . . . . . . . (245,676) (174,124)
Interest expense . . . . . . . . . . . . . . . . . (1,231,832) (860,523)
Interest income. . . . . . . . . . . . . . . . . . 34,772 36,030
Nonoperating income. . . . . . . . . . . . . . . . 145,204 100,181
------------ ------------
(1,297,532) (898,436)
------------ ------------
Net (loss). . . . . . . . . . . . . . . . . . . (3,690,163) (3,750,309)
Preferred dividends, Series 1. . . . . . . . . . . . 132,195 133,919
------------ ------------
Net (loss) attributable to common stockholders. $(3,822,358) $(3,884,228)
============ ============
Net (loss) per common share outstanding . . . . $ (0.30) $ (0.36)
Weighted average common shares outstanding . . . . . 12,764,498 10,890,173
See Notes to Consolidated Financial Statements.
F-4
THE FEMALE HEALTH COMPANY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
YEARS ENDED SEPTEMBER 30, 2000 AND 1999
- --------------------------------------------------------------------------------
Accumulated
Additional Unearned Other Cost of
Preferred Common Paid-in Consulting Comprehensive Accumulated Treasury
Stock Stock Capital Fees Income Deficit Stock
------------ -------- ----------- ------------ --------------- ------------- ----------
Balance at September 30, 1998. $ 6,800 $104,157 $43,833,844 $ - $ 304,980 $(41,295,874) $ (19,330)
Issuance of 482,964 shares
of Common Stock under
the equity line of credit. - 4,685 480,315 - - - -
Issuance of 20,718 shares
of Common Stock upon
conversion of Preferred
Stock. . . . . . . . . . . (200) 200 - - - - -
Issuance of 120,000 shares
of Common Stock upon
exercise of warrants . . . - 1,200 128,760 - - - -
Issuance of 175,000 shares
of Common Stock for
consulting services. . . . - 1,750 184,188 (185,938) - - -
Issuance of warrants with
convertible debentures . . - - 1,276,300 - - - -
Issuance of 15,000 shares
of Common Stock under
stock bonus plan . . . . . - 150 23,288 - - - -
Issuance of 18,000 shares
of Common Stock upon
exercise of stock options. - 180 16,695 - - - -
Issuance of warrants with
short-term notes payable . - - 253,515 - - - -
Issuance of 30,691 shares
of Common Stock as
payment of preferred
stock dividends. . . . . . - 307 31,058 - - - -
Issuance of warrants for
consulting services. . . . - - 99,483 (99,483) - - -
Preferred Stock dividends. . - - - - - (133,919) -
Purchase of 10,000 shares
of Common Stock held in
Treasury . . . . . . . . . - - - - - - (12,746)
Issuance of 666,671 shares
of Common Stock. . . . . . - 6,667 493,333 - - - -
Amortization of unearned
consulting fees. . . . . . . - - - 84,047 - - -
Comprehensive income (loss):
Net (loss) . . . . . . . . . - - - - - (3,750,309) -
Foreign currency
translation adjustment . . - - - - (115,133) - -
Comprehensive income (loss). . (3,865,442)
Balance at September 30, 1999. $ 6,600 $119,296 $46,820,779 $ (201,374) $ 189,847 $(45,180,102) $ (32,076)
============ ======== =========== ============ =============== ============= ==========
Total
------------
Balance at September 30, 1998. $ 2,934,577
Issuance of 482,964 shares
of Common Stock under
the equity line of credit. 485,000
Issuance of 20,718 shares
of Common Stock upon
conversion of Preferred
Stock. . . . . . . . . . . -
Issuance of 120,000 shares
of Common Stock upon
exercise of warrants . . . 129,960
Issuance of 175,000 shares
of Common Stock for
consulting services. . . . -
Issuance of warrants with
convertible debentures . . 1,276,300
Issuance of 15,000 shares
of Common Stock under
stock bonus plan . . . . . 23,438
Issuance of 18,000 shares
of Common Stock upon
exercise of stock options. 16,875
Issuance of warrants with
short-term notes payable . 253,515
Issuance of 30,691 shares
of Common Stock as
payment of preferred
stock dividends. . . . . . 31,365
Issuance of warrants for
consulting services. . . . -
Preferred Stock dividends. . (133,919)
Purchase of 10,000 shares
of Common Stock held in
Treasury . . . . . . . . . (12,746)
Issuance of 666,671 shares
of Common Stock. . . . . . 500,000
Amortization of unearned
consulting fees. . . . . . . 84,047
Comprehensive income (loss):
Net (loss) . . . . . . . . . (3,750,309)
Foreign currency
translation adjustment . . (115,133)
Comprehensive income (loss)
Balance at September 30, 1999. $ 1,722,970
============
F-5
THE FEMALE HEALTH COMPANY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
YEARS ENDED SEPTEMBER 30, 2000 AND 1999
- --------------------------------------------------------------------------------
Accumulated
Additional Unearned Other Cost of
Preferred Common Paid-in Consulting Comprehensive Accumulated Treasury
Stock Stock Capital Fees Income Deficit Stock
------------ -------- ----------- ------------ --------------- ------------- ----------
Issuance of 197,093 shares
of Common Stock under
the equity line of credit. - 1,971 95,029 - - - -
Issuance of 200,000 shares
of Common Stock for
consulting services. . . . - 2,000 112,055 (114,055) - - -
Issuance of warrants with
convertible debentures . . - - 157,700 - - - -
Forfeiture of 6,000 shares
of Common Stock under
stock bonus plan . . . . . - (60) (17,190) - - - -
Issuance of warrants with
short-term notes payable . - - 193,289 - - - -
Issuance of 20,005 shares
of Common Stock as
payment of interest on
debentures . . . . . . . . - 200 16,356 - - - -
Issuance of 41,352 shares
of Common Stock as
payment of preferred
stock dividends. . . . . . - 413 33,185 - - - -
Preferred Stock dividends. . - - - - - (132,195) -
Issuance of 1,421,669
shares of Common
Stock. . . . . . . . . . . - 14,217 820,783 - - - -
Amortization of unearned
consulting fees. . . . . . . - - - 224,614 - - -
Comprehensive income (loss):
Net (loss) . . . . . . . . . - - - - - (3,690,163) -
Foreign currency
translation adjustment . . - - - - (134,186) - -
Comprehensive income (loss). . (3,824,349)
Balance at September 30, 2000. $ 6,600 $138,037 $48,231,986 $ (90,815) $ 55,661 $(49,002,460) $ (32,076)
============ ========= ============ ============ =============== ============= ==========
Total
------------
Issuance of 197,093 shares
of Common Stock under
the equity line of credit. 97,000
Issuance of 200,000 shares
of Common Stock for
consulting services. . . . -
Issuance of warrants with
convertible debentures . . 157,700
Forfeiture of 6,000 shares
of Common Stock under
stock bonus plan . . . . . (17,250)
Issuance of warrants with
short-term notes payable . 193,289
Issuance of 20,005 shares
of Common Stock as
payment of interest on
debentures . . . . . . . . 16,556
Issuance of 41,352 shares
of Common Stock as
payment of preferred
stock dividends. . . . . . 33,598
Preferred Stock dividends. . (132,195)
Issuance of 1,421,669
shares of Common
Stock. . . . . . . . . . . 835,000
Amortization of unearned
consulting fees. . . . . . . 224,614
Comprehensive income (loss):
Net (loss) . . . . . . . . . (3,690,163)
Foreign currency
translation adjustment . . (134,186)
------------
Comprehensive income (loss)
Balance at September 30, 2000. $ (693,067)
============
See Notes to Consolidated Financial Statements.
F-6
THE FEMALE HEALTH COMPANY
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED SEPTEMBER 30, 2000 AND 1999
- --------------------------------------------------------------------------------
2000 1999
------------ ------------
OPERATING ACTIVITIES
Net (loss). . . . . . . . . . . . . . . . . . . . . . . . . . . . . $(3,690,163) $(3,750,309)
Adjustments to reconcile net (loss) to net cash (used in)
operating activities:
Depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . 425,899 468,758
Amortization of intellectual property rights . . . . . . . . . . 110,025 119,501
Provision for (recovery of) inventory obsolescence . . . . . . . 40,286 (6,394)
Provision for doubtful accounts, returns and discounts . . . . . (224,846) 22,460
Issuance of common stock for bonuses and consulting services . . - 23,438
Amortization of unearned consulting fees . . . . . . . . . . . . 224,614 84,047
Amortization of discounts on notes payable
and convertible debentures . . . . . . . . . . . . . . . . . . 957,192 671,854
Amortization of deferred income realized on U.K. grant . . . . . (53,490) (142,723)
Amortization of deferred gain on sale and leaseback of building. (84,495) (91,772)
Amortization of debt issuance costs. . . . . . . . . . . . . . . 245,676 174,124
Changes in operating assets and liabilities:
Accounts receivable. . . . . . . . . . . . . . . . . . . . . . 869,242 (507,929)
Inventories. . . . . . . . . . . . . . . . . . . . . . . . . . 438,442 (105,433)
Prepaid expenses and other current assets. . . . . . . . . . . 30,676 149,617
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . (222,543) 128,165
Accrued expenses and other current liabilities . . . . . . . . (98,352) (78,733)
------------ ------------
Net cash (used in) operating activities . . . . . . . . . . (1,031,837) (2,841,329)
------------ ------------
INVESTING ACTIVITIES
Capital expenditures, net cash (used in) investing activities . . . (11,284) (22,637)
------------ ------------
FINANCING ACTIVITIES
Proceeds from issuance of common stock. . . . . . . . . . . . . . . 835,000 500,000
Proceeds from issuance of common stock under the
equity line of credit . . . . . . . . . . . . . . . . . . . . . . 97,000 485,000
Proceeds from issuance of common stock upon exercise of puts. . . . - 146,835
Proceeds from related party notes issued. . . . . . . . . . . . . . - 300,000
Proceeds from convertible debentures issued . . . . . . . . . . . . - 1,305,000
Purchase of common stock held in treasury . . . . . . . . . . . . . - (12,746)
Dividend paid on preferred stock. . . . . . . . . . . . . . . . . . (40,150) (161,670)
Payments on long-term debt and capital lease obligations. . . . . . - (638,620)
Net cash provided by financing activities . . . . . . . . . 891,850 1,923,799
------------ ------------
Effect of exchange rate changes on cash . . . . . . . . . . . . . . . $ 37,684 $ 30,589
------------ ------------
Net (decrease) in cash. . . . . . . . . . . . . . . . . . . (113,587) (909,578)
Cash at beginning of year . . . . . . . . . . . . . . . . . . . . . . 570,709 1,480,287
------------ ------------
Cash at end of year . . . . . . . . . . . . . . . . . . . . . . . . . $ 457,122 $ 570,709
============ ============
Supplemental Cash Flow Disclosures:
Interest paid . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 191,634 $ 190,444
Supplemental Schedule of Noncash Financing Activities:
Issuance of warrants on convertible debentures and notes payable. . $ 350,989 $ 1,529,815
Common stock issued for payment of preferred stock dividends
and convertible debenture interest. . . . . . . . . . . . . . . . 50,154 31,365
Preferred dividends declared, Series 1. . . . . . . . . . . . . . . 132,195 133,919
Renewal of notes payable with related parties . . . . . . . . . . . 1,300,000 1,000,000
See Notes to Consolidated Financial Statements.
F-7
THE FEMALE HEALTH COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- ----------------------------------------------
NOTE 1. NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
Principles of consolidation and nature of operations: The consolidated
- ----------------------------------------------------------
financial statements include the accounts of the Company and its wholly-owned
subsidiaries, The Female Health Company - UK and The Female Health Company - UK,
plc. All significant intercompany transactions and accounts have been eliminated
in consolidation. The Female Health Company ("FHC" or the "Company") is
currently engaged in the marketing, manufacture and distribution of a consumer
health care product known as the Reality female condom, "Reality," in the U.S.
and "femidom" or "femy" outside the U.S. The Female Health Company - UK, is the
holding company of The Female Health Company - UK, plc, which operates a 40,000
sq. ft. leased manufacturing facility located in London, England.
The product is currently sold or available in either or both commercial (private
sector) and public sector markets in 30 countries. It is commercially marketed
directly by the Company in the United States and the United Kingdom and through
marketing partners globally.
Use of estimates: The preparation of financial statements in conformity with
- ------------------
generally accepted accounting principles requires management to make estimates
and use assumptions that affect certain reported amounts and disclosures.
Actual results may differ from those estimates.
Significant accounting estimates include the following:
Trade receivables include a provision for sales returns and trade allowances,
which is based on management's estimate of future product returns from customers
in connection with unsold product which has expired or is expected to expire
before it is sold. The estimated cost for product returns, price discounts and
trade allowances are accrued when the initial sale is recorded.
The market value of inventory is based on management's best estimate of future
sales and the time remaining before the existing inventories reach their
expiration dates.
The Company evaluates intellectual property rights for impairment by comparing
the net present value of the asset's estimated future income stream to the
asset's carrying value.
Although management uses the best information available, it is reasonably
possible that the estimates used by the Company will be materially different
from the actual results. These differences could have a material effect on the
Company's future results of operations and financial condition.
Cash: Substantially all of the Company's cash was on deposit with one financial
- ----
institution.
Inventories: Inventories are valued at the lower of cost or market. The cost
- -----------
is determined using the first-in, first-out (FIFO) method. Inventories are also
written down for management's estimates of product which will not sell prior to
its expiration date. Write downs of inventories establish a new cost basis
which is not increased for future increases in the market value of inventories
or changes in estimated obsolescence.
F-8
NOTE 1. NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Foreign currency translation: In accordance with Financial Accounting Standards
- ----------------------------
No. 52, "Foreign Currency Translation", the financial statements of the
Company's international subsidiaries are translated into U.S. dollars using the
exchange rate at each balance sheet date for assets and liabilities, the
historical exchange rate for stockholders' equity and a weighted average
exchange rate for each period for revenues, expenses, and gains and losses.
Translation adjustments are recorded as a separate component of stockholders'
equity as the local currency is the functional currency.
Equipment and furniture and fixtures: Depreciation and amortization is computed
- ------------------------------------
by the estimated useful lives of the respective assets which range as follows:
Equipment 5 - 10 years
Furniture and fixtures 3 years
Intellectual property rights: The Company holds patents on the female condom in
- ----------------------------
the United States, the European Union, Japan, Canada, Australia and The People's
Republic of China and holds patents on the manufacturing technology in various
countries. The Company also licenses the trademark "Reality" in the United
States and has trademarks on the names "femidom" and "femy" in certain foreign
countries. Intellectual property rights are amortized on a straight-line basis
over their estimated useful life of twelve years.
Financial instruments: The Company has no financial instruments for which the
- ----------------------
carrying value materially differs from fair value.
Revenue Recognition: Revenues from product sales are recognized as the products
- -------------------
are shipped to the customers.
Research and Development Costs: Research and development costs are expensed as
- -------------------------------
incurred. The amount of costs expensed for the years ended September 2000 and
1999 was $67,099 and $122,196, respectively.
Stock-Based Compensation: The value of stock options awarded to employees is
- -------------------------
measured using the intrinsic value method prescribed by Accounting Principles
Board Opinion No. 25 (APB 25), "Accounting for Stock Issued to Employees." The
Company has provided pro forma disclosures in Note 7 of net income as if the
fair value-based method prescribed by Financial Accounting Standard No. 123,
"Accounting for Stock-Based Compensation," ("FAS 123") was used in measuring
compensation expense.
Advertising: The Company's policy is to expense production costs in the period
- -----------
in which the advertisement is initially presented to consumers.
F-9
NOTE 1. NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Income taxes: The Company files separate income tax returns for its foreign
- -------------
subsidiaries. Statement of Financial Accounting Standards No. 109, "Accounting
for Income Taxes" (FAS 109) requires recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that have been
included in the financial statements or tax returns. Under this method,
deferred tax assets and liabilities are determined based on the differences
between the financial statements and tax bases of assets and liabilities using
enacted tax rates in effect for the year in which the differences are expected
to reverse. Deferred tax assets are also provided for carryforwards for income
tax purposes. In addition, the amount of any future tax benefits is reduced by a
valuation allowance to the extent such benefits are not expected to be realized.
Earnings per share (EPS): Basic EPS is computed by dividing income available to
- ------------------------
common stockholders by the weighted average number of common shares outstanding
for the period. Diluted EPS is computed giving effect to all dilutive potential
common shares that were outstanding during the period. Dilutive potential
common shares consist of the incremental common shares issuable upon conversion
of convertible preferred shares or convertible debt and the exercise of stock
options and warrants for all periods. Fully diluted (loss) per share is not
presented since the effect would be anti-dilutive.
Other comprehensive income: Accounting principles generally require that
- ----------------------------
recognized revenue, expenses, gains and losses be included in net income.
Although certain changes in assets and liabilities, such as foreign currency
translation adjustments, are reported as a separate component of the equity
section of the balance sheet, such items, along with net income, are components
of comprehensive income.
New accounting pronouncements: In June 1998, the FASB adopted SFAS 133,
- -------------------------------
Accounting for Derivative Instruments and Hedging Activities. SFAS 133
establishes accounting and reporting standards requiring that every derivative
instrument (including certain derivative instruments embedded in other
contracts) be recorded in the balance sheet as either an asset or liability
measured at its fair value. SFAS 133 requires that changes in the derivative's
fair value be recognized currently in earnings unless specific hedge accounting
criteria are met. Special accounting for qualifying hedges allows a
derivative's gains and losses to offset related results on the hedged item in
the income statement, and requires that a company must formally document,
designate and assess the effectiveness of transactions that receive hedge
accounting. In June 1999, the FASB adopted SFAS 137, Accounting for Derivative
Instruments and Hedging Activities Deferral of the Effective Date of FASB
Statement No. 133. SFAS 133, as amended by SFAS 137, is effective for all
fiscal quarters of all fiscal years beginning after June 15, 2000. Management
believes that the adoption of FAS No. 133 will have no material impact on the
Company.
Reclassifications: Certain expenses on the statement of income for the year
- -----------------
ended September 30, 1999, have been reclassified to be consistent with the
presentation shown for the year ended September 30, 2000.
F-10
NOTE 2. INVENTORIES
The components of inventory consist of the following at September 30, 2000:
Raw materials . . . . . . . . . $210,933
Work in process . . . . . . . . 193,182
Finished goods. . . . . . . . . 160,700
Less allowance for obsolescence (74,000)
---------
$490,815
=========
NOTE 3. LEASES
The Company entered into a seven-year operating lease with a third party for
office space effective September 12, 1994. The Company has also guaranteed an
affiliate's lease with an unrelated third party which expires January 31, 2001.
On November 1, 1998 the office space was sublet for the remaining term of the
lease. Rental expense under the affiliate lease was $15,797 and $14,999 in 2000
and 1999, respectively, which is net of sublease rentals of $39,204 and $35,018
in 2000 and 1999, respectively.
On December 10, 1996, the Company entered into what is in essence a sale and
leaseback agreement with respect to its 40,000 square foot manufacturing
facility located in London, England. The Company received $3,365,000 (1,950,000
pounds) for leasing the facility to a third party for a nominal annual rental
charge and for providing the third party with an option to purchase the facility
for one pound during the period December 2006 to December 2027.
As part of the same transaction, the Company entered into an agreement to lease
the facility back from the third party for base rents of $304,000 (195,000
pounds) per year payable quarterly until 2016. The lease is renewable through
December 2027. The Company was also required to make a security deposit of
$304,000 (195,000 pounds) to be reduced in subsequent years. The facility had a
net book value of $1,398,819 (810,845 pounds) on the date of the transaction.
The $1,966,181 (1,139,155 pounds) gain which resulted from this transaction will
be recognized ratably over the initial term of the lease. Unamortized deferred
gain as of September 30, 2000 was $1,373,212 (925,585 pounds).
In 1987, a subsidiary entered into a lease for office and factory space expiring
January 31, 2001. These offices and factory space were vacated and subsequently
this space was subleased to a third party for a period expiring January 31,
2001. At the time the sublease was entered into a liability was established for
all future costs to the end of the lease, net of expected sublease receipts.
F-11
NOTE 3. LEASES (CONTINUED)
Details of operating lease expense in total and separately for transactions with
related parties are as follows:
September 30,
2000 1999
-------- --------
Operating lease expense:
Factory and office leases . . . . . . . . $614,333 $691,399
Affiliate lease (net of sublease rentals) 15,797 14,999
Other . . . . . . . . . . . . . . . . . . 19,063 22,231
-------- --------
$649,193 $728,629
======== ========
Future minimum payments under operating leases, including the affiliate lease
guarantee, consisted of the following at September 30, 2000:
Rentals
Receivable
Under
Operating Subleases
---------- ----------
2001 . . . . . . . . . $ 427,324 $ 13,068
2002 . . . . . . . . . 315,450 -
2003 . . . . . . . . . 315,450 -
2004 . . . . . . . . . 313,334 -
2005 . . . . . . . . . 303,615 -
Thereafter . . . . . . 3,402,342 -
---------- ----------
Total minimum payments $5,077,515 $ 13,068
========== ==========
F-12
NOTE 4. NOTES PAYABLE AND LONG-TERM DEBT
During 1999, the Company renewed a $1,000,000 note with Mr. Dearholt, a current
director of the Company. The outstanding note payable had an interest rate of
12%. As part of the transaction, the Company issued Mr. Dearholt warrants to
purchase 200,000 shares of the Company's common stock at $1.16 per share, which
represented 80% of the average trading price for the five trading days prior to
the closing date for the transaction and resulted in an initial discount on the
note of $194,574. Any stock issued under the warrants carry certain registration
rights. The warrants expire in 2008. The discount in combination with the note's
12% coupon resulted in an effective interest rate of 35 percent on the note.
Additionally, during 1999 the Company borrowed $250,000 from Mr. Dearholt and
$50,000 from O.B. Parrish, also a current director of the Company. Each note
payable bears interest at 12%. As part of the transactions, the Company issued
Mr. Dearholt and Mr. Parrish warrants to purchase 50,000 and 10,000 shares of
the Company's common stock at $1.35 and $1.25 per share, respectively, which
represented 80% of the average trading price for the five trading days prior to
the closing date for the transaction and resulted in an initial discount on the
notes of $49,219 and $9,722, respectively. Any stock issued under the warrants
carry certain registration rights. The warrants expire in 2008 and 2007,
respectively. The discount in combination with the notes' 12% coupon resulted in
an effective interest rate of 35 percent for each note.
During 2000, the Company renewed the $1,000,000 note with Mr. Dearholt. The
outstanding note payable bears interest at 12% and is payable in full in 2001.
As part of the transaction, the Company issued Mr. Dearholt warrants to purchase
250,000 shares of the Company's common stock at $.71 per share which represented
80% of the average trading price for the five trading days prior to the closing
date for the transaction and resulted in an initial discount on the note of
$148,999. Any stock issued under the warrants carry certain registration rights.
The warrants expire in 2010. In addition, if the Company defaults on its
obligation under the note, the Company is required to issue an additional
250,000 shares of its common stock to Mr. Dearholt in addition to all other
remedies to which Mr. Dearholt may be entitled. The note is recorded at
September 30, 2000, net of unamortized discount of $71,641. The discount in
combination with the note's 12% coupon resulted in an effective interest rate of
27 percent on the note.
Additionally, during 2000 the Company renewed the $250,000 note with Mr.
Dearholt and $50,000 note with O.B. Parrish. Each note payable bears interest at
12% and is payable in full in 2001. As part of the transactions, the Company
issued Mr. Dearholt and Mr. Parrish warrants to purchase 62,500 and 12,500
shares of the Company's common stock at $.77 and $.72 per share, respectively,
which represented 80% of the average trading price for the five trading days
prior to the closing date for the transaction and resulted in an initial
discount on the notes of $36,853 and $7,437, respectively. Any stock issued
under the warrants carry certain registration rights. The warrants expire in
2010, for each note. Also if the Company defaults on its obligation under the
note, the Company is required to issue an additional 62,500 and 12,500 shares of
its common stock to Mr. Dearholt and Mr. Parrish, respectively, in addition to
all other remedies to which each is entitled. The notes are recorded at
September 30, 2000, net of unamortized discounts of $13,639 and $2,875,
respectively. The discount in combination with the notes' 12% coupon resulted in
an effective interest rate of 27 percent for each note.
F-13
NOTE 4. NOTES PAYABLE AND LONG-TERM DEBT (CONTINUED)
On May 19 and June 3, 1999, the Company issued an aggregate of $1,500,000 of
convertible debentures and warrants to purchase 1,875,000 shares of the
Company's common stock to five accredited investors. These warrants expire in
2004. Interest on the convertible debentures is due at a rate of 8% per annum,
payable quarterly in either cash or, at the investor's option, common stock of
the Company at its then current market value. From December 2, 1999 to February
11, 2000, interest on the convertible debentures was at the rate of 10%
annually, and then returned to 8% annually. Repayment of the convertible
debentures is secured by a first security interest in all of the Company's
assets. In addition, if the Company defaults in payment of the principal or
interest due on the convertible debentures in accordance with their terms, the
Company must immediately issue 1,500,000 shares of its common stock to the
investor at no cost. The issuance of these shares will not affect any of the
outstanding warrants then held by the investor, which warrants will continue in
effect in accordance with their terms.
Additionally, warrants to purchase 337,500 shares of the Company's common stock
were issued to the Company's placement agent in this offering. The warrants have
a term of five years and are exercisable at an exercise price equal to the
lesser of 70% of the market price of the common stock at the time of the
exercise or $1.00. The warrants were valued at $224,800 which was recorded as
additional paid-in capital.
The convertible debentures beneficial conversion feature is valued at $336,400
and the warrants to purchase 1,875,000 shares of the Company's common stock are
valued at $715,100. In accordance with SEC reporting requirements for such
transactions, the Company recorded the value of the beneficial conversion
feature and warrants (a total of $1,051,500) as additional paid-in capital. The
corresponding amount of $1,051,500 was recorded as a discount on convertible
debentures and is amortized over 1 year using the interest rate method. The note
is recorded net of a discount of $101,664 at September 30, 2000. The discount
in combination with the debentures' 8% coupon resulted in an effective interest
rate of 159 percent for the debentures.
The original principal balance plus any accrued but unpaid interest of the
convertible debentures may be convertible into shares of the Company's common
stock at the investor's election, at any time after one year, based on a per
share price equal to the lesser of (a) 70% of the market price of the Company's
common stock at the time of conversion or $1.00. The convertible debentures were
originally payable one year after issuance. However, the Company elected, under
the terms of the convertible debentures, to extend the due date to two years
after issuance. As a result of the Company making this election, the Company
issued to the investors at the time of the extension, 375,000 additional
warrants to purchase shares of the Company's common stock on the same terms as
the previously issued warrants. These warrants expire in 2005. The warrants
were valued at $157,700 and recorded as additional paid-in capital.
On April 6, 1999 the Company restructured its $602,360 (370,000 pounds) Aage V.
Jensen Charity Foundation note payable. The terms included immediate payment of
$177,000 (110,000 pounds) as of the date of the restructuring agreement and
required nine installment payments beginning April 15, 1999 and concluding on
December 10, 1999. To avoid incurring additional interest related to the loan,
the Company paid off the entire loan on June 10, 1999.
F-14
NOTE 5. INCOME TAXES
A reconciliation of income tax expense and the amount computed by applying the
statutory Federal income tax rate to loss before income taxes as of September
30, 2000 and 1999, is as follows:
September 30,
2000 1999
------------ ------------
Tax credit statutory rates . . . . . . . . . . . . . . $(1,254,700) $(1,275,100)
Nondeductible expenses . . . . . . . . . . . . . . . . 59,100 59,300
State income tax, net of federal benefits. . . . . . . (175,900) (177,700)
Benefit of net operating loss not recognized, increase
in valuation allowance . . . . . . . . . . . . . . . 1,371,500 1,374,500
Other. . . . . . . . . . . . . . . . . . . . . . . . . - 19,000
------------ ------------
$ - $ -
============ ============
As of September 30, 2000, the Company had federal and state net operating loss
carryforwards of approximately $35,428,000 for income tax purposes expiring in
years 2005 to 2016. The benefit relating to $1,537,800 of these net operating
losses relates to exercise of common stock options and will be credited directly
to stockholders' equity when realized. The Company also has investment tax and
research and development credit carryforwards for income tax purposes
aggregating approximately $127,000 at September 30, 2000, expiring in years 2006
to 2010. The Company's U.K. subsidiary, The Female Health Company - UK, plc
subsidiary has U.K. net operating loss carryforwards of approximately
$65,770,000 as of September 30, 2000. These U.K. net operating loss
carryforwards can be carried forward indefinitely to be used to offset future
U.K. taxable income. Significant components of the Company's deferred tax
assets and liabilities are as follows at September 30, 2000:
Deferred tax assets:
Federal net operating loss carryforwards . . $12,046,000
State net operating loss carryforwards . . . 2,335,000
Foreign net operating loss carryforwards . . 19,732,000
Foreign capital allowances . . . . . . . . . 906,000
Tax credit carryforwards . . . . . . . . . . 127,000
Accounts receivable allowances . . . . . . . 48,000
Other. . . . . . . . . . . . . . . . . . . . 17,000
------------
Total gross deferred tax assets. . . . . . . . 35,211,000
Valuation allowance for deferred tax assets. . 35,194,000
------------
Deferred tax assets net of valuation allowance 17,000
Deferred tax liabilities:
Equipment, furniture and fixtures. . . . . . (17,000)
------------
Net deferred tax assets. . . . . . . . . . . . $ -
============
The valuation allowance increased (decreased) by $(4,213,500) and $1,711,000 for
the years ended September 30, 2000 and 1999, respectively.
F-15
NOTE 6. ROYALTY AGREEMENTS
The Company has royalty agreements for sales of its products which provide for
royalty payments based on sales quantities and achievement of specific sales
levels. However, no royalty expense was incurred for the years ended September
30, 1999 or 2000.
NOTE 7. COMMON STOCK
Stock Option Plans
The Company has various stock option plans that authorize the granting of
options to officers, key employees and directors to purchase the Company's
common stock at prices generally equal to the market value of the stock at the
date of grant. Under these plans, the Company has 94,028 shares available for
future grants as of September 30, 2000. The Company has also granted options to
one of its legal counsel and an affiliate. Certain options are vested and
exercisable upon issuance, others over periods up to four years and still others
based on the achievement of certain performance criteria by the Company and
market prices of its common stock.
Summarized information regarding all of the Company's stock options is as
follows:
Weighted
Average
Number of Exercise
Shares Price
---------- ---------
Outstanding at September 30,1998. 1,174,478 $ 2.29
Granted . . . . . . . . . . . . 1,876,000 0.86
Exercised . . . . . . . . . . . (18,000) 0.01
Expired or canceled . . . . . . (79,178) 6.75
----------
Outstanding at September 30, 1999 2,953,300 1.27
Granted . . . . . . . . . . . . 50,000 0.50
Exercised . . . . . . . . . . . - -
Expired or canceled . . . . . . (85,900) 0.93
----------
Outstanding at September 30, 2000 2,917,400 $ 1.26
==========
Options shares exercisable at September 30, 2000 and 1999 are 438,300 and
425,766, respectively.
F-16
NOTE 7. COMMON STOCK (CONTINUED)
Options Outstanding and Exercisable
Range of Number Wghted. Avg. Wghted. Avg. Number Wghted. Avg.
Exercise Outstanding Remaining Exercise Exercisable Exercise
Prices At 9/30/00 Life Price at 9/30/00 Price
- ------------- ----------- ------------ ------------- ----------- -------------
$ 0.50 50,000 10.0 $ 0.50 - $ -
0.85 1,784,500 7.9 0.85 - -
1.56 16,000 5.3 1.56 16,000 1.56
2.00 1,066,900 3.8 2.00 422,300 2.00
- ------------- ----------- ------------ ------------- ----------- -------------
.50 to $2.00 2,917,400 6.4 $ 1.26 438,300 $ 1.98
============= =========== ============ ============= =========== =============
Stock options have been granted to employees at, or in excess of, fair market
value at the date of grant. Accordingly, in accordance with APB 25 and related
interpretations, no compensation cost has been recognized related to such stock
option grants.
Had compensation cost for the Company's stock option plans been determined based
on the fair value at the grant dates for all awards consistent with the method
set forth under FASB Statement No. 123, "Accounting for Stock-Based
Compensation" ("FAS 123") the Company's net loss and loss per share would have
been increased to the pro forma amounts indicated below:
Year Ending September 30,
Loss Loss
2000 Per Share 1999 Per Share
------------ ----------- ------------ -----------
Net loss attributable to common
stockholders. . . . . . . . . $(3,822,355) $ (0.30) $(3,884,228) $ (0.36)
Compensation expense related to
stock options granted . . . . (413,656) (0.03) (371,902) (0.03)
------------ ----------- ------------ -----------
$(4,236,011) $ (0.33) $(4,256,130) $ (0.39)
============ =========== ============ ===========
As the provisions of FAS 123 have been applied only to options granted since
September 30, 1995, the resulting pro forma compensation cost is not
representative of that to be presented in future years, when the pro forma cost
would be fully reflected.
The fair value of options was estimated at the date of grant using the
Black-Scholes option pricing model assuming expected volatility of 63.4% and
risk-free interest rates of 5.38% and 5.00% for 2000 and 1999, respectively; and
expected lives of one to three years and 0.0% dividend yield in both periods.
The weighted average fair value of options granted was $.35 and $.61 for the
years ended September 30, 2000 and 1999, respectively.
F-17
NOTE 7. COMMON STOCK (CONTINUED)
The Black-Scholes option valuation model was developed for use in estimating the
fair value of traded options which have no vesting restrictions and are fully
transferable. Because the Company's employee stock options have characteristics
different from those of traded options, and because changes in the input
assumptions can materially affect the fair value estimate, the model may not
provide a reliable single measure of the fair value of its employee stock
options.
Stock Bonus Plan
During 1997, the Company adopted a stock bonus plan ("1997 Bonus Plan") to
provide stock bonuses in lieu of cash bonuses to key employees who are
responsible for the Company's future growth and financial success. The 1997
Bonus Plan provides for the award of up to 200,000 shares which are
nontransferable and subject to a risk of forfeiture for one year subsequent to
grant date. During the year ended September 30, 1999, 15,000 shares of
restricted stock were issued to key employees. No shares of restricted stock
were issued to key employees during the year ended September 30, 2000. Expense
under the plan was $23,438 for the year ended September 30, 1999.
Common Stock Purchase Warrants
The Company enters into consulting agreements with separate third party
professionals to provide investor relations services and financial advisory
services. In connection with the consulting agreements, the Company granted
warrants to purchase common stock. At September 30, 2000, 175,000 warrants
were exercisable.
In 1999, the Company issued 100,000 warrants. The value of the warrants of
$99,483 was recognized as unearned consulting fees and additional paid-in
capital and the expense is being recognized over the term of the agreement. In
2000 the Company did not issue any warrants related to such arrangements.
No warrants were exercised during 2000. At September 30, 2000, the following
warrants were outstanding:
Number
Outstanding
------------
Warrants issued in connection with:
Financial advisory services contract $ 175,000
Convertible Debentures . . . . . . . 2,587,500
Convertible Preferred Stock. . . . . 176,000
Equity Line of Credit. . . . . . . . 200,000
Notes Payable. . . . . . . . . . . . 1,225,000
------------
Outstanding at September 30, 2000. . $ 4,363,500
F-18
NOTE 7. COMMON STOCK (CONTINUED)
At September 30, 2000, the Company had reserved a total of 9,101,400 shares of
its common stock for the exercise of options and warrants outstanding. This
amount includes shares reserved to satisfy obligations due if the Company
defaults on the payment of interest or principal on $1.3 million of notes due
between February and March 2000, and the convertible debentures due May and June
2000.
Issuance of Stock
The Company has issued common stock to consultants for providing investor
relation services. In 1999, the Company issued 175,000 shares of common stock
with a market value of $185,938 which was recorded as unearned consulting fees
which is being recognized over the term of the agreement. In 2000, the Company
issued 200,000 shares of common stock with a market value of $114,055 which was
recorded as unearned consulting fees and is being recognized over the term of
the agreement.
NOTE 8. PREFERRED STOCK
The Company has outstanding 660,000 shares of 8% cumulative convertible
preferred stock (Series 1). Each share of preferred stock is convertible into
one share of the Company's common stock on or after August 1, 1998. Annual
preferred stock dividends will be paid if and as declared by the Company's Board
of Directors. No dividends or other distributions will be payable on the
Company's common stock unless dividends are paid in full on the preferred stock.
The preferred stock may be redeemed at the option of FHC, in whole or in part,
on or after August 1, 2000, subject to certain conditions, at $2.50 per share
plus accrued and unpaid dividends. In the event of a liquidation or dissolution
of the Company, the preferred stock would have priority over the Company's
common stock. During 1999, 20,718 shares were converted into common stock.
NOTE 9. EQUITY LINE OF CREDIT
On November 19, 1998, the Company executed an agreement with a private investor,
Kingsbridge (the Equity Line Agreement). This agreement provides for the
Company, at its sole discretion, subject to certain restrictions, to sell
("put") to the investor up to $6.0 million of the Company's common stock,
subject to a minimum put of $1.0 million over the duration of the agreement.
The Equity Line Agreement expires 24 months after the effective date of the
registration statement which was February 1999 and, among other things, provides
for minimum and maximum puts ranging from $100,000 to $1,000,000 depending on
the Company's stock price and trading volume. The Company is required to draw
down a minimum of $1 million during the two-year period. If the Company does
not draw down the minimum, the Company is required to pay the investor a 12% fee
on that portion of the $1 million minimum not drawn down at the end of the
two-year period. Upon execution of the agreement, the Company issued Kingsbridge
200,000 warrants to purchase common stock at $2.17 per share. As of September
30, 2000, the Company had placed four puts for the combined cash proceeds of
$582,000 providing the selling stockholders with a total of 680,057 shares of
the Company's common stock.
F-19
NOTE 9. EQUITY LINE OF CREDIT (CONTINUED)
The timing and amount of the stock sales under the agreement are totally at the
Company's discretion, subject to the Company's compliance with each of the
following conditions at the time the Company requests a stock sale under the
agreement:
- The registration statement the Company filed with the SEC for resales
of stock by Kingsbridge must remain in effect.
- All of the Company's representations and warranties in the agreement
must be accurate and the Company must have complied with all of the
obligations in the agreement.
- There may not be any injunction, legal proceeding or law prohibiting
the Company's sale of the stock to Kingsbridge.
- The sale must not cause Kingsbridge's ownership of the Company's
common stock to exceed 9.9% of the outstanding shares of the Company's
common stock.
- The trading price of the Company's common stock over a
five-trading-day period preceding the date of the sale must equal or
exceed $1.00 per share.
- The average daily trading volume of the Company's common stock for a
twenty- trading-day period preceding the date of the sale must equal
or exceed 17,000 shares.
The trading price of the Company's common stock was below $1.00 per share as of
September 30, 2000. Although Kingsbridge waived the condition relating to the
trading price for the fourth put completed during the third quarter of fiscal
year 2000, the Company can make no assurance that Kingsbridge will waive this
condition or any other condition under the Equity Line Agreement if the Company
cannot satisfy such conditions to use the Equity Line Agreement if needed in the
near future.
NOTE 10. EMPLOYEE RETIREMENT PLAN
Effective October 1, 1997, the Company adopted a Simple Individual Retirement
Account (IRA) plan for its employees. Employees are eligible to participate in
the plan if their compensation reaches certain minimum levels and are allowed to
contribute up to a maximum of $6,000 annual compensation to the plan. The
Company has elected to match 100% of employee contributions to the plan up to a
maximum of 3% of employee compensation for the year ended September 30, 2000.
The Company elected to match 1% of employee compensation during the prior year.
Company contributions were $17,539 and $6,541 for 2000 and 1999, respectively.
F-20
NOTE 11. INDUSTRY SEGMENTS AND FINANCIAL INFORMATION ABOUT FOREIGN AND
DOMESTIC OPERATIONS
The Company currently operates primarily in one industry segment which includes
the development, manufacture and marketing of consumer health care products.
The Company operates in foreign and domestic regions. Information about the
Company's operations in different geographic areas (determined by the location
of the operating unit) is as follows.
September 30,
(Amounts in Thousands) 2000 1999
Net revenues:
United States . . . . . $ 2,116 $ 2,350
International . . . . . 3,651 2,365
Operating profit (loss):
United States . . . . . (917) (1,221)
International . . . . . (1,476) (1,631)
Identifiable assets
United States . . . . . 661 1,760
International . . . . . 3,460 4,747
On occasion, the Company's U.S. unit sells product directly to customers located
outside the U.S. Were such transaction reported by geographic destination of
the sale rather than the geographic location of the unit, U.S. revenues would be
decreased and International revenues increased by $37,000 and $177,000 in 2000
and 1999, respectively.
NOTE 12. CONTINGENT LIABILITIES
The testing, manufacturing and marketing of consumer products by the Company
entail an inherent risk that product liability claims will be asserted against
the Company. The Company maintains product liability insurance coverage for
claims arising from the use of its products. The coverage amount is currently
$5,000,000 for FHC's consumer health care product.
NOTE 13. RELATED PARTIES
It has been and currently is the policy of the Company that transactions between
the Company and its officers, directors, principal shareholders or affiliates
are to be on terms no less favorable to the Company than could be obtained from
unaffiliated parties. The Company intends that any future transactions between
the Company and its officers, directors, principal shareholders or affiliates
will be approved by a majority of the directors who are not financially
interested in the transaction.
F-21
NOTE 14. CONTINUING OPERATIONS
The Company's consolidated financial statements have been prepared on a going
concern basis which contemplates the realization of assets and the settlement of
liabilities and commitments in the normal course of business. The Company
incurred a loss of $3.8 million for the year ended September 30, 2000, and as of
September 30, 2000, had an accumulated deficit of $49.0 million. At September
30, 2000, the Company had working capital of ($1.4) million and stockholders'
deficit of ($.7) million. In the near term, the Company expects operating and
capital costs to continue to exceed funds generated from operations, due
principally to the Company's fixed manufacturing costs relative to current
production volumes and the ongoing need to commercialize the female condom
around the world. As a result, operations in the near future are expected to
continue to use working capital. Management recognizes that the Company's
continued operations depend on its ability to raise additional capital through a
combination of equity or debt financing, strategic alliances and increased sales
volumes.
At various points during the developmental stage of the product, the Company was
able to secure resources, in large part through the sale of equity and debt
securities, to satisfy its funding requirements. As a result, the Company was
able to obtain FDA approval, worldwide rights, manufacturing facilities and
equipment and to commercially launch the female condom.
Management believes that recent developments, including the Company's agreement
with the UNAIDS, a joint United Nations program on HIV/AIDS, provide an
indication of the Company's early success in broadening awareness and
distribution of the female condom and may benefit efforts to raise additional
capital and to secure additional agreements to promote and distribute the female
condom throughout other parts of the world.
On September 29, 1997, the Company entered into an agreement with Vector
Securities International, Inc. (Vector), an investment banking firm specializing
in providing advice to healthcare and life-science companies. Pursuant to this
agreement, as extended, Vector will act as the Company's exclusive financial
advisor for the purposes of identifying and evaluating opportunities available
to the Company for increasing shareholder value. These opportunities may
include selling all or a portion of the business, assets or stock of the Company
or entering into one or more distribution arrangements relating to the Company's
product. There can be no assurance that any such opportunities will be available
to the Company or, if so available, that the Company will ultimately elect or be
able to consummate any such transaction. Management is currently determining
whether the Company should seek to extend this arrangement.
The Company has also obtained an equity line of credit. See Note 9 for details.
On May 19, 1999 and June 3, 1999 the Company issued an aggregate $1.5 million of
convertible debentures and warrants to purchase 1,875,000 shares of the
Company's common stock to five accredited investors. See Note 4 for additional
detail.
Between September and November 1999 the Company completed a private placement
where 983,333 shares of the Company's common stock were sold for $737,500, of
which $500,000 was received through September 30, 1999. The stock sales were
directly with accredited investors and included one current director of the
Company. The Company provided the shares to these investors at a $.75 share
price.
F-22
NOTE 14. CONTINUING OPERATIONS (CONTINUED)
During the year ended September 30, 2000, the Company completed private
placements where 1,305,000 shares of the Company's common stock were sold for
$697,500 of which $597,500 was received through September 30, 2000. The stock
sales were directly with accredited investors and included two current directors
of the Company. The Company provided the shares to these investors at prices
which ranged from $.50 and $.75.
While the Company believes that its existing capital resources will be adequate
to fund its currently anticipated capital needs, if they are not the Company may
need to raise additional capital until its sales increase sufficiently to cover
operating expenses. In addition, there can be no assurance that the Company
will satisfy the conditions required for it to exercise puts under the Equity
Line Agreement. Accordingly, the Company may not be able to realize all or any
of the funds available to it under the Equity Line Agreement.
Further, there can be no assurance, assuming the Company successfully raises
additional funds or enters into business agreements with third parties, that the
Company will achieve profitability or positive cash flow. If the Company is
unable to obtain adequate financing, management will be required to sharply
curtail the Company's efforts to promote the female condom and to curtail
certain other of its operations or, ultimately, cease operations.
F-23
THE FEMALE HEALTH COMPANY AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET
June 30,
2001
-------------
ASSETS
Current Assets:
Cash $ 468,920
Accounts receivable, net 1,323,721
Inventories 367,744
Prepaid expenses and other current assets 250,038
-------------
TOTAL CURRENT ASSETS 2,410,423
Intellectual property rights, net 486,520
Other assets 138,544
PROPERTY, PLANT AND EQUIPMENT 3,572,586
Less accumulated depreciation and amortization (2,512,211)
-------------
Net property, plant, and equipment 1,060,375
-------------
TOTAL ASSETS $ 4,095,862
=============
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)
Current Liabilities:
Notes payable, related parties, net of unamortized discount 1,281,956
Accounts payable 333,227
Accrued expenses and other current liabilities 495,452
Preferred dividends payable 100,543
-------------
TOTAL CURRENT LIABILITIES 2,211,178
Note payable, bank, net of unamortized discount 598,471
Convertible debentures 450,000
Deferred gain on lease of facility 1,254,530
-------------
TOTAL LIABILITIES 4,514,179
STOCKHOLDERS' EQUITY (DEFICIENCY):
Convertible preferred stock 6,600
Common stock 146,683
Additional paid-in-capital 49,625,703
Unearned consulting compensation (104,637)
Accumulated deficit (50,078,593)
Accumulated other comprehensive income 18,003
Treasury stock, at cost (32,076)
-------------
Total Stockholders' Equity (Deficiency) (418,317)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) $ 4,095,862
=============
See notes to unaudited condensed consolidated financial statements.
F-24
THE FEMALE HEALTH COMPANY AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Nine Months Ended
June 30,
--------------------------
2001 2000
------------ ------------
Net revenues. . . . . . . . . . . . . . . . . . $ 4,959,512 $ 3,923,425
Cost of products sold . . . . . . . . . . . . . 3,998,978 3,612,216
------------ ------------
Gross profit. . . . . . . . . . . . . . . . . . 960,534 311,209
------------ ------------
Advertising & promotion . . . . . . . . . . . . 110,155 169,000
Selling, general and administrative . . . . . . 1,463,584 2,085,001
------------ ------------
Total operating expenses. . . . . . . . . . . . 1,573,739 2,254,001
------------ ------------
Operating (loss). . . . . . . . . . . . . . . . (613,205) (1,942,792)
Amortization of debt issuance costs . . . . . . - 245,676
Interest, net and other expense . . . . . . . . 363,199 937,561
------------ ------------
(Loss) before income taxes. . . . . . . . . . . (976,404) (3,126,029)
Provision for income taxes. . . . . . . . . . . - -
------------ ------------
Net (loss). . . . . . . . . . . . . . . . . . . (976,404) (3,126,029)
Preferred dividends, Series 1 . . . . . . . . . 99,729 99,090
------------ ------------
Net (loss) attributable to common stockholders. $(1,076,133) $(3,225,119)
============ ============
Net (loss) per common share outstanding . . . . $ (0.07) $ (0.26)
Weighted average common shares outstanding. . . 14,392,258 12,522,230
See notes to unaudited condensed consolidated financial statements.
F-25
THE FEMALE HEALTH COMPANY AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended
June 30,
--------------------------
2001 2000
------------ ------------
OPERATIONS:
Net (loss) . . . . . . . . . . . . . . . . . . . . . . . $ (976,404) $(3,126,029)
Adjusted for noncash items:
Depreciation and amortization . . . . . . . . . . . . . 385,044 474,443
Amortization of discounts on notes payable and
convertible debentures. . . . . . . . . . . . . . . . 239,556 844,997
Changes in operating assets and liabilities . . . . . . (273,014) 961,986
------------ ------------
Net cash (used in) operating activities. . . . . . . . . (624,818) (844,603)
------------ ------------
INVESTING ACTIVITIES:
Capital expenditures, Net cash (used in)
investing activities . . . . . . . . . . . . . . . . . (36,415) (11,579)
------------ ------------
FINANCING ACTIVITIES:
Proceeds from issuance of convertible debentures . . . . 450,000 -
Dividend paid on preferred stock . . . . . . . . . . . . (107,186) (39,002)
Proceeds from issuance of common stock . . . . . . . . . 300,000 719,500
Borrowing on note payable, bank. . . . . . . . . . . . . 1,500,000 -
Principal payment on convertible debenture . . . . . . . (1,500,000) -
Net cash provided by financing activities. . . . . . . . 642,814 680,498
------------ ------------
Effect of exchange rate changes on cash. . . . . . . . . 30,217 781
------------ ------------
INCREASE (DECREASE) IN CASH. . . . . . . . . . . . . . . 11,798 (174,903)
Cash at beginning of period. . . . . . . . . . . . . . . 457,122 570,709
------------ ------------
CASH AT END OF PERIOD. . . . . . . . . . . . . . . . . . $ 468,920 $ 395,806
============ ============
Schedule of noncash financing and investing
activities:
Common stock issued for payment for consulting services. $ 93,760 $ 79,680
Issuance of warrants on notes payable. . . . . . . . . . 239,556 350,989
Renewal of notes payable with related parties. . . . . . 1,300,000 1,300,000
Common stock issued for payment of preferred
stock dividends and convertible debenture
interest . . . . . . . . . . . . . . . . . . . . . . . 39,293 48,160
Preferred dividends declared, Series 1 . . . . . . . . . 99,729 99,090
See notes to unaudited condensed consolidated financial statements.
F-26
THE FEMALE HEALTH COMPANY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------
NOTE 1 - Basis of Presentation
-----------------------
The accompanying financial statements are unaudited but in the opinion of
management contain all the adjustments (consisting of those of a normal
recurring nature) considered necessary to present fairly the financial position
and the results of operations and cash flow for the periods presented in
conformity with generally accepted accounting principles for interim financial
information and Article 10 of Regulation S-X. Accordingly, they do not include
all of the information and footnotes required by generally accepted accounting
principles for complete financial statements.
Operating results for the nine months ended June 30, 2001 are not necessarily
indicative of the results that may be expected for the fiscal year ending
September 30, 2001. For further information, refer to the consolidated
financial statements and footnotes thereto included in the Company's annual
report on Form 10-KSB for the fiscal year ended September 30, 2000.
Principles of consolidation and nature of operations:
- ----------------------------------------------------------
The consolidated financial statements include the accounts of the Company and
its wholly-owned subsidiaries, The Female Health Company - UK and The Female
Health Company - UK, plc. All significant intercompany transactions and
accounts have been eliminated in consolidation. The Female Health Company
("FHC" or the "Company") is currently engaged in the marketing, manufacture and
distribution of a consumer health care product known as the Reality female
condom, "Reality," in the U.S. and "femidom" or "femy" outside the U.S. The
Female Health Company - UK, is the holding company of The Female Health Company
- - UK, plc, which operates a 40,000 sq. ft. leased manufacturing facility located
in London, England.
Reclassification:
- -----------------
Certain expenses on the statements of income for the nine months ended June 30,
2000 have been reclassified to be consistent with the presentation shown for the
nine months ended June 30, 2001.
NOTE 2 - Earnings Per Share
--------------------
Earnings per share (EPS): Basic EPS is computed by dividing income available to
- -------------------------
common stockholders by the weighted average number of common shares outstanding
for the period. Diluted EPS is computed giving effect to all dilutive potential
common shares that were outstanding during the period. Dilutive potential
common shares consist of the incremental common shares issuable upon conversion
of convertible preferred or convertible debt and the exercise of stock options
and warrants for all periods. Fully diluted (loss) per share is not presented
since the effect would be anti-dilutive.
F-27
THE FEMALE HEALTH COMPANY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------
NOTE 3 - Comprehensive (Loss)
---------------------
Total comprehensive (loss) was $(1,113,791) for the nine months ended June 30,
2001 and $(3,323,002) for the nine months ended June 30, 2000.
NOTE 4 - Inventories
-----------
The components of inventory consist of the following:
June 30, 2001
---------------
Raw material and work in process $ 316,551
Finished goods . . . . . . . . . 108,033
---------------
Inventory, gross . . . . . . . . 424,584
Less: Inventory reserves . . . . (56,840)
Inventory, net . . . . . . . . . $ 367,744
===============
NOTE 5 - Financial Condition
--------------------
The Company's consolidated financial statements have been prepared on a going
concern basis which contemplates the realization of assets and the settlement of
liabilities and commitments in the normal course of business. The Company
incurred a net loss of $1.1 million for the nine months ended June 30, 2001 and
as of June 30, 2001 had an accumulated deficit of $50.1 million. At June 30,
2001, the Company had working capital of $0.2 million and stockholders' equity
of $(0.4) million. Management recognizes that the Company's continued
operations depend on its ability to raise additional capital through a
combination of equity or debt financing, strategic alliances and increased sales
volumes.
At various points during the developmental stage of the product, the Company was
able to secure resources, in large part through the sale of equity and debt
securities, to satisfy its funding requirements. As a result, the Company was
able to obtain FDA approval, worldwide rights, manufacturing facilities and
equipment and to commercially launch the female condom.
Management believes that recent developments, including the Company's agreement
with the UNAIDS, a joint United Nations program on HIV/AIDS, provide an
indication of the Company's early success in broadening awareness and
distribution of the female condom and may benefit future efforts to raise
additional capital and to secure additional agreements to promote and distribute
the female condom throughout other parts of the world.
F-28
THE FEMALE HEALTH COMPANY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------
NOTE 5- Financial Condition - (Continued)
------------------------------------
On May 19, 1999 and June 3, 1999 the Company issued an aggregate $1.5 million of
convertible debentures and warrants to purchase 1,875,000 shares of the
Company's common stock to five accredited investors.
Between September and November 1999 the Company completed a private placement
where 983,333 shares of the Company's common stock were sold for $737,500, of
which $500,000 was received through September 30, 1999. The stock sales were
directly with accredited investors and included one current director of the
Company. The Company sold the shares to these investors at a price of $0.75 per
share.
During the year ended September 30, 2000, the Company completed private
placements where 1,305,000 shares of the Company's common stock were sold for
$697,500 of which $597,500 was received through September 30, 2000. The stock
sales were directly with accredited investors and included two current directors
of the Company. The Company sold the shares to these investors at prices which
ranged from $0.50 and $0.75 per share.
On March 30, 2001 the Company issued an aggregate $250,000 of convertible
debentures to one accredited investor. The debentures are due March 30, 2004,
bear interest payable at a rate of 12% per annum, and are convertible into the
Company's common stock based on a price per share equal to 70% of the market
price of the common stock the day immediately prior to the date a conversion
notice is provided to the Company but in no event shall the stock price be below
$0.50 or more than $1.00. The Company did not issue warrants in connection with
this issuance.
On May 18, 2001 the Company entered into an agreement with Heartland Bank
providing for a $2,000,000 credit facility. The Company may borrow under the
credit facility from time to time subject to a number of conditions, including
obtaining personal guarantees of 125% of the amount outstanding under the credit
facility. Principal and unpaid interest are due May 18, 2004. The credit
facility bears interest payable at a rate of 10% per annum and payments of
interest are due monthly. Heartland Bank was issued warrants for entering into
the credit facility. The warrants are exercisable to purchase the number of
shares of the Company's common stock equal to $500,000 divided by the warrant
exercise price as of the date of exercise. The warrant purchase price is equal
to 70% of the "market price" of the Common Stock as of the day immediately prior
to the date the exercise notice is given to the Company, but in no event shall
the per share price be less than $0.50 or more than $1.00. The warrants are
valued at $270,800 and are recorded by the Company as additional paid in capital
and a discount on the note.
F-29
THE FEMALE HEALTH COMPANY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------
NOTE 5- Financial Condition - (Continued)
------------------------------------
To secure the credit facility the Company was required by the bank to obtain
guarantees of 125% of the amounts outstanding under the credit facility. The
Company has currently borrowed $1,500,000 under the credit facility and has
obtained guarantees from five guarantors of the amount outstanding on the loan,
including three members of the Company's Board of Directors and a trust for the
benefit of the Company's Chairman of the Board and Chief Executive Officer. The
Company issued warrants to the five guarantors for their personal guarantees.
The warrants are exercisable to purchase the number of shares of the Company's
common stock equal to the guarantee amount of such guarantor divided by the
warrant purchase price as of the date of exercise. The warrant purchase price
is equal to 70% of the "market price" of the Common Stock as of the day
immediately prior to the date the exercise notice is given to the Company, but
in no event shall the per share price be less than $0.50 or more than $1.00.
Two of the guarantors received additional warrants to purchase 100,000 shares of
common stock each at a warrant purchase price of $0.50 per share because each of
them guaranteed $500,000 under the credit facility. The warrants are valued at
$667,578 and are recorded by the Company as additional paid in capital and a
discount on the note.
The Company used the proceeds of the credit facility to pay off $1,500,000 of
convertible debentures which were due between May 19 and June 3, 2001.
On June 1, 2001 the Company issued an aggregate $200,000 of convertible
debentures to two accredited investors. The debentures are due May 30, 2004,
bear interest payable at a rate of 10% per annum, and are convertible into the
Company's common stock based on a price per share equal to be $0.50. The
Company did not issue warrants in connection with this issuance.
During the nine months ended June 30, 2001, the Company completed private
placements where 600,000 shares of the Company's common stock were sold for
$300,000. The stock sales were directly with accredited investors and included
one director of the Company. The Company sold the shares to these investors at
price of $0.50 per share.
Until internally generated funds are sufficient to meet cash requirements, the
Company will remain dependent upon its ability to generate sufficient capital
from outside sources. While management believes that revenue from sales of the
female condom will eventually exceed operating costs and that ultimately
operations will generate sufficient funds to meet capital requirements, there
can be no assurance that such level of operations will ultimately be achieved,
or be achieved in the near term. Likewise, there can be no assurance that the
Company will be able to source all or any portion of its required capital
through the sale of debt or equity or, if raised, the amount will be sufficient
to operate the Company until sales of the female condom generate sufficient
revenues to fund operations. In addition, any funds raised may be costly to the
Company and/or dilutive to stockholders. If the Company is not able to source
the required funds or any future capital which becomes required, the Company may
be forced to sell certain of its assets or rights or cease operations.
F-30
THE FEMALE HEALTH COMPANY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------
NOTE 6 - Industry Segments And Financial Information About Foreign and Domestic
-----------------------------------------------------------------------
Operations
- ----------
The Company currently operates primarily in one industry segment which includes
the development, manufacture and marketing of consumer health care products.
The Company operates in foreign and domestic regions. Information about the
Company's operations in different geographic areas (determined by the location
of the operating unit) is as follows:
Nine Months Ended
June 30,
(Amounts in Thousands) 2001 2000
---------- --------
Net revenues:
United States. . . . $ (4) $ 1,542
International. . . . 4,964 2,381
Operating (loss):
United States. . . . (267) (328)
International. . . . (346) (1,615)
Identifiable assets:
United States. . . . 210 1,082
International. . . . 3,886 3,640
On occasion, the Company's U.S. unit sells product directly to customers located
outside the U.S. Were such transaction reported by geographic destination of
the sale rather than the geographic location of the unit, U.S. revenues would be
decreased and international revenues increased by $0 and $37,000 as of June 30,
2001 and 2000, respectively. Beginning October 1, 2000 primarily all revenues
derived from sales to the U.S. public and trade sectors were accounted for as
international revenues. In the first nine months of fiscal 2001 U.S. sales
comprised $2,023,502 of the international total.
F-31
THE FEMALE HEALTH COMPANY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------
Note 7 - Recent Accounting Pronouncements
----------------------------------
Statement of Financial Accounting Standard ("SFAS") No. 133, Accounting for
Derivative Instruments and Hedging Activities, as amended by SFAS 137 and 138
establishes accounting and reporting standards requiring that every derivative
instrument (including certain derivative instruments embedded in other
contracts) be recorded in the balance sheet as either an asset or liability
measured at its fair value. SFAS 133 requires that changes in the derivative's
fair value be recognized currently in earnings unless specific hedge accounting
criteria are met. Special accounting for qualifying hedges allows a
derivative's gains and losses to offset related results on the hedged item in
the income statement, and requires that a company must formally document,
designate and asses the effectiveness of transactions that receive hedge
accounting. SFAS 133 was effective January 1, 2001. The Company adopted SFAS
133 and the implementation of this standard did not have a material impact on
the Company's financial statements.
SFAS 140, Accounting for Transfers and Servicing of Financial Assets and
Extinguishments of Liabilities, a replacement of SFAS 125, Accounting for
Transfers and Servicing of Financial Assets and Extinguishments of Liabilities
revised the standards for accounting for securitizations and other transfers of
financial assets and collateral and requires certain disclosures, but it carries
over most of SFAS 125's provisions without reconsideration. SFAS 140 provides
consistent standards for distinguishing transfers of financial assets that are
sales from transfers that are secured borrowings. The provisions of SFAS 140
are effective for transfers after March 31, 2001. It is effective for
disclosures about securitizations and collateral and for recognition and
reclassification of collateral for fiscal years ending after December 15, 2000.
The Company adopted SFAS 140 and the implementation of this standard did not
have a material impact on the Company's financial statements.
On June 30, 2001, the Financial Accounting Standards Board finalized Statement
of Financial Accounting Standards No. 141, Business Combinations. SFAS 141
requires all business combinations initiated after June 30, 2001 to be accounted
for using the purchase method. The Company is in the process of evaluating the
impact of SFAS 141.
On June 30, 2001, the Financial Accounting Standards Board finalized Statement
of financial Accounting Standards No. 142, Goodwill and Other Intangible Assets.
Under the provisions of SFAS 142, goodwill is no longer subject to amortization
over its estimated useful life, but instead will be subject to at least annual
assessments for impairment by applying a fair-value based test. SFAS 142 also
requires that an acquired intangible asset should be separately recognized if
the benefit of the intangible asset is obtained through contractual or other
legal rights, or if the asset can be sold, transferred, licensed, rented or
exchanged, regardless of the acquirer's intent to do so. The provisions of SFAS
142 are effective for fiscal years beginning after December 31, 2001. The
Company is in the process of evaluating its Goodwill and Intangible assets for
impairment under the provisions of SFAS 142.
F-32
YOU SHOULD RELY ONLY ON INFORMATION CONTAINED IN THIS PROSPECTUS. WE HAVE
NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION DIFFERENT FROM THAT
CONTAINED IN THIS PROSPECTUS. THE SELLING STOCKHOLDERS LISTED IN THIS
PROSPECTUS IS OFFERING TO SELL, AND SEEKING OFFERS TO BUY, SHARES OF COMMON
STOCK ONLY IN JURISDICTIONS WHERE OFFERS AND SALES ARE PERMITTED.
NO ACTION IS BEING TAKEN IN ANY JURISDICTION OUTSIDE THE UNITED STATES TO
PERMIT A PUBLIC OFFERING OF THE COMMON STOCK OR POSSESSION OR DISTRIBUTION OF
THIS PROSPECTUS IN ANY SUCH JURISDICTION. PERSONS WHO COME INTO POSSESSION OF
THIS PROSPECTUS IN JURISDICTIONS OUTSIDE THE UNITED STATES ARE REQUIRED TO
INFORM THEMSELVES ABOUT AND TO OBSERVE ANY RESTRICTIONS AS TO THIS OFFERING AND
THE DISTRIBUTION OF THIS PROSPECTUS APPLICABLE TO THAT JURISDICTION.
THE FEMALE HEALTH COMPANY
12,250,844 SHARES OF COMMON STOCK
____________________
PROSPECTUS
____________________
November, 2001
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 24. Indemnification of Directors and Officers.
Pursuant to sections 180.0850 to 180.0859 of the Wisconsin Business
Corporation Law, directors and officers of the Company are entitled to mandatory
indemnification from the Company against certain liabilities and expenses (i) to
the extent such officers or directors are successful in the defense of a
proceeding and (ii) in proceedings in which the director or officer is not
successful in the defense thereof, unless (in the latter case only) it is
determined that the director or officer breached or failed to perform his duties
to the Company and such breach or failure constitute: (a) willful failure to
deal fairly with the Company or its shareholders in connection with a matter in
which the director or officer had a material conflict of interest; (b) a
violation of the criminal law unless the director or officer had reasonable
cause to believe his or her conduct was lawful or had no reasonable cause to
believe his or her conduct was unlawful; (c) a transaction from which the
director or officer derived an improper personal profit; or (d) willful
misconduct. It should be noted that section 180.0859 of the Wisconsin Business
Corporation Law specifically states that it is the public policy of Wisconsin to
require or permit indemnification in connection with a proceeding involving
securities regulation, as described therein, to the extent required or permitted
under sections 180.0850 to 180.0858 as described above. Additionally, under the
Wisconsin Business Corporation Law, directors of the Company are not subject to
personal liability to the Company, its shareholders or any person asserting
rights on behalf thereof for certain breaches or failures to perform any duty
resulting solely from their status as such directors, except in circumstances
paralleling those in subparagraphs (a) through (d) outlined above.
Consistent with sections 180.0850 to 180.0859 of the Wisconsin Business
Corporation Law, Article VIII of the Company's Amended and Restated By-Laws
provides that the Company shall indemnify any person in connection with legal
proceedings threatened or brought against him by reason of his present or past
status as an officer or director of the Company in the circumstances described
above. Article VIII of the Amended and Restated By-Laws also provides that the
directors of the Company are not subject to personal liability to the Company,
its shareholders or persons asserting rights on behalf thereof, as provided in
the Wisconsin Business Corporation Law. The Amended and Restated By-Laws also
contain a nonexclusivity clause which provides in substance that the
indemnification rights under the Amended and Restated By-Laws shall not be
deemed exclusive of any other rights to which those seeking indemnification may
be entitled under any agreement with the Company, any Amended and Restated
By-Law or otherwise.
The indemnification provided as set forth above is not exclusive of any
other rights to which a director or an officer of the Company may be entitled.
The general effect of the foregoing provisions is to reduce the
circumstances in which an officer or director may be required to bear the
economic burdens of the foregoing liabilities and expenses.
II-1
Item 25. Other Expenses of Issuance and Distribution.
The expenses in connection with the offering are as follows:
ITEM AMOUNT*
- ---------------------------- --------
Registration fee . . . . . . $ 765
Printing expenses. . . . . . 5,000
Legal fees and expenses. . . 10,000
Accounting fees and expenses 5,000
Miscellaneous expenses . . . 5,000
--------
Total. . . . . $ 25,765
========
____________
* All amounts estimated except the registration fee.
Item 26. Recent Sales of Unregistered Securities.
On March 25, 1997, 1998, 1999, 2000 and 2001, the Company extended a $1
million, one-year promissory note payable by the Company to Stephen M. Dearholt
for a previous loan Mr. Dearholt made to the Company. The promissory note is
now payable in full on March 25, 2002 and bears interest at 12% annually,
payable monthly. The borrowing transactions were effected in the form of a
promissory note from the Company to Mr. Dearholt and related Note Purchase and
Warrant Agreements and a Stock Issuance Agreement. Under the 1997, 1998 and
1999 Note Purchase and Warrant Agreements, the Company issued to Mr. Dearholt
warrants to purchase 200,000 shares of common stock in 1997 at an exercise price
of $1.848 per share, 200,000 shares of common stock in 1998 at an exercise price
of $2.25 per share and 200,000 shares of common stock in 1999 at an exercise
price of $1.16 per share. In connection with the extension of the note to March
25, 2001, the Company issued warrants to purchase 250,000 shares of our common
stock in 2000 at an exercise price of $0.71 per share. In connection with the
extension of the note to March 25, 2002, the Company issued warrants to purchase
250,000 shares of our common stock in 2001 at an exercise price of $0.45 per
share. In each case, the exercise price of the warrants equaled 80% of the
market price of the common stock on the date of issuance. The warrants expire
upon the earlier of their exercise or on March 25, 2005 for the warrants issued
in 1997, March 25, 2007 for the warrants issued in 1998, March 25, 2009 for the
warrants issued in 1999, March 25, 2010 for the warrants issued in 2000, and
March 25, 2011 for the warrants issued in 2001. In consideration of Mr.
Dearholt's agreement to extend the note's due date to March 25, 2000, the
Company extended the expiration date of warrants held by Mr. Dearholt to
purchase 200,000 shares of our common stock from March 25, 2001 to March 25,
2002.
The Company believes that the sales described above were exempt from
registration under section 4(2) of the Securities Act and/or Regulation D
promulgated under the Securities Act because such sales were made to one person
who is an accredited investor and a director of the Company. Mr. Dearholt also
represented to the Company that he was purchasing for investment without a view
to further distribution. Restrictive legends were placed on all instruments
evidencing the securities described above.
On May 19, 1999 and June 3, 1999, the Company issued an aggregate of
$1,500,000 of convertible debentures and warrants to purchase 1,875,000 shares
of the Company's common stock to five accredited investors. The convertible
debentures bear interest at 8% per annum and have a one-year term; provided,
however, that the Company may extend the repayment term for an additional one
year if, upon such extension, it issues to the investors warrants to purchase
375,000 shares of the Company's common stock having the same terms and
conditions as the warrants issued to the investors in the private placement. The
investors may convert the convertible debentures into common stock at any time
after one year
II-2
from the date they were issued as follows: (a) the first 50% of the original
principal balance of the convertible debentures, plus any accrued but unpaid
interest thereon, is convertible into common stock based on a per share price
equal to the lesser of (i) 70% of the market price of the common stock at the
time of conversion or (ii) $1.25; and (b) the second 50% of the original
principal balance plus any accrued but unpaid interest thereon is convertible
into common stock based on the per share price equal to the lesser of (i) 70% of
the market price of the common stock at the time of conversion or (ii) $2.50. As
part of this offering, the Company also issued to the investors warrants to
purchase 1,875,000 shares of the Company's common stock. The warrants are
exercisable by the investors at any time within five years after their date of
issuance at an exercise price per share equal to the lesser of (a) 70% of the
market price of the Company's common stock from the date of exercise or (b)
$1.00. As part of the consideration that the Company paid R.J. Steichen &
Company, the Company's placement agent in the private placement of the
convertible debentures and warrants, the Company issued to R.J. Steichen
warrants to purchase a total of 337,500 shares of the Company's common stock.
The warrants issued to R.J. Steichen are exercisable at any time commencing one
year after the date of the private placement and for a period of four years
thereafter at an exercise price of $1.00 per share.
The Company believes it has satisfied the exemption from the securities
registration requirement provided by section 4(2) of the Securities Act and
Regulation D promulgated thereunder in this offering since the securities were
sold in a private placement to only sophisticated, accredited investors, each of
whom provided representations which the Company deemed necessary to satisfy
itself that they were accredited investors and were purchasing for investment
and not with a view to resale in connection with a public offering.
On September 24, 1999, the Company completed a private placement of 666,671
shares of its common stock to nine investors. Each share of common stock was
sold for a purchase price of $0.75, representing a discount of 12% from the
market price on the date that the shares were sold. In connection with this
private placement, the Company agreed to register the investors' resale of these
shares pursuant to this registration statement. The Company raised approximately
$500,000 of proceeds, net of issuance cost of $0 in connection with this private
placement. The Company believes that it has satisfied the exemption from the
securities registration requirement provided by section 4(2) of the Securities
Act and Regulation D promulgated thereunder in this offering since the
securities were sold in a private placement to only accredited investors, most
of whom had a preexisting personal or business relationship with the Company or
its officers or directors and each of whom provided representations which the
Company deemed necessary to satisfy itself that they were accredited investors
and were purchasing for investment and not with a view to resale in connection
with a public offering. In addition, the common stock issued to these investors
contained restrictive legends indicating that the shares had not been registered
and, therefore, cannot be resold unless the resale was registered under the
Securities Act or an exemption from such registration requirement was available.
On February 18, 1999, the Company borrowed $50,000 from O.B. Parrish, the
Company's Chairman and Chief Executive Officer. The borrowing was completed
through the execution of a $50,000, one-year promissory note payable by the
Company to Mr. Parrish and a Note Purchase and Warrant Agreement and Stock
Issuance Agreement. Mr. Parrish was granted warrants to purchase 10,000 shares
of our common stock at an exercise price of $1.35 per share. The exercise price
of the warrants equaled 80% of the average market price of our common stock for
the five trading days prior to the date of issuance. The warrants expire upon
the earlier of their exercise or nine years after the date of their issuance.
Effective February 18, 2000, the Company extended the due date of the note to
February 18, 2001, and in connection with this extension, the Company issued to
Mr. Parrish warrants to purchase 12,500 shares of our common stock at an
exercise price of $0.72 per share, which equaled 80% of the average market price
of our common stock for the five trading days prior to the date of issuance.
Effective February 18, 2001, the Company extended the due date of the note to
February 18, 2002, and in connection with this extension, the Company issued to
Mr. Parrish warrants to purchase 14,000 shares of our common stock at an
exercise price of $0.40 per share, which equaled 75% of the average market price
of our common stock for the five trading days prior to the date of issuance. The
warrants expire upon the earlier of their exercise or ten years after the date
of their issuance.
II-3
On February 12, 1999, the Company borrowed $250,000 from Mr. Dearholt. The
borrowing was effectuated in the form of a $250,000, one-year promissory note
payable by the Company to Mr. Dearholt. As part of this transaction, the
Company entered into a Note Purchase and Warrant Agreement and a Stock Issuance
Agreement. Mr. Dearholt received a warrant to purchase 50,000 shares of our
common stock at an exercise price of $1.248 per share. The exercise price of
the warrants equaled 80% of the average market price of the common stock for the
five trading days prior to the date of issuance. The warrants expire upon the
earlier of their exercise or nine years after the date of their issuance.
Effective February 12, 2000, the Company extended the due date of the note to
February 12, 2001, and in connection with this extension, the Company issued to
Mr. Dearholt warrants to purchase 62,500 shares of our common stock at an
exercise price of $0.77 per share, which equaled 80% of the average market price
of our common stock for the five trading days prior to the date of issuance.
Effective February 12, 2001, the Company extended the due date of the note to
February 12, 2002, and in connection with this extension, the Company issued to
Mr. Dearholt warrants to purchase 70,000 shares of our common stock at an
exercise price of $0.40 per share, which equaled 75% of the average market price
of our common stock for the five trading days prior to the date of issuance.
The warrants expire upon the earlier of their exercise or ten years after the
date of their issuance.
The Company has sold 129,506 shares of common stock on February 26, 1999,
157,356 shares of common stock on March 10, 1999, 196,102 shares of common stock
on April 10, 1999 and 197,093 shares of common stock on May 31, 2000 to a
private investor under an equity line agreement. The Company received net cash
proceeds of $145,500, $145,500, $194,000, and $97,000 respectively, from these
sales. As part of this offering, the Company also issued to the investor
warrants to purchase 200,000 shares of the Company's common stock at an exercise
price of $2.17 per share. The Company also issued warrants to purchase 100,000
shares of the Company's common stock at an exercise price of $1.625 to this
investor on February 12, 1999 in connection with a consulting agreement. The
Company believes it has satisfied the exemption from the securities registration
requirement provided by section 4(2) of the Securities Act and Regulation D
promulgated thereunder in this offering since the securities were sold in a
private placement to a sophisticated, accredited investor, who provided
representations which the Company deemed necessary to satisfy itself that it was
an accredited investor and was purchasing for investment and not with a view to
resale in connection with a public offering.
The Company sold 316,668 shares of common stock to three investors in
November 1999. The Company received cash proceeds of $237,500 from these sales.
The Company believes it has satisfied the exemption from the securities
registration requirement provided by section 4(2) of the Securities Act and
Regulation D promulgated thereunder in this offering since the securities were
sold in a private placement to sophisticated, accredited investors, who provided
representations which the Company deemed necessary to satisfy itself that they
were accredited investors and were purchasing for investment and not with a view
to resale in connection with a public offering.
The Company sold 100,000 shares of common stock to one investor in January
2000. The Company received cash proceeds of $75,000 from this sale. The
Company believes it has satisfied the exemption from the securities registration
requirement provided by section 4(2) of the Securities Act and Regulation D
promulgated thereunder in this offering since the securities were sold in a
private placement to a sophisticated, accredited investor, who provided
representations which the Company deemed necessary to satisfy itself that he was
an accredited investor and was purchasing for investment and not with a view to
resale in connection with a public offering.
The Company sold 80,001 shares of common stock to three investors in
February 2000. The Company received cash proceeds of $60,000 from these sales.
The Company believes it has satisfied the exemption from the securities
registration requirement provided by section 4(2) of the Securities Act and
Regulation D promulgated thereunder in this offering since the securities were
sold in a private placement to sophisticated, accredited investors, who provided
representations which the Company deemed necessary to satisfy itself that they
were accredited investors and were purchasing for investment and not with a view
to resale in connection with a public offering.
In June, 2000, the Company sold 500,000 shares of its common stock to two
investors, including 400,000 shares to a trust for the benefit of a child of
Stephen M. Dearholt, a director of the Company. The Company received cash
proceeds of $250,000 from this sale. The Company believes it has satisfied the
exemption from the securities registration requirement provided by section 4(2)
of the Securities Act and Regulation D promulgated thereunder in this offering
since the securities were sold in a private placement to sophisticated,
accredited investors, who provided representations which the Company deemed
necessary to satisfy itself that were accredited investors and were purchasing
for investment and not with a view to resale in connection with a public
offering.
II-4
On May 19, 2000 and June 3, 2000, the Company issued warrants to purchase
375,000 shares of common stock to five investors, in connection with the
one-year extension of the due date of $1,500,000 of convertible debentures with
the exercise price of the warrants is the lesser of 70% of market value or $1.00
per share. The warrants expire upon the earlier of their exercise or four years
after the date of their issuance. The Company believes that it has satisfied
the exemption from the securities registration requirement provided by section
4(2) of the Securities Act in connection with this issuance.
On June 15, 2000, the Company issued 150,000 shares of common stock to one
person as compensation for consulting services. The Company believes that it
has satisfied the exemption from the securities registration requirement
provided by section 4(2) of the Securities Act in connection with this issuance.
Effective March 30, 2001, the Company issued a $250,000 convertible
debentures to one accredited investor. The convertible debenture bears interest
at 12% per annum and has a three-year term. The investor may convert the
convertible debenture into common stock at any time based on a conversion rate
of $0.50 per share. The Company believes it has satisfied the exemption from
the securities registration requirement provided by section 4(2) of the
Securities Act and Regulation D promulgated thereunder in this offering since
the securities were sold in a private placement to a sophisticated, accredited
investor, who provided representations which the Company deemed necessary to
satisfy itself that he was an accredited investor and was purchasing for
investment and not with a view to resale in connection with a public offering.
The Company entered into a loan agreement on May 18, 2001, providing for a
three-year loan commitment from a bank of up to $2,000,000. The Company may
borrow under this loan agreement from time to time subject to a number of
conditions, including obtaining personal guarantees of 125% of the amount
outstanding under the loan. In connection with the loan, the Company issued
warrants to the lender to purchase the number of shares of common stock equal to
$500,000 divided by the warrant purchase price as of the date of exercise. The
warrant purchase price is the price per share equal to 70% of the market price
of our common stock at the time of exercise, but in no event will the warrant
purchase price be less than $0.50 per share or more than $1.00 per share.
Five persons provided guarantees equal in total to the $1.5 million
outstanding under the loan. The guarantors included James R. Kerber, a member
of the Company's board of directors, Stephen M. Dearholt, a member of the
Company's board of directors, Richard E. Wenninger, a member of the Company's
board of directors, and a trust for the benefit of O.B. Parrish, the Company's
Chairman of the Board and Chief Executive Officer. Each guarantor may be liable
to the lender for up to 125% of the guarantor's guarantee amount if the Company
defaults under the loan. The Company issued warrants to the guarantors to
purchase the number of shares of common stock equal to the guarantee amount of
such guarantor divided by the warrant purchase price as of the date of exercise.
The warrant purchase price is the price per share equal to 70% of the market
price of common stock at the time of exercise, but in no event will the warrant
purchase price be less than $0.50 per share or more than $1.00 per share. The
Company also issued additional warrants to purchase 100,000 shares of common
stock at an exercise price of $0.50 per share to each of Stephen M. Dearholt and
Richard E. Wenninger because each of them guaranteed $500,000 under the loan.
The Company believes it has satisfied the exemption from the securities
registration requirement provided by section 4(2) of the Securities Act and
Regulation D promulgated thereunder in this offering since the warrants were
sold in a private placement to only sophisticated, accredited investors, each of
whom provided representations which the Company deemed necessary to satisfy
itself that they were accredited investors and were purchasing for investment
and not with a view to resale in connection with a public offering.
Effective June 1, 2001, the Company issued an aggregate of $200,000 of
convertible debentures to two accredited investors. The convertible debentures
bear interest at 10% per annum and have a three-year term. The investors may
convert the convertible debentures into common stock at any time based on a
conversion rate of $0.50 per share. The Company believes it has satisfied the
exemption from the securities registration requirement provided by section 4(2)
of the Securities Act and Regulation D promulgated thereunder in this offering
since the securities were sold in a private placement to only sophisticated,
accredited investors, each of whom provided representations which the Company
deemed necessary to satisfy itself that they were accredited investors and were
purchasing for investment and not with a view to resale in connection with a
public offering.
II-5
On August 1, 2001, the Company issued 1,000,000 shares of common stock to
one accredited investor for a total purchase price of $500,000. The Company
believes it has satisfied the exemption from the securities registration
requirement provided by section 4(2) of the Securities Act and Regulation D
promulgated thereunder in this offering since the securities were sold in a
private placement to a sophisticated, accredited investor, who provided
representations which the Company deemed necessary to satisfy itself that he was
an accredited investor and was purchasing for investment and not with a view to
resale in connection with a public offering.
II-6
Item 27. Exhibits. The following exhibits are filed as part of this
Registration Statement.
EXHIBIT NO. DESCRIPTION
- ------------ --------------------------------------------------------------------------------------
3.1 Amended and Restated Articles of Incorporation of the Company.(20)
3.2 Articles of Amendment to the Amended and Restated Articles of Incorporation of the
Company. (26)
3.3 Amended and Restated By-Laws of the Company.(3)
4.1 Amended and Restated Articles of Incorporation (same as Exhibit 3.1).
4.2 Articles of Amendment to Amended and Restated Articles of Incorporation of the
Company (same as Exhibit 3.2).
4.3 Articles II, VII and XI of the Amended and Restated By-Laws of the Company
(included in Exhibit 3.3).
5 Legal Opinion of Reinhart Boerner Van Deuren s.c. regarding legality of securities
being issued.
10.1 Employment Agreement between John Wundrock and the Company dated October 1,
1989.(3)
10.2 Wisconsin Pharmacal Company, Inc. (k/n/a The Female Health Company) 1990 Stock
Option Plan.(4)
10.3 Reality Female Condom Clinical Trial Data Agreement between the Company and
Family Health International dated September 24, 1992.(6)
10.4 Trademark License Agreement for Reality Trademark.(7)
10.5 Office space lease between the Company and John Hancock Mutual Life Insurance
Company dated June 1, 1994.(8)
10.6 Employment Agreement dated September 10, 1994 between the Company and
Dr. Mary Ann Leeper.(9)
10.7 1994 Stock Option Plan.(10)
10.8 Investor relations and development services Consulting Agreement between the
Company and C.C.R.I. Corporation dated March 13, 1995.(11)
10.9 Consultant Warrant Agreement dated March 13, 1995 between the Company and
C.C.R.I. Corporation, as amended on April 22, 1996.(12)
10.10 Company Promissory Note payable to Stephen M. Dearholt for $1 million dated
March 25, 1996 and related Note Purchase and Warrant Agreement, warrants and Stock
Issuance Agreement.(13)
10.11 Outside Director Stock Option Plan.(12)
10.12 Exclusive Distribution Agreement between Chartex International Plc and Taiho
Pharmaceutical Co., Ltd. dated October 18, 1994.(14)
II-7
10.13 Supply Agreement between Chartex International Plc and Deerfield Urethane, Inc.
dated August 17, 1994.(14)
10.14 Employment Letter dated February 28, 1990 from Chartex Resources Ltd. to Michael
Pope and Board Amendments thereto.(14)
10.15 Grant Letter dated March 7, 1996 from the Government Office for London of the
Secretary of State of Trade and Industry regarding economic development grant to the
Company.(14)
10.16 Letter Amendment to Asset Sale Agreement dated April 29, 1996 between the
Company and Dowty Seals Limited and Chartex International Plc.(14)
10.17 Form of Warrant issued by the Company to certain foreign investors as of
September 12, 1996.(15)
10.18 Fund Raising Agreement dated May 1, 1998 by and between Hartinvest-Medical
Ventures and the Company. (12)
10.19 Change of Control Agreement dated January 27, 1999, between The Female Health
Company and Michael Pope.(16)
10.20 Company Promissory Note to Stephen M. Dearholt for $250,000 dated February 1,
1999 and related Note Purchase And Warrant Agreement, warrants and Stock issuance
Agreement.(16)
10.21 Company Promissory Note to O.B. Parrish for $50,000 dated February 1, 1999 and
related Note Purchase And Warrant Agreement, warrants and Stock issuance
Agreement.(16)
10.22 Company Promissory Note to Stephen M. Dearholt for $1 million dated March 25,
1999 and related Note Purchase and Warrant Agreement, Warrant and Stock Issuance
Agreement.(16)
10.23 Form of Registration Rights Agreement between the Company and certain private
placement investors dated as of June 1, 1999.(17)
10.24 Amendment to Registration Rights Agreement between the Company and Private
Placement Investors dated as of June 1, 1999.(17)
10.25 $1 million Convertible Debenture issued by the Company to Gary Benson dated
May 19, 1999.(17)
10.26 $100,000 Convertible Debenture issued by the Company to Daniel Bishop dated
June 3, 1999.(17)
10.27 $100,000 Convertible Debenture issued by the Company to Robert Johander dated
June 3, 1999.(17)
10.28 $100,000 Convertible Debenture issued by the Company to Michael Snow dated
June 3, 1999.(17)
10.29 $100,000 Convertible Debenture issued by the Company to W.G. Securities Limited
Partnership dated June 3, 1999.(17)
II-8
10.30 Warrant to purchase 1,250,000 shares of the Company's common stock issued to Gary
Benson on May 19, 1999.(17)
10.31 Warrant to purchase 125,000 shares of the Company's common stock issued to Daniel
Bishop on June 3, 1999.(17)
10.32 Warrant to purchase 125,000 shares of the Company's common stock issued to Robert
Johander on June 3, 1999.(17)
10.33 Warrant to purchase 250,000 shares of the Company's common stock issued to Michael
Snow on June 3, 1999.(17)
10.34 Warrant to purchase 125,000 shares of the Company's common stock issued to
W.G. Securities Limited Partnership on June 3, 1999.(17)
10.35 Form of Common Stock Purchase Warrant to acquire 337,500 shares issued to
R.J. Steichen as placement agent.(17)
10.36 Form of Change of Control Agreement between the Company and each of O.B. Parrish
and Mary Ann Leeper.(20)
10.37 Lease Agreement among Chartex Resources Limited, P.A.T. (Pensions) Limited and
The Female Health Company.(18)
10.38 Agreement dated March 14, 1997, between the Joint United Nations Programme on
HIV/AIDS and Chartex International PLC.(19)
10.39 Company promissory note payable to Stephen M. Dearholt for $1 million dated
March 25, 1997, and related stock purchase and warrant agreement, warrants and stock
issuance agreement.(21)
10.40 1997 Stock Option Plan.(19)
10.41 Employee Stock Purchase Plan.(19)
10.42 Agreement dated September 29, 1997, between Vector Securities International and The
Female Health Company.(19)
10.43 Private Equity Line of Credit Agreement between the Company and Kingsbridge
Capital Limited dated November 19, 1998.(2)
10.44 Registration Rights Agreement between the Company and Kingsbridge Capital Limited
dated as of November 19, 1998.(2)
10.45 Warrant to Purchase up to 200,000 shares of common stock of the Company issued to
Kingsbridge Capital Limited as of November 19, 1998.(2)
10.46 Agreement between Kingsbridge Capital Limited and the Company dated February 12,
1999.(23)
10.47 Consulting Agreement between the Company and Kingsbridge Capital Limited dated
February 12, 1999.(23)
II-9
10.48 Registration Rights Agreement between Kingsbridge Capital Limited and the Company
dated February 12, 1999.(23)
10.49 Warrant for 100,000 shares of the Company's common stock issued to Kingsbridge
Capital Limited as of February 12, 1999.(23)
10.50 Company Promissory Note to Stephen M. Dearholt for $250,000 dated February 12,
2000 and related Warrants.(24)
10.51 Company Promissory Note to O.B. Parrish for $50,000 dated February 18, 2000 and
related Warrants.(24)
10.52 Company Promissory Note to Stephen M. Dearholt for $1 million dated March 25,
2000 and related Warrants.(24)
10.53 Stock Purchase Agreement, dated as of June 14, 2000, between The Female Health
Company and The John W. Dearholt Trust.(25)
10.54 Warrant to purchase 250,000 shares of the Company's common stock issued to Gary
Benson on May 19, 2000. (25)
10.55 Warrant to purchase 25,000 shares of the Company's common stock issued to Daniel
Bishop on June 3, 2000. (25)
10.56 Warrant to purchase 25,000 shares of the Company's common stock issued to Robert
Johander on June 3, 2000. (25)
10.57 Warrant to purchase 50,000 shares of the Company's common stock issued to Michael
Snow on June 3, 2000. (25)
10.58 Warrant to purchase 25,000 shares of the Company's common stock issued to W.G.
Securities Limited Partnership on June 3, 2000. (25)
10.59 Stock Purchase Agreement, dated as of June 14, 2000, between the Company and The
John W. Dearholt Trust. (25)
10.60 Exclusive Distribution Agreement, dated as of ______, 2000, between the Company
and Mayer Laboratories, Inc. (26)
10.61 Amended and Restated Convertible Debenture issued by the Company to Richard E.
Wenninger dated March 30, 2001. (27)
10.62 Amended and Restated Promissory Note to Stephen M. Dearholt for $250,000 dated
February 12, 2001 and related warrants. (5)
10.63 Amended and Restated Promissory Note to O.B. Parrish for $50,000 dated February
18, 2001 and related warrants. (5)
10.64 Amended and Restated Promissory Note to Stephen M. Dearholt for $1,000,000 dated
March 25, 2001 and related warrants. (27)
10.65 Loan Agreement, dated as of May 18, 2001, between the Company and Heartland
Bank. (27)
II-10
10.66 Registration Rights Agreement, dated as of May 18, 2001, between the Company and
Heartland Bank. (27)
10.67 Warrant dated May 18, 2001 from the Company to Heartland Bank. (27)
10.68 Warrants dated May 18, 2001 from the Company to Stephen M. Dearholt.
10.69 Warrant dated May 18, 2001 from the Company to James R. Kerber.
10.70 Warrant dated May 18, 2001 from the Company to Tom Bodine.
10.71 Warrant dated May 18, 2001 from the Company to The Geneva O. Parrish 1996 Living
Trust.
10.72 Warrants dated May 23, 2001 from the Company to Richard E. Wenninger.
10.73 Registration Rights Agreement, dated as of May 18, 2001, among the Company and
certain guarantors.
21 Subsidiaries of Registrant. (22)
23.1 Consent of McGladrey & Pullen, LLP
23.2 Consent of Reinhart Boerner Van Deuren s.c. (included in Exhibit 5).
24 Power of Attorney (incorporated by reference to the signature page hereof).
____________
(1) Incorporated herein by reference to the Company's 1995 Form 10-KSB.
(2) Incorporated herein by reference to the Company's Form SB-2 Registration
Statement filed December 8, 1998.
(3) Incorporated herein by reference to the Company's Registration Statement on
Form S-18, Registration No. 33-35096, as filed with the Securities and
Exchange Commission on May 25, 1990.
(4) Incorporated herein by reference to the Company's December 31, 1990 Form
10-Q.
(5) Incorporated herein by reference to the Company's March 31, 2001 Form
10-QSB.
(6) Incorporated herein by reference to Pre-Effective Amendment No. 1 to the
Company's Registration Statement on Form S-1, Registration No. 33-51586, as
filed with the Securities and Exchange Commission on September 28, 1992.
(7) Incorporated herein by reference to the Company's 1992 Form 10-KSB.
(8) Incorporated herein by reference to the Company's June 30, 1994 Form 10-Q.
(9) Incorporated herein by reference to the Company's Registration Statement on
Form S-2, Registration No. 33-84524, as filed with the Securities and
Exchange Commission on September 28, 1994.
II-11
(10) Incorporated herein by reference to the Company's 1994 Form 10-KSB.
(11) Incorporated herein by reference to the Company's March 31, 1995 Form 10-Q.
(12) Incorporated herein by reference to the Company's Form S-1 Registration
Statement filed with the Securities and Exchange Commission on April 23,
1996.
(13) Incorporated herein by reference to the Company's June 30, 1995 Form 10-Q.
(14) Incorporated herein by reference to Pre-Effective Amendment No. 1 to the
Company's Form S-1 Registration Statement filed with the Securities and
Exchange Commission on June 5, 1996.
(15) Incorporated herein by reference to the Company's 1996 Form 10-K.
(16) Incorporated herein by reference to the Company's March 31, 1999 Form
10-QSB.
(17) Incorporated herein by reference to the Company's June 30, 1999 Form
10-QSB.
(18) Incorporated herein by reference to the Company's December 31, 1996 Form
10-QSB.
(19) Incorporated herein by reference to the Company's Form 10-KSB/A-1 for the
year ended September 30, 1997.
(20) Incorporated herein by reference to the Company's Form SB-2 Registration
Statement filed with the Securities and Exchange Commission on October 19,
1999.
(21) Incorporated herein by reference to the Company's March 31, 1997 Form
10-QSB.
(22) Incorporated herein by reference to the Company's Form 10-KSB for the year
ended September 30, 1999.
(23) Incorporated herein by reference to the Company's December 31, 1998 Form
10-QSB.
(24) Incorporated herein by reference to the Company's March 31, 2000 Form
10-QSB.
(25) Incorporated herein by reference to the Company's June 30, 2000 Form
10-QSB.
(26) Incorporated herein by reference to the Company's Form SB-2 Registration
Statement filed with the Securities and Exchange Commission on September
21, 2000.
(27) Incorporated herein by reference to the Company's June 30, 2001 Form
10-QSB.
Item 28. Undertakings.
The small business issuer hereby undertakes as follows:
(a) Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to directors, officers and controlling persons of
the small business issuer pursuant to the foregoing provisions, or otherwise,
the small business issuer has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a claim
for indemnification against such liabilities (other than the payment by the
small business issuer of expenses incurred or paid by a director, officer or
controlling person of the small business issuer in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the small
II-12
business issuer will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as
expressed in the Act and will be governed by the final adjudication of such
issue.
(b) File, during any period in which offers and sales of securities may be
made pursuant to this registration, a post-effective amendment to this
registration statement to:
(i) include any prospectus required by section 10(a) (3) of the
Securities Act;
(ii) reflect in the prospectus any facts or events which, individually
or together, represent a fundamental change in the information in the
registration statement; and
(iii) include any additional or changed material information on the
plan of distribution.
(c) For determining liability under the Securities Act, treat each
post-effective amendment as a new registration statement of the securities
offered, and the offering of the securities at that time to be the initial bona
fide offering.
(d) File a post-effective amendment to remove from registration any of the
securities that remain unsold at the end of the offering.
II-13
SIGNATURES
In accordance with the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form SB-2 and authorized this Registration
Statement to be signed on its behalf by the undersigned, in the City of Chicago,
State of Illinois, on the 9th day of November, 2001.
THE FEMALE HEALTH COMPANY
BY /s/ O.B. Parrish
-----------------------------------
Its Chairman and Chief Executive Officer
-----------------------------------
POWER OF ATTORNEY
Each person whose signature appears below hereby appoints O.B. Parrish and
Mary Ann Leeper, and each of them individually, his true and lawful
attorney-in-fact, with power to act with or without the other and with full
power of substitution and resubstitution, in any and all capacities, to sign any
or all amendments (including post-effective amendments) to the Registration
Statement and file the same with all exhibits thereto, and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents full power and authority to do and perform
each and every act and thing requisite and necessary to done in and about the
premises, as fully to all intents and purposes as he or she might or could do in
person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or their substitutes, may lawfully cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed below by the following persons in the
capacities and on the dates indicated:
SIGNATURE TITLE DATE
- --------------------------------- ----------------------------- ----------------
/s/ O.B. Parrish
- ---------------------------------
O.B. Parrish Chairman of the Board, Chief November 9, 2001
Executive Officer and Director
(Principal Executive Officer)
/s/ Mary Ann Leeper
- ---------------------------------
Mary Ann Leeper, Ph.D. President and Chief Operating November 9, 2001
Officer and Director
/s/ Robert R. Zic
- ---------------------------------
Robert R. Zic Principal Accounting Officer November 9, 2001
/s/ William R. Gargiulo
- ---------------------------------
William R. Gargiulo, Jr. Secretary and Director November 9, 2001
/s/ David R. Bethune
- ---------------------------------
David R. Bethune Director November 9, 2001
/s/ Stephen M. Dearholt
- ---------------------------------
Stephen M. Dearholt Director November 9, 2001
/s/ James R. Kerber
- ---------------------------------
James R. Kerber Director November 9, 2001
/s/ Michael R. Walton
- ---------------------------------
Michael R. Walton Director November 9, 2001
- ---------------------------------
Richard E. Wenninger Director November __, 2001
II-14
EXHIBIT INDEX
EXHIBIT PAGE
NUMBER DESCRIPTION NUMBER
- ------- ---------------------------------------------------- ------
5 Legal Opinion of Reinhart Boerner Van Deuren s.c.
10.68 Warrants dated May 18, 2001 from the Company to
Stephen M. Dearholt.
10.69 Warrant dated May 18, 2001 from the Company to
James R. Kerber.
10.70 Warrant dated May 18, 2001 from the Company to
Tom Bodine.
10.71 Warrant dated May 18, 2001 from the Company to
The Geneva O. Parrish 1996 Living Trust.
10.72 Warrants dated May 23, 2001 from the Company to
Richard E. Wenninger.
10.73 Registration Rights Agreement, dated as of May 18,
2001, among the Company and certain guarantors.
23.1 Consent of McGladrey & Pullen, LLP